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Abstract
Autistic spectrum disorder (ASD) represents a neurodevelopmental disorder
characterized by impairment of social communication and restricted/repetitive
behavior patterns or interests. Brain histamine and acetylcholine play a crucial role in
cognitive functions. Considering this, the effects of systemic sub-chronic treatment
with H3R antagonist DL77 (5, 10, or 15 mg/kg) on autistic-like behavioral parameters,
oxidative stress, and neuroinflammation in male Tuck-Ordinary (TO) and C57BL/6
(C57) mice, prenatally exposed to valproic acid (VPA, 500 mg/kg), were investigated.
Furthermore,

the

effects

of

dual-active

H3R

antagonist

and

balanced

acetylcholinesterase inhibitor E100 (5, 10, or 15 mg/kg) on autistic-associated
abnormalities of VPA- exposed male C57 mice as well as BTBR T+tf/J (BTBR) mice
were assessed. The results showed that VPA-exposed mice exhibited significantly
lower sociability and social novelty preference compared to VPA-exposed TO and
C57 mice pretreated with DL77 (10 mg/kg) or (15 mg/kg), respectively. Moreover, the
same doses of DL77 attenuated repetitive/compulsive behaviors of both strain of mice,
without appreciable effects on disturbed anxiety and hyperactivity when compared to
the reference drug donepezil (1 mg/kg). The amelioration in autistic-like phenotypes
by DL77 were accompanied by the attenuation of oxidative stress by increasing
glutathione

and

decreasing

malondialdehyde

levels,

and

attenuation

of

proinflammatory cytokines interleukin-1β, interleukin-6 and tumor necrosis factor-α
in brain tissues from VPA-exposed mice. Comparing the results observed for DL77,
the dual-active E100 (10 mg/kg) showed significantly higher improvement of autistic
behavioral alterations in VPA-exposed C57 mice, and significantly palliated disturbed
anxiety levels. In addition, E100 attenuated several pro-inflammatory cytokines and
inflammatory mediators through the suppression of upregulated NF-κB signaling.
Immunofluorescence analysis showed significant reduction in ionized calciumbinding adaptor molecule-1 increased expression in VPA-exposed C57 mice by E100,
demonstrating attenuation of activated microglia. Similarly, oxidative stress status was
also mitigated by E100 in brain tissues. The promising effects of E100 on autistic
features in C57 mice were further complemented with the results following treatment
with E100 (5 mg/kg) in BTBR mice as idiopathic model of ASD. These results provide

viii
evidence that simultaneous modulation of brain histaminergic and cholinergic
neurotransmissions may have therapeutic efficacy for core symptoms of ASD. Further
preclinical investigations are still necessary to corroborate and expand these observed
data.

Keywords: ASD, mouse models, histamine H3 receptor antagonists, autistic-like
behaviors, neuroinflammation, oxidative stress.
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)Title and Abstract (in Arabic

دور مثبطات مستقبل الهيستامين  H3في تعديل السلوك التوحدي واستجابات االلتهاب
المركزي المتغيرة في نماذج فئران مختلفة من اضطراب طيف التوحد
الملخص

يمثل اضطراب طيف التوحد ( )ASDاضطرابًا في النمو العصبي ويتميز بضعف
التواصل االجتماعي وأنماط أو اهتمامات سلوكية مقيدة أو متكررة ،ويلعب الهستامين و األسيتيل
كولين دورا ً حاسما ً في الوظائف اإلدراكية .وبامعان النظر  ،فقد تم فحص آثار المعالجة شبه
المزمنة لدى مثبطات مستقبل الهستامين  ، 10 ،5 DL77) H3Rأو  15ملغ  /كلغ) على
المعامالت السلوكية الشبيهة بالتوحد  ،واإلجهاد التأكسدي  ،والتهاب األعصاب في ذكور فئران
) Tuck-Ordinary (TOو  ، )C57( C57BL/6التي تعرضت قبل الوالدة لحمض فالبرويك
(  500 ،VPAملغم  /كغم)  .كما ايضا تم اختبار وتقييم  ، 10 ، 5) E100أو  15مجم  /كجم)
ثنائي الفعالية كمثبطات مستقبل الهستامين  H3Rوكذلك مثبط االستيل كولينيستراز على
االعراَض المرتبطة بالتوحد على فئران  C57الذكور و كذلك فئران ).BTBR T+tf/j (BTBR
كبيرا في التواصل
ضا
وقد أكدت النتائج أن الفئران المعالجه بـ  VPAقد أظهرت انخفا ً
ً
االجتماعي وتفضيل الوحدة االجتماعية مقارنة بفئران  TOو  C57المعرضة لـ  VPAو المعالجة
بـ 10 ( DL77مجم  /كجم) أو ( 15مجم  /كجم) على التوالي .عالوة على ذلك  ،فإن نفس
جرعات  DL77أدت إلى إنخفاض في السلوكيات المتكررة  /القهريّة لكلتا الساللتين  ،دون آثار
ملحوظة على القلق المضطرب وفرط النشاط عند مقارنتها بالعقار المرجعي دونيبزيل ( 1مغ /
كغ) .وقد رافق التحسن في األنماط الظاهرية الشبيهة بالتوحد بواسطة  DL77باستعادة اإلجهاد
التأكسدي عن طريق زيادة ال glutathioneوانخفاض مستويات ، malondialdehyde
وتخفيف السيتوكينات الموالية لاللتهابات  interleukin -6 ،interleukin-1βو Tumor
 necrosis factor-αعلى أنسجة المخ لدى الفئران التي تعرضت قبل الوالدة ل .VPA
بمقارنة النتائج التي لوحظت في  ، DL77أظهر المركب  E100ثنائي الفعالية ( 10مغ
 /كغ) تحسنا أعلى بكثير في التغيرات السلوكية التوحدية في فئران  C57المعرضة لـ ، VPA

x

ومستويات القلق المضطربة بشكل ملحوظ .باإلضافة إلى ذلك  ،خفف  E100العديد من
السيتوكينات المؤيدة لاللتهابات و وسطاء االلتهابات من خالل قمع إشارة  NF-κBالمنتظمة.
كبيرا في زيادة التعبير مهيء
ضا
أظهر ) )Immunofluorescence analysisانخفا ً
ً
رابط الكالسيوم األيوني الجزئ ١-في فئران  C57المعرضة لـ  ، VPAمما يدل ‘لى اثار E100
ضا عن
على توهين الخاليا المجهرية المنشطة .وبالمثل  ،تم تخفيف حالة اإلجهاد التأكسدي أي ً
طريق  E100في أنسجة المخ .وتم فهم اآلثار الواعدة لـ  E100على ميزات التوحد في الفئران
 C57مع النتائج التي لوحظت مع )E100 5مجم  /كجم) في الفئران  BTBRكنموذج مجهول
السبب من .ASD
توفر هذه النتائج ً
دليال على أن التعديل المتزامن للناقالت العصبية الهيستامينية والكولينينية
في الدماغ قد يكون له فعالية عالجية لألعراض األساسية لـ  .ASDولكن ،ال تزال هناك حاجة
للمزيد من التجارب والدراسات قبل السريرية لتأكيد وتطوير هذه النتائج التي تم الحصول عليها.
مفاهيم البحث الرئيسية ، ASD :نماذج الفأر  ،مثبطات مستقبالت الهستامين  ، H3السلوكيات
الشبيهة بالتوحد  ،االلتهاب العصبي  ،اإلجهاد التأكسدي.
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Chapter 1: Introduction
1. 1 Autism Spectrum Disorder
Autistic spectrum disorder (ASD) is a biologically based neurodevelopmental
disorder affecting two major core behavioral symptoms, namely impairments in social
skills and restricted /repetitive behavioral pattern or interest of ASD patients (Baronio,
Castro, Gonchoroski et al., 2015). These core symptoms can be observed before the
age of three years and are lasting for the whole lifetime (Andres, 2002). ASD has
become a high priority for scientists and health care providers, and has also attracted
the public attention because of reported increase in its prevalence (Sheldrick & Carter,
2018; Xu, Strathearn, Liu et al., 2018). The worldwide estimated prevalence of
individuals with ASD diagnosis is strikingly high with prevalence varying across
numerous studies, but it is estimated that one in 160 children has an ASD worldwide,
and it is expected to increase globally (Arvidsson, Gillberg, Lichtenstein et al., 2018).
Despite its increasing prevalence, the pathophysiology of ASD is still understood
incompletely, and this can be attributed to challenges in identifying suitable animal
models and the complexity of the neurobiology in brain function (Nestler & Hyman,
2010). Several lines of evidence suggest that strong genetic and environmental factors
raise the occurrence of ASD in childhood (Baronio et al., 2015). Additionally, the
heterogenicity of clinical and behavioral symptoms in autistic children is part of the
difficulty in understanding the pathophysiology of this disorder, and consequently no
specific treatment can be effective to all autistic children. Therefore, subgrouping of
children based on their responding to intervention is essential (James, Melnyk, Fuchs
et al., 2009). Studying the drug effects on core symptoms in ASD is very challenging,
despite advances in early diagnosis and intervention, efficacious reversal of these core
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autistic symptoms is still not approved to date. To date, there are no efficient
therapeutic interventions that target the core symptoms of ASD, namely social
communication impairments and restricted/repetitive behavior (Sheldrick et al., 2018;
Xu et al., 2018). However, pharmacological interventions may be used to provide
symptomatic control of associated comorbidities but not to treat core deficits (Hanson,
Kalish, Bunce et al., 2007; Wong & Smith, 2006). These associated symptoms of ASD
include inattention, hyperactivity, anxiety, sleep disturbances, irritability, aggression
and self-injuries. Psychiatric drugs are frequently used for treating these symptoms in
autistic children (Findling, 2005). Currently, risperidone and aripiprazole are the only
two US Food and Drug Administration (FDA) approved drugs for treating behavioral
symptoms associated with ASD, mainly for irritability (Matson, Sipes, Fodstad et al.,
2011). Targeting ASD core symptoms for complete and effective treatment has been
challenging and not yet achieved as mentioned earlier. Therefore, developing drug
therapies for improving and perhaps treating the core symptoms of ASD is
significantly important, aiming to improve the quality of life for the suffering patients
and easing the burden on their families.
1.1.1 Etiology of ASD
ASD is broadly considered to be a multi-factorial disorder that results from
genetic as well as non-genetic risk factors. There is cumulative evidence for the
involvement of genetic factors in the etiology of ASD, since siblings born in families
with ASD are at 35–40% greater risk to develop ASD and with an increase in the
current rate of approximately 1% from a rate of 0.05% in 1970s (Stubbs, Henley, &
Green, 2016). Moreover, genetic studies revealed that alteration in the developmental
pathways of neuronal and axonal structures that are strongly involved in
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synaptogenesis emerge from single gene mutations (Chang, Gilman, Chiang et al.,
2015; Geschwind, 2011; Voineagu, Wang, Johnston et al., 2011). It is likely that
interactions between multiple genes, and variability in expression as a result of
epigenetic factors and exposure to environmental factors are responsible for
ASD (Muhle, Trentacoste, & Rapin, 2004). In a previous clinical study involving a
twin, it was appraised that the risk of developing ASD was 35–40% due to genetic
variability, and the remaining 60% was contributed to by prenatal, perinatal, and
postnatal environmental factors (Hallmayer, Cleveland, Torres et al., 2011).
Accordingly, environmental factors implicated with ASD included prenatal and
perinatal complications (Glasson, Bower, Petterson et al., 2004; Maramara, He, &
Ming, 2014), birth and neonatal complications (Gardener, Spiegelman, & Buka, 2011;
Guinchat, Thorsen, Laurent et al., 2012), viral infection, autoimmune diseases, and
exposure to teratogens and maternal anticonvulsants such as valproic acid (VPA)
(Kern & Jones, 2006; Kolevzon, Gross, & Reichenberg, 2007). Therefore, an increased
understanding of the interface between genetic and environmental factors in the
pathogenesis of ASD may lead to an optimized therapeutic strategy.
1.2 Central histamine and histaminergic system (HS)
Histamine and its receptors have long been known as part of immune and
gastrointestinal systems but their discovery in the central nervous system (CNS) and
their role in behavior, was largely studied in recent years. The possibility of histamine
targeting treatments has recently received considerable attention, basically in
neurogenerative diseases (Sadek, Saad, Sadeq et al., 2016c). The role of histamine in
cognition, sleep, sensory, motor functions and neuroinflammation have attracted
considerable interest (Haas, Sergeeva, & Selbach, 2008; Shan, Bao, & Swaab, 2015;
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Witkin & Nelson, 2004). Moreover, histamine was suggested through recent evidence
to have a role in regulating microglial activation (Dong, Zhang, Zeng et al., 2014;
Frick, Rapanelli, Abbasi et al., 2016), cytokine release (Rocha, Pires, Esteves et al.,
2014) and migration (Ferreira, Santos, Goncalves et al., 2012). The HS in the CNS
consists of cell bodies of histaminergic neurons confined in one area of posterior
hypothalamus called tuberomammillary nucleus (TMN), sending projections to spinal
cord, brain stem and many telencephalic brain areas (Brown, Stevens, & Haas, 2001;
Haas et al., 2008) (Figure 1). Hence, central histamine has been suggested to be a
regulator of activity of the “whole brain” (Wada, Inagaki, Yamatodani et al., 1991).

Figure 1: Histaminergic neuronal projections from tuberomammillary nucleus
(TMN).
Innervations originates from TMN to all over the CNS from ventral part to
the hypothalamus and septum, and from dorsal part to the thalamus, hippocampus, amygdala, and
forebrain. There is one descending pathway to the brain stem, cerebellum and spinal cord. Adapted from
(Sadek, et al., 2016c).

Histamine is biosynthesized mainly in the TMN, where the dietary amino acid
pre-cursor L-histidine is decarboxylated and converted to histamine by a specific
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enzyme called histidine decarboxylase (HDC). The central histamine action is
inactivated by histamine N-methyltransferase (HNMT) in the extracellular space
throughout the brain (Brown et al., 2001; Haas et al., 2008; Prell, Hough, Khandelwal
et al., 1996). In the CNS, histamine biosynthesis and release is modulated by H3 autoreceptors through cAMP/PKA dependent pathways (Bongers, Bakker, & Leurs, 2007).
Histamine may be able to activate both ligand-operated channels and receptors linked
to second messengers. With regard to receptors, the effects of histamine are exerted
through activation of four different G-protein coupled receptors (GPCR) subtypes
namely H1-H4R, expressed through the brain (Arrang, Devaux, Chodkiewicz et al.,
1988; Arrang, Garbarg, & Schwartz, 1983, 1985, 1987; Hill, 1990; Hill, Ganellin,
Timmerman et al., 1997; Lovenberg, Roland, Wilson et al., 1999), however, H1-3Rs
are highly founded in the brain and H4Rs have extremely low expression through CNS
with unclear function (Sadek & Stark, 2016e; Schneider & Seifert, 2016). The H3Rs
are predominantly and heterogeneously expressed in the CNS. They are mainly
expressed in the basal ganglia, globus pallidus, hippocampus, cerebellum and cortex
in humans (Li, Zhu, & Wang, 2014; Martinez-Mir, Pollard, Moreau et al., 1990). As
mentioned earlier pre-synaptic H3R are coupled to Gi/Go-proteins and function as
auto-receptors that control firing of histamine neurons modulating synthesis and
release of histamine with high constitutive activity. In addition, H3Rs function as
hetero-receptors and can also regulate the release of other neurotransmitters like
dopamine (DA), serotonin (5-HT), norepinephrine (NE), acetylcholine (ACh), λamino butyric acid (GABA) and glutamate (Glu) in several brain regions. Thus,
blockade

of

inhibitory

histamine

H3

auto-receptors

reinforces

histamine

neurotransmission, while antagonism of H3 hetero-receptors accelerates the
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corticolimbic liberation of ACh, NE, DA, 5-HT and GABA and Glu (Brown et al.,
2001; Haas et al., 2008) (Figure 2). Accordingly, the brain HS and its modulation have
been implicated in many brain disorders, suggesting that it may play a critical role in
their pathophysiology.

Figure 2: Schematic illustration of histaminergic System (HS).
Possible mechanisms by which histamine H3 receptor antagonists provide various pharmacological
effects. Adapted from (Eissa, Al-Houqani, Sadeq et al., 2018).

1.2.1 Histamine receptors
Ash and Schild discovered the H1R in 1966, while studying the effect of
antihistamine drugs in the rat uterus and stomach (Ash & Schild, 1966). The three
other receptors (H2R, H3R, and H4R) were identified after that. The four receptors are
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part of the GPCR superfamily, and they all present with constitutive activity
(Bhowmik, Khanam, & Vohora, 2012; Nijmeijer, Leurs, & Vischer, 2010; Schneider,
Schnell, Strasser et al., 2010; Threlfell, Exley, Cragg et al., 2008). Activation of these
receptors without the presence of agonist was proven by the discovery of constitutively
active mutant receptors (Seifert & Wenzel-Seifert, 2002). Ligand binding to a receptor
may initiate activity (agonist with positive intrinsic activity) or abolish the effect of an
agonist (antagonist with zero intrinsic activity). The agonists stabilize the receptor in
active conformation, while the inverse agonists stabilize the receptor in inactive
conformation hence, reduces the activity (negative intrinsic activity) (Tao, 2008). Two
isoforms of the H3R are highly constitutively active: the wild type and an isoform with
a deletion in the third intracellular loop (Bond & Ijzerman, 2006).
H1R is found in different tissues and cells, including smooth muscle, brain,
and lymphocytes (Chang, Tran, & Snyder, 1979; Hill & Young, 1978). H1R signal
transduction results in activation of phospholipase C, which promotes the inositol
triphosphate-dependent release of Ca2+ from intracellular stores and diacylglycerolsensitive activation of protein kinase C (Haas et al., 2008; Smit, Hoffmann,
Timmerman et al., 1999). H1R is involved in the modulation of important processes
and mice lacking this receptor display different impairments, such as, in spatial
memory and in sleep-wake characteristics (Huang, Mochizuki, Qu et al., 2006;
Masuoka & Kamei, 2007).
Similarly, as H1R, H2R presents with typical GPCR characteristics. Its
activation stimulates adenylyl cyclase leading to cyclic adenosine monophosphate
(cAMP) production, a second messenger that has different roles in the cell (Hegstrand,
Kanof, & Greengard, 1976). The role of H2R in the CNS is not understood completely,

8
but basic research reports that H2R is related to the processes of learning and memory,
motor control, and thermoregulation (Dai, Kaneko, Kato et al., 2007; Tabarean,
Sanchez-Alavez, & Sethi, 2012).
H3R is mainly found in the brain, as reported it regulates food intake, memory,
acetylcholine release, and consolidation of fear memories (Cangioli, Baldi, Mannaioni
et al., 2002; Gemkow, Davenport, Harich et al., 2009). H3R’s activation inhibits
cAMP synthesis and activates MAP kinases and the AKT/GSK3β axis (Bakker,
Timmerman, & Leurs, 2002; Bongers, Sallmen, Passani et al., 2007; Mariottini,
Scartabelli, Bongers et al., 2009). When activated, the receptor inhibits cell firing and
decreases the release of histamine by histaminergic neurons, moreover inhibits
secretion of norepinephrine, serotonin, and other neurotransmitters by nonhistaminergic neurons (Gomez-Ramirez, Ortiz, & Blanco, 2002; Threlfell et al., 2008;
Yamasaki, Tamai, & Matsumura, 2001). Recently, mice lacking H3R reported several
alterations. They presented with enhanced histaminergic neurotransmission, which led
to changes in the behavioral phenotype (Gondard, Anaclet, Akaoka et al., 2013).
H4R was the last histamine receptor to be identified. It is mainly implicated
with immune functions, however its presence in the brain, the bone marrow, peripheral
blood, spleen, thymus, small intestine, colon, heart, and lung is known (Moya-Garcia,
Rodriguez, Morilla et al., 2011; Nakamura, Itadani, Hidaka et al., 2000; Zampeli &
Tiligada, 2009). It is involved in modulation of different processes, for example,
dendritic cell activity, interleukin (IL) release, and likely regulation of blood brain
barrier permeability (Karlstedt, Jin, & Panula, 2013; Mommert, Gschwandtner,
Koether et al., 2012; Simon, Laszlo, Lang et al., 2011).
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1.2.2 Implication of HS in brain disorders and ASD
The HS has been reported to be involved in several brain disorders such as in
Alzheimer’s disease (AD), schizophrenia (SCH), sleep disorders, drug dependence,
and Parkinson’s disease (PD) (Baronio, Gonchoroski, Castro et al., 2014).
In recent studies it was reported that histaminergic signalling abnormalities
may contribute to rare diseases such as Tourette syndrome (TS) (Paschou, Fernandez,
Sharp et al., 2013). TS was also reported to be among the most prevalently comorbid
neurodevelopmental disorders with ASD (Gillberg & Billstedt, 2000), sharing genetic
risk factors (Clarke, Lee, & Eapen, 2012; Fernandez, Sanders, Yurkiewicz et al.,
2012). Additionally, both conditions share features of neuroinflammation (Kern,
Geier, Sykes et al., 2015; Muller, 2007; Theoharides, Tsilioni, Patel et al., 2016), and
increased microglia activation (Frick et al., 2016). Histamine plays a role in
neuroinflammation (Jutel, Blaser, & Akdis, 2005; Theoharides et al., 2016), and
microglia regulation (Dong et al., 2014; Ferreira et al., 2012; Frick et al., 2016; Rocha
et al., 2014), suggests the HS may partly mediate the neuroinflammatory phenotype
associated with these disorders. A study of TS reported a rare non-sense mutation in
HDC, a gene encoding Histidine decarboxylase enzyme that synthesizes histamine
from histidine (Karagiannidis, Dehning, Sandor et al., 2013). Other recent studies of
ASD also implicate potential involvement of HS in this disorder as de novo deletions
overlap in Histamine N-methyl transferase, a gene which encodes the enzyme that
inactivates histamine (Griswold, Ma, Cukier et al., 2012; Mulatinho, de Carvalho
Serao, Scalco et al., 2012). Furthermore, analysis of gene mapping of rare copy number
variant in TS reported significant overlap with those revealed in ASD (Fernandez et
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al., 2012). All of these findings and overlaps between the two disorders, raised the
possibility of the implication of HS in ASD.
In addition, replicated findings suggested that SCH and ASD may share similar
biological pathways demonstrating that both conditions have structural variation at
regions 16p11.2 (McCarthy, Makarov, Kirov et al., 2009; Weiss, Shen, Korn et al.,
2008), 22q11.2 (Guilmatre, Dubourg, Mosca et al., 2009; Vassos, Collier, Holden et
al., 2010) and 1q21.1 (Brunetti-Pierri, Berg, Scaglia et al., 2008; Ikeda, Aleksic, Kirov
et al., 2010; Mefford, Muhle, Ostertag et al., 2010; Stefansson, Rujescu, Cichon et al.,
2008), which are susceptibility factors for a variety of neurodevelopmental
phenotypes.Moreover, copy number variations and deleterious mutations in synaptic
organizing proteins including NRXN1 have been associated with both SCH and ASD
(Gauthier, Siddiqui, Huashan et al., 2011). Other recent publications of single-genome
wide copy number variation revealed rare variants at NRXN1 and catenin alpha3 loci
suggesting a risk factor overlap with both ASD and SCH. In addition to the genetic
overlap between both disorders, they also share behavioral symptoms. Social cognitive
impairments are a hallmark behavioral deficit of both ASD and SCH (Couture, Penn,
&

Roberts,

2006;

Meyer,

Feldon,

&

Dammann,

2011).

Furthermore,

neuroinflammation as a consequence of microglia activation plays an important role
in both SCH and ASD (Nakagawa & Chiba, 2016). Considering these evidences, it is
suggested that HS dysfunction may be involved in the aetiology of ASD, since both
SCH and TS disorders have substantial genetic and symptomatic overlap with ASD.
1.2.3 Role of H3R antagonists in CNS diseases and ASD
Exploring the potential role of histamine H3R antagonist in number of CNS
diseases like AD, epilepsy, attention deficit hyperactivity disorder (ADHD),
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narcolepsy (Baronio et al., 2015.; Baronio et al., 2014; Kasteleijn-Nolst Trenite,
Parain, Genton et al., 2013; Savage, Rosenberg, Wolff et al., 2010; Witkin et al., 2004),
SCH (Passani & Blandina, 2011) and recently in Tics, TS (Rapanelli & Pittenger,
2016b) and ASD (Baronio et al., 2015), suggest that H3R antagonists may be a
potential therapeutic agent for treatment of several symptoms including cognitive
impairments. Investigations of H3R antagonist/inverse agonist GSK239512 to assess
cognitive enhancing effects showed positive results on memory, attention (Nathan,
Boardley, Scott et al., 2013) and displayed improvement in episodic memory in
patients with AD (Grove, Harrington, Mahler et al., 2014). Preclinical studies reported
that ciproxifan (CPX), an imidazole based H3R antagonist demonstrated
improvements in hyperactivity and memory deficits after administration of this drug
in a mouse model of AD (Bardgett, Davis, Schultheis et al., 2011). On the other
hand, treatment with JNJ-10181457, a selective non-imidazole H3R antagonist
reversed cognitive deficits induced by the muscarinic cholinergic antagonist
scopolamine (Galici, Boggs, Aluisio et al., 2009), impairments that are commonly
featured in ASD. These evidences suggest the potential role of H3R antagonists in
rescuing core symptoms of ASD through modulation of cognitive functions. Cognition
include self-regulation and social cognition that allows people to appropriately
regulate actions related to social issues, and to make plans (Heatherton & Wagner,
2011).
Moreover, recent clinical trials demonstrated the successful effect of pitolisant
(Wakix®), an H3R antagonist in treatment of narcolepsy (Baronio et al., 2014).
Pitolisant is approved by the European Medicines Agency (EMA) and is the first in
class drug to be introduced into clinics. Pitolisant was also suggested to be effective in
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epilepsy, which is highly comorbid with ASD (Kasteleijn-Nolst Trenite et al., 2013).
In addition, clinical studies revealed the positive effects of H1R and H2R antagonists
in children and adolescence with ASD suffering from behavioral and sleep
disturbances (Linday, Tsiouris, Cohen et al., 2001; Rossi, Posar, Parmeggiani et al.,
1999). Again, accumulated evidence supports the implication of HS in ASD.
Additionally, a recent study revealed that impairments in social behavior was
ameliorated by H3R antagonists in rodents exposed to phencyclidine (PCP),
suggesting its therapeutic value for ASD (Griebel, Pichat, Pruniaux et al., 2012). Based
on these findings, Baronio et al. (2015) assessed for the first time the effect of
imidazole based H3R antagonist CPX in an animal model of autism induced by
prenatal exposure to VPA. The effect of acute administration of CPX (3 mg/kg) 30
minutes before the behavioral test demonstrated efficacy of improving some social
impairments and stereotypies in VPA mice. These results suggested that some of the
main clinical alterations displayed in ASD could be improved at late time stage, as at
adulthood, although at that stage when the tests were carried out many changes had
already occurred during brain development and have reached equilibrium. Regardless,
a single application of CPX was sufficient to attenuate behavioral deficits (Baronio et
al., 2015).
Although several imidazole based H3R antagonists as CPX, showed potency
and selectivity in preclinical animal experiments with oral bioavailability (Ligneau,
Lin, Vanni-Mercier et al., 1998; Stark, Sadek, Krause et al., 2000), this drug class
appeared to have poor CNS penetration and incidence of off-target activity at H4R or
other receptors. In addition, imidazole-based agents showed powerful CYP450
isoenzyme inhibitory properties developing many metabolic interactions (Berlin,
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Boyce, & Ruiz Mde, 2011; Panula, Chazot, Cowart et al., 2015; Sadek & Stark,
2016e). Consequently, medicinal chemistry efforts developed new chemical entities of
various non-imidazole H3R antagonists (Figure 3) with higher affinity and selectivity
than the imidazole based H3R antagonist.
DL77, is a novel non-imidazole H3R antagonist that strongly resembles
pitosilant in structure (Figure 4) (Sadek, Saad, Latacz et al., 2016b). In previous
studies, DL77 showed improvements in cognitive performance by exerting its action
through different

memory stages,

namely acquisition, consolidation,

and

retrieval (Sadek, Saad, Subramanian et al., 2016d). A very recent preclinical study
demonstrated that DL77 ameliorated cognitive deficits induced by the N-methyl-Daspartate (NMDA) receptor antagonist MK801 in an inhibitory passive avoidance
paradigm and in novel object recognition tests in rats (Eissa, Khan, Ojha et al., 2018).
These findings demonstrated the potential role of DL77 for treatment of
neuropsychiatric disorders associated with cognitive symptoms (Sadek et al., 2016d).
As mentioned earlier, social cognitive deficits are a hallmark characteristic of ASD
(Couture et al., 2006). Moreover, H3R antagonist DL77 provided promising
anticonvulsant activity in experimental epilepsy models (Sadek et al., 2016d). Clinical
reports estimated that approximately 20-25% of children with ASD have epilepsy
(Woolfenden, Sarkozy, Ridley et al., 2012). It was also reported in a recent population
study that 44% of children with ASD were subsequently diagnosed with epilepsy and
54% of children with epilepsy were subsequently diagnosed with ASD (Jokiranta,
Sourander, Suominen et al., 2014).
Additionally, several studies demonstrated that H3R antagonists are effective
in behavioral impairment and memory deficit in animal model of SCH (Steele,

14
Minshew, Luna et al., 2007), symptoms which are also found in patients of ASD.
However, the preclinical use of numerous non-imidazole-based H3R antagonists, e.g.
ABT-239 and A-431404, ameliorated ketamine- and/or MK-801-induced cognitive
impairments in experimental rats, demonstrating enhanced results when compared
with reference antipsychotics like risperidone or olanzapine (Brown, Whitehead,
Basso et al., 2013b).
To this end, based on the accumulation of evidences, the focus on
pharmacological evaluation of H3R antagonist DL77 with its high in-vitro H3R
affinity/selectivity and potent in-vivo H3R antagonist activity, on the ASD‐like
behavioral phenotypes in genetic (BTBR) and nongenetic (VPA induced) animal
model of ASD has been proposed.

Figure 3: Structural development from imidazole-based to non-imidazole-based
Histamine H3 receptor antagonist.
Adapted from (Sadek et al., 2016c).
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Figure 4: Structural relationship between Pitolisant and DL77.
Showing similar in vitro affinities, and in vivo antagonist potencies. a Central histamine H3R assay in
vivo after p.o. administration to mice, n=3. b [125I] Iodoproxyfan binding assay at human H3R stably
expressed in CHO-K1 cells, n=3. c[3H] Histamine binding assay performed with cell membrane
preparation of Sf9 cells transiently expressing the human histamine H4R and co-expressed with Gαi2
and Gβ1γ2 subunits, n=3. d [3H] Pyrilamine binding assay performed with cell membrane preparation
of CHO-hH1Rcells stably expressing the human H1R, n=3.
Abbreviations: H3R: H3 receptor; p.o.: peroral, CHO: Chinese hamster ovary Adapted from (Sadek et
al., 2016b; Sadek et al., 2016d).

1.3 Correlation of neurotransmitter dysfunction in ASD
Research has also focused on the study of neurotransmitters, in search of
sensitive and specific markers of ASD as well as potential therapeutic interventions.
Several central neurotransmitters (e.g., 5-HT, ACh, DA, GABA and Glu) play a role
in initial brain development and the etiology of ASD. Disruption of brain
neurotransmitters early during the development phase of the CNS may provide a
rational for pharmacological intervention that helps to cure and maybe even preclude
some of the severe behavioral symptoms of ASD. Ideally, research in genetics may be
able to explain these neurochemical defects at birth, providing possible appropriate
insight into medical treatment for infants who are at increased risk for ASD. Growing
evidence suggests that a variety of neurotransmitter systems such as ACh, 5-HT, DA,
GABA, Glu, and HA are implicated in the onset and progression of ASD -along with
genetic and environmental factors discussed below- (Bacchelli, Battaglia, Cameli et
al., 2015; Chen, Davis, Guter et al., 2017; Ellenbroek & Ghiabi, 2015; Hellings,
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Arnold, & Han, 2017; Hellmer & Nystrom, 2017; Naaijen, Bralten, Poelmans et al.,
2017; Nakai, Nagano, Saitow et al., 2017; Paval, 2017; Paval, Rad, Rusu et al., 2017;
Shah & Wing, 2006; Wang, Almeida, Spornick et al., 2015) (Figure 5).

Figure 5: Reported findings in different brains of ASD patients with altered central
transmission.
Adapted from (Eissa et al., 2018).

1.3.1 Serotonin
Among all neurotransmitters investigated so far in ASD, 5-HT has motivated
the most research efforts and investigations. 5-HT signaling facilitates several neural
processes including neurogenesis, cell migration and survival, synaptogenesis, and
synaptic plasticity. Interestingly, high 5-HT levels in the blood have been described
for up to 45% of tested ASD subjects (Chen, Penagarikano, Belgard et al., 2015; Chen
et al., 2017; Ellenbroek, August, & Youn, 2016). Moreover, preclinical investigations
using ASD-like animal models reported that hyperserotonemia significantly reduced
the motivation for social interest through inhibition of separation distress, potentially
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accounting for the social impairments found in ASD individuals (Ellenbroek et al.,
2016; Nakai et al., 2017) . Furthermore, 5-HT was found to accumulate mainly in
platelets utilizing the specific 5-HT transporter. In line with these findings, genetic
studies of linkage stated that the 17q11.2 region containing the 5-HT transporter
gene SLC6A4 polymorphisms appear to be associated with ASD, as Gly56 conversion
to Ala56 in the transporter protein resulted in autistic phenotypic features combined
with an amplified p38-mitogen-activated protein kinases (MAPK)-sensitive basal
phosphorylation process. In addition and in a previous study, higher clearance rates of
hippocampal 5-HT were observed and hence hyperserotonemia, which led to a
significant hypersensitivity of brain 5-HT (1A) as well as 5-HT (2A) receptors, social
impairment and repetitive behavior (Veenstra-VanderWeele, Muller, Iwamoto et al.,
2012) (Figure 5).
1.3.2 Dopamine
Dopamine (DA) plays a fundamental role in brain functioning, and the
pathophysiological role of dopaminergic system (DS) deficits in ASD is well
recognized, with the wide clinical use of antipsychotics that mainly target the D2
receptors (D2Rs) (Baronio et al., 2014; Seeman, 2010) Interestingly, and in a very
recent preclinical study, it has been shown that mice with increased dopaminergic
neurotransmission in the dorsal striatum via the suppression of dopamine transporter
(DAT) expression in substantia nigra neurons or the optogenetic stimulation of the
nigro-striatal circuitry exhibited significant deficits in sociability and repetitive
behaviors relevant to ASD pathology in several rodent models, while these behavioral
changes were blocked by using D1R antagonists (Lee, Kim, Kim et al., 2017).
Therefore, D1R agonists produced typical autistic-like behaviors in normal mice or the
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genetic knockout (KO) of D2Rs (Lee et al., 2017). Furthermore, the siRNA-mediated
inhibition of D2Rs in the dorsal striatum was shown to replicate ASD-like phenotypes
in D2R KO mice (Lee et al., 2017). With regard to the DS, genetic studies have
demonstrated that mutations of DS-associated genes such as the DAT (Hamilton,
Campbell, Sharma et al., 2013), DA receptors (Hettinger, Liu, Schwartz et al., 2008;
Qian, Chen, Forssberg et al., 2013), and enzymes of DA biosynthesis (Nguyen, Roth,
Kyzar et al., 2014) are implicated in ASD. These studies expanded the evidence of
genetically linking between DA transporter and ASD (Bowton, Saunders, Reddy et al.,
2014; Hamilton et al., 2013). ASD is strongly associated with a mutation in the DA
transporter gene SLC6A3, which codes for a protein that contributes to regulation of
DA levels in the brain. In fact, DAT is the crucial regulator of DA homeostasis and
alteration of this homeostasis as a consequence of DAT dysfunction is associated with
ASD and other neuropsychiatric conditions (Hamilton et al., 2013; Hellings et al.,
2017; Paval, 2017; Paval et al., 2017). Moreover, it has been found that the
dopaminergic fibers arising from the ventral tegmental area (VTA) project to the
prefrontal cortex and to regions of the limbic system, such as the nucleus accumbens
(NAcc), forming the mesocorticolimbic (MCL) circuit. This circuit was found to be
involved in high order brain functions, such as emotional social behavior, reward,
motivation and cognition (Paval et al., 2017) (Hellings et al., 2017) (Figure 5).
Notably, the DS has been related to behavioral skills belonging to executive
functioning, such as analyzing, planning and prioritizing (Baronio et al., 2014;
Seeman, 2010). In line with that, children diagnosed with ASD were found to show
deficits in tasks linked to executive functioning, including response/selection,
planning/working memory and flexibility (Hellings et al., 2017; Paval et al., 2017).
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Moreover, the DS has strongly been linked to social behavior, attentional skills and
perception, and motor activity, while developmental abnormalities in these areas have
all been linked to ASD as well (Hellings et al., 2017; Paval et al., 2017)
1.3.3 GABA and Glutamate
GABAergic as well as glutamatergic systems are also proposed as potential
mechanisms for ASD. Consequently, mutations in the respective synaptic proteins
would lead to defective neurotransmission at excitatory and inhibitory synapses,
leading to disruption of excitatory-inhibitory balance of neurotransmission in
postsynaptic neurons, a key mechanism which has strongly been associated with ASD
(Jamain, Betancur, Quach et al., 2002; Naaijen et al., 2017). In addition to numerous
reports stating the duplication of 15q11-13 locus in ASD populations, a majority of
the cases do not show mutations at this locus. However, they do exhibit abnormalities
in the expression of protein encoded by 15q11-13 gene, as reported. These results
demonstrated the involvement of 15q11-13 locus in ASD, either directly by mutation
or indirectly by epigenetic factors (Hogart, Nagarajan, Patzel et al., 2007; Nakai et al.,
2017). This site employs numerous genes coding for particular subunits of GABA
receptors, namely GABRB3, GABRA5 and GABRG3. There are numerous signalling
and scaffolding proteins which are implicated in normal development and GABA
synapse function. Therefore, mutations in the genes encoding these proteins
consequently result in GABAergic dysfunction, hence inhibitory signalling deficits.
For example, deletions in gene encoding a protein contactin-associated protein 2
(CNTNAP2) has been linked to autism (Gregor, Albrecht, Bader et al., 2011; Nord,
Roeb, Dickel et al., 2011; Stephan, 2008). Moreover, deficiency in CNTNAP2 results
in reduction in GAD1 (Glutamate Decarboxylase 1), parvalbumin and inhibitory

20
interneurons along with impairments in inhibitory signalling (Penagarikano,
Abrahams, Herman et al., 2011; Soghomonian, Zhang, Reprakash et al., 2017). This
evidence suggests an association between mutations affecting the function of GABA
and ASD. Furthermore, reduced expression of GABAergic genes and lower density of
GABA related proteins have been found in brains of ASD patients. Consequently,
alterations in GABA-A receptor genes and other genes expressed on GABA
interneurons, as well as GABA biosynthesis enzymes (GAD 65 and GAD 67) in the
cerebellum and parietal cortex, are strongly implicated in ASD (Coghlan, Horder,
Inkster et al., 2012; Fatemi, Halt, Stary et al., 2002).
On the contrary, an increased level in the expression of excitatory Glu receptor
AMPA, and of Glu transporter proteins were observed in individuals diagnosed with
ASD, with highest expression abnormalities found in the cerebellum (Purcell, Jeon,
Zimmerman et al., 2001) (Figure 5). Based on the aforementioned, altered expression
of genes related to GABA and/or Glu might be linked to several ASD phenotypic
features including cognitive deficits and/or hyperactivity (Jamain et al., 2002; Naaijen
et al., 2017). Moreover, abnormalities in both neurotransmitters including an increase
in the excitatory Glu and/or decrease in the inhibitory GABA were found to lead to
epileptic seizure, a clinical feature which is commonly observed in ASD patients
(Ballaban-Gil & Tuchman, 2000; Gillberg, Lundstrom, Fernell et al., 2017; Levisohn,
2007).
1.3.4 Acetylcholine
The brain cholinergic neurotransmission system with ACh plays an essential
role in regulating ASD-related behavioral symptoms including attention (Arnold,
Burk, Hodgson et al., 2002), cognitive flexibility (Ragozzino, Pal, Unick et al., 1998),
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social interaction (Avale, Chabout, Pons et al., 2011) and stereotypical behaviors
(Bacchelli et al., 2015; Hellmer et al., 2017; McConville, Sanberg, Fogelson et al.,
1992; Wang et al., 2015). Mounting evidence suggests the involvement of cholinergic
system dysfunction in the phenotypic outcomes of ASD-related behavioral features, in
both humans and animal models - (Karvat & Kimchi, 2014). In ASD patients, there
are remarkable abnormalities in the cholinergic system. Anatomically there is
irregularity in the number and structure of neurons in a basal forebrain cholinergic
nucleus of patients diagnosed with ASD (Kemper & Bauman, 1998). Also, a decrease
in the level of choline, the precursor of the neurotransmitter ACh and the agonist for
nicotinic-cholinergic receptor (nAChR), was determined in individuals diagnosed with
ASD (Friedman, Shaw, Artru et al., 2006), with the severity of ASD related to the
decreased level of cytosolic ACh (Sokol, Dunn, Edwards-Brown et al., 2002).
Moreover, and by using immunohistochemical analyses, abnormalities in nAChR were
observed in several brain regions (e.g. neocortex, cerebellum, thalamus and striatum)
of ASD patients, specifically with the major abnormalities being reduction in nAChR
subunits and muscarinic receptors (M1 type) (Mukaetova-Ladinska, 2017;
Mukaetova-Ladinska, Westwood, & Perry, 2010). Moreover, brain ACh like several
other brain neurotransmitters, e.g. DA, 5-HT and GABA, playing a key role in ASD
are regulated by different central mechanisms including histamine H3 hetero-receptors
(H3Rs), highlighting the potential for HS involvement in ASD. Genetically, studies
reported duplications and mutations in CHRNA7, the gene encoding the α7nAChR
subunit, in ASD patients (Leblond, Heinrich, Delorme et al., 2012), (Mikhail, Lose,
Robin et al., 2011), whereas deletion of the CHRNB2 gene, encoding the β2-subunit
of nAChR was observed in other cases (Granon, Faure, & Changeux, 2003).
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Furthermore, autism related behavior may be linked to M1 type mAChR inhibition
(McCool, Patel, Talati et al., 2008) and cholinergic cell damage (Walker, Diefenbach,
& Parikh, 2007) (Figure 5). Consequently, social deficits and repetitive behaviors are
the main phenotypic ASD features connected to disruption in cholinergic
neurotransmission system (Wang et al., 2015). Also, reduced attention (Arnold et al.,
2002), decreased cognitive flexibility (Ragozzino et al., 1998), reduced social
communications (Avale et al., 2011) and conventional behaviors have been strongly
linked to cholinergic neurotransmission dysfunction (Bacchelli et al., 2015; Hellmer
et al., 2017; McConville et al., 1992; Wang et al., 2015).
1.3.5 Histamine
As mentioned earlier, the brain HS was found to display a critical role in
cognition, sleep and other neuropsychiatric disorders including SCH and TS that share
comorbidity with ASD (Wright, Shin, Rajpurohit et al., 2017). Moreover, in addition
to the altered gene expression found for histamine-N-methyltransferase (HNMT)
enzyme , an enzyme responsible for metabolism of central histamine (HA), gene
alteration was also reported for histamine receptor subtypes H1-, H2-, and H3R
(Wright et al., 2017). Notably, there has been a rising interest in studying the role of
brain HA on behaviors in both physiological conditions and psychiatric diseases, e. g.
SCH (Sadek et al., 2016c; Sadek & Stark, 2016e). Interestingly and as revealed in
several clinical reports, patients with SCH shared a variety of common symptoms and
genetic factors with ASD (Carroll & Owen, 2009; Konstantareas & Hewitt, 2001).
Moreover, a significant role for the brain HA has been projected, and a range of several
H3R ligands has been developed so far for dual-targeting of both dopaminergic as well
as histaminergic neurotransmissions (Baronio et al., 2014; Bishara, 2010).
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Furthermore and as discussed above, deficits in regulations of various other
neurotransmitters including DA, 5-HT, GABA, and Glu are postulated (Witkin et al.,
2004). Therefore, the role of central HA which influences behavior in CNS disorders,
may be considered an important pharmacological target for therapeutic purposes (Haas
et al., 2008; Naddafi & Mirshafiey, 2013; Shan, Bossers, Luchetti et al., 2012;
Tiligada, Kyriakidis, Chazot et al., 2011). There is particular interest in brain H3Rs, as
brain H3Rs act as auto-receptors or hetero-receptors and regulate the biosynthesis and
release of HA and several other neurotransmitters, which consequently play a role in
cognitive and homeostatic processes, as shown in (Figure 2 & 5). Therefore, there is
an indirect indication that histaminergic neurotransmission may have a significant role
in SCH and that potent and selective H3R antagonists could lead to therapeutic
improvements of cognitive symptoms associated with SCH and ASD (Brown,
Whitehead, Basso et al., 2013a; Esbenshade, Browman, Bitner et al., 2008; Sadek et
al., 2016c; von Coburg, Kottke, Weizel et al., 2009; Witkin et al., 2004).
To date there are scarce literature studies concerning the association of H3R
antagonists and treatment of ASD behavioral deficits. Accordingly and in a previous
preclinical study, the imidazole-based H3R antagonists, namely thioperamide and
ciproxifan, improved impaired prepulse inhibition in an animal model of SCH (Brown
et al., 2013a) (Figure 2). Thioperamide and ciproxifan are selective and potent
imidazole-based H3R antagonists that are widely used in preclinical animal
experiments (Ligneau et al., 1998; Stark et al., 2000). (Brown et al., 2013a).
Interestingly, H3R antagonists possess antioxidant activity which could increase their
potential clinical use, since oxidative stress is, also, considered as possible mediators
of intensified symptoms of SCH and ASD (Mahmood, Khanam, Pillai et al., 2012b).
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Moreover, a study considering the effectiveness of the non-imidazole H3R antagonist
ABT-288 in the treatment of cognitive deficits linked with SCH revealed that
schizophrenic features remained constant during the whole time period of the study,
with acceptable safety, tolerability and pharmacokinetic profile of ABT-288 at a 15fold higher dose and 12-fold higher exposures in subjects with SCH than previously
observed in healthy volunteers (Coruzzi, Pozzoli, Adami et al., 2012) (Hsieh,
Chandran, Salyers et al., 2010). Moreover, the use of a H3R antagonist ameliorated
behavioral impairments in an animal model of SCH, including spatial working
memory deficit, an abnormality which also characterizes patients with ASD (Steele et
al., 2007). Also, as mentioned previously, a recent preclinical study reported that an
acute systemic administration of ciproxifan palliated some sociability impairments and
stereotypic behavior in an animal model of VPA-induced ASD in mice (Baronio et al.,
2015). However, further research efforts are still necessary to support these initial
observations and to achieve enhanced understanding of pathophysiology and
therapeutic management of ASD. Based on the aforementioned observations,
numerous brain neurotransmitters, e.g. 5-HT, DA, GABA, Glu, ACh, and HA appear
to be implicated in the pathophysiology of ASD, since disruption of genes encoding
different

proteins

(receptors

and/or

catalysing

biosynthesis

enzymes

for

neurotransmitters) that affect the respective neurotransmission functionality leads to a
variety of phenotypic features of ASD. Interestingly, the above discussed dysfunctions
of neurotransmitters, namely 5-HT, DA, GABA, Glu, ACh, and HA were, also, found
to be influentially implicated in the clinical outcome features of SCH, a disorder that
is comorbid and shares multiple aetiologies and risk factors with ASD (Chisholm, Lin,
Abu-Akel et al., 2015; Devor, Andreassen, Wang et al., 2017).
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1.4 Current pharmacological intervention
Based on the aforementioned abnormalities in genes as well as various
neurotransmitter systems, studying the effects of a given drug on core symptoms in
ASD is very challenging. Despite advances in early diagnosis and intervention,
efficacious reversal of core autistic symptoms is still not accomplished to date. At the
present time there is no definite pharmacological treatment for ASD but treatments for
ASD are based on behavioral therapies and the use of highly controlled learning
environments. The recent approaches to treatment of ASD set behavioral therapy and
atypical language development, as keystone for ASD therapy along with other
treatments that tends to ameliorate associated symptoms and not the core deficits
(Srinivasan, 2009). The heterogeneity of clinical and behavioral features in children
diagnosed with ASD contributes to the difficulty in understanding the pathophysiology
of this disorder, and consequently, no specific treatment can be effective for all ASD
children. Therefore, subgrouping of children based on responses to intervention is
essential (James et al., 2009). As mentioned above, targeting ASD core symptoms for
complete and effective treatment has been challenging and not yet achieved, however
several pharmacological medications maybe effective in various associated symptoms
that often cause significant impairments in ASD (Volkmar, Cook, Pomeroy et al.,
1999). These associated symptoms of ASD include inattention, hyperactivity, anxiety,
sleep disturbances, irritability, repetitive behavior, aggression and self-injury.
Antipsychotics are often used for therapeutic management of ASD symptoms in
children (Findling, 2005). Currently, atypical antipsychotics risperidone and
aripiprazole are the only two drugs which have so far been approved by FDA for
improving behavioral symptoms associated with ASD (Matson et al., 2011), however,
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there are several other pharmacological interventions that show effective clinical
management of ASD symptoms. The most promising drugs reported for managing
behavioral and neurological symptoms of ASD are acting on different brain targets
and are summarized in (Table 1). Accordingly, therapeutic benefits have been
observed and described with several classes of drugs including selective serotonin
reuptake inhibitors (sertraline, citalopram, fluoxetine) for anxiety and repetitive
behaviors, psychostimulant (methylphenidate) for hyperactivity, opioid antagonist
(naltrexone) for hyperactivity, and atypical antipsychotics (risperidone, olanzapine,
clozapine) for temper tantrums, aggression, or self-injurious behavior (Aman, 2004;
Kumar, Prakash, Sewal et al., 2012; Moore, Eichner, & Jones, 2004). Notably,
numerous candidates of the classes discussed below have progressed to several phases
of clinical trials.
1.4.1 Atypical antipsychotics
Clozapine belongs to the class of atypical antipsychotics because it shows
capability of binding to 5-HT and DA receptors (Chen, Bedair, McKay et al., 2001;
Gobbi & Pulvirenti, 2001; Zuddas, Ledda, Fratta et al., 1996). It is an atypical
antipsychotic medication mainly used for SCH that does not improve following use of
other antipsychotic medications. In patients with SCH and schizoaffective disorder it
may decrease the rate of suicidal behavior. It is possibly more effective than typical
antipsychotics and in patients who are resistant to other medications. Clozapine was
found to improve hyperactivity and aggression in ASD children, adolescents and
adults, but has a limited clinical use because of its hematological safety profile, the
potential to lower the seizure threshold in patients, necessitating therapeutic
monitoring of patients taking this medication (Chen et al., 2001; Gobbi et al., 2001;

27
Zuddas et al., 1996). The antipsychotic medication with risperidone is mainly used in
ASD patients with SCH, bipolar disorder, and/or irritability symptoms, as this drug
has been revealed to be superior to placebo in treating irritability, repetitive behavior,
aggression, anxiety, depression and nervousness (McCracken, McGough, Shah et al.,
2002; McDougle, Holmes, Carlson et al., 1998). Moreover, risperidone has shown a
neuroprotective effect and has enhanced the antioxidant and neuroprotective activity
of astroglia cells in brain disorders such as ASD without clinical evidence of
extrapyramidal side effects or seizures except mild sedative effects (McCracken et al.,
2002; McDougle, Holmes, et al., 1998). However, other side effects with use of
risperidone were reported to include increased appetite, fatigue, dizziness and
drowsiness (Table 1) (McCracken et al., 2002; McDougle, Holmes, et al., 1998).
Aripiprazole is another atypical antipsychotic primarily recommended for the
treatment of SCH and bipolar disorder. Other uses include an add-on treatment for
major depressive disorder, tic disorders and irritability associated with ASD. It shows
a different mechanism of action from those of the other atypical antipsychotics (e.g.,
clozapine, and risperidone) by acting rather as a partial agonist on the D2Rs and 5HT1A receptors (Hirsch & Pringsheim, 2016; Marcus, Owen, Kamen et al., 2009;
Owen, Sikich, Marcus et al., 2009). However, it displays an antagonist profile at 5HT2A and 5-HT7 receptors and acts as a partial agonist at the 5-HT2C receptor, both
with high affinity (Hirsch et al., 2016; Marcus et al., 2009; Owen et al., 2009). The
latter action may be the reason for the minimal weight gain observed during the course
of therapy with aripiprazole.
1.4.2 Neurotransmitter reuptake inhibitors
The class of neurotransmitter reuptake inhibitors, e.g. fluoxetine (selective
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serotonin reuptake inhibitor) (SSRI) has shown numerous prospective therapeutic
benefits, including decreases in rituals, stereotyped and repetitive monotonous
behaviors in ASD children and adolescents (DeLong, Ritch, & Burch, 2002; Fatemi,
Realmuto, Khan et al., 1998; Hollander, Phillips, Chaplin et al., 2005). Fluoxetine is a
SSRI which does not significantly inhibit norepinephrine and dopamine reuptake at
therapeutic doses (DeLong et al., 2002; Fatemi et al., 1998; Hollander et al., 2005). It
does, however, delay the reuptake of serotonin, resulting in serotonin persisting longer
when it is released (DeLong et al., 2002; Fatemi et al., 1998; Hollander et al., 2005).
Fluoxetine was found to produce some adverse effects including disinhibition,
hypomania, agitation, and hyperactivity (DeLong et al., 2002; Fatemi et al., 1998;
Hollander et al., 2005). Fluvoxamine is a drug which functions as a SSRI and σ1
receptor agonist (DeLong et al., 2002; Fatemi et al., 1998; Hollander et al., 2005).
Fluvoxamine is used mainly for the treatment of obsessive-compulsive disorder and is
also used to treat major depressive disorder and anxiety disorders such as panic
disorder and post-traumatic stress disorder. Notably, fluvoxamine is approved to treat
social anxiety disorder (DeLong et al., 2002; Fatemi et al., 1998; Hollander et al.,
2005). Fluvoxamine has also shown similar potential effects as fluoxetine against
autistic disorder (DeLong et al., 2002; Fatemi et al., 1998; Hollander et al., 2005). In
a clinical trial, fluvoxamine was found to be well tolerated in ASD adults and it has
improved compulsive as well as repetitive behaviors and aggression (DeLong et al.,
2002; Fatemi et al., 1998; Hollander et al., 2005). Other SSRIs, including sertraline,
paroxetine and escitalopram, showed almost the same potential benefits and adverse
effects as compared to fluoxetine and fluvoxamine (Hellings, Kelley, Gabrielli et al.,
1996; McDougle, Brodkin, Naylor et al., 1998). Venlafaxine is another SSRI which
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has, also, shown improvements of restricted behaviors, decreased interests, social
deficits, hyperactivity and communication problems in individuals with ASD
(Hellings et al., 1996; McDougle, Brodkin, et al., 1998) (Table 1).
1.4.3 Tricyclic antidepressants
The second-generation tricyclic antidepressant nortriptyline is used in the
therapeutic management of major depression and childhood nocturnal enuresis
(bedwetting), chronic fatigue syndrome, chronic pain and migraine, and labile affect
in some neurological brain disorders (Campbell, Fish, Shapiro et al., 1971; Kurtis,
1966). Clomipramine is another tricyclic antidepressant used for the treatment of
obsessive-compulsive disorder, panic disorder, major depressive disorder, and chronic
pain (Gordon, State, Nelson et al., 1993; Sanchez, Campbell, Small et al., 1996).
Interestingly, nortriptyline has been described to be effective in children with ASD as
it improved the hyperactivity, aggressiveness, and ritualized behavior, while
imipramine was not well tolerated in ASD children (Campbell et al., 1971; Kurtis,
1966). In a previous clinical trial, 58% of ASD subjects have found clomipramine to
be superior to placebo and the antidepressant desipramine in improving ASD
symptoms, anger, and compulsive and ritualized behaviors (Gordon et al., 1993;
Sanchez et al., 1996). In another clinical study, clomipramine has caused several
adverse effects such as sedation and worsening of behaviors like aggression,
irritability, and hyperactivity (Gordon et al., 1993; Sanchez et al., 1996) (Table 1).
1.4.4 Anticonvulsants
Lamotrigine, a member of the sodium channel blocking class of
anticonvulsants clinically used in the treatment of children diagnosed with epilepsy,
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decreased symptoms in approximately 62% of ASD individuals, and no considerable
change among placebo-treated and lamotrigine-treated patients was observed in a
study comprising 35 patients diagnosed with ASD (Uvebrant & Bauziene, 1994). On
the contrary, VPA with its anticonvulsant effect due toblockade of voltage-dependent
sodium channels and increased GABA levels in the brain, has shown -as an orphan
drug- valuable effects in improving various symptoms and psychiatric comorbidities,
e.g. receptive language, affective instability, and aggression, without appreciable
clinical effects on core symptoms of ASD (Jobski, Hofer, Hoffmann et al., 2017;
Uvebrant et al., 1994). Notably, VPA has been reported to be an inhibitor for histone
deacetylase (HDAC), an enzyme which plays –together with other HDACs- an
essential regulating role in gene transcription and phenotypic differentiation
(Balasubramaniyan, Boddeke, Bakels et al., 2006; Chomiak, Turner, & Hu, 2013;
Hsieh & Gage, 2004, 2005; Jessberger, Nakashima, Clemenson et al., 2007).
Accordingly, numerous studies reported that specific expression forms of HDAC1 and
HDAC2, which are categorized as class I of HDACs, in the murine brain are existent
at various developmental ages with HDAC1 expressed in neural stem cells/progenitors
and glia, and HDAC2 being upregulated in postmitotic neuroblasts and various but not
in fully differentiated glia (Chomiak et al., 2013). Therefore, modulation of HDAC in
diverse cell types and at several maturational time points may possibly lead to the
observation of intensely diverse clinical outcomes and may explain why HDAC
inhibition (for instance with VPA) in adulthood leads to improvement of ASD-like
features in animals exposed prenatally to VPA (Chomiak et al., 2013). In previous
studies, in utero exposure to VPA in mice induced ASD-like behavioral social
interaction deficits, anxiety and spatial learning incapacity (Kataoka, Takuma, Hara et
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al., 2013). However, all these behavioral impairments were ameliorated following
chronic (5-weeks) treatment with VPA (30 mg/kg/d, i.p.) (Kataoka et al., 2013;
Takuma, Hara, Kataoka et al., 2014), suggesting that dose (300-600 mg/kg for acute
induction of ASD or 30 mg/kg for chronic treatment goals) or time point (prenatal or
8-week old animals) of using VPA determines whether it is ASD-inducing or palliating
cognitive dysfunction (Takuma et al., 2014). VPA-induced ASD in rodents will be
discussed in more details under section Non-genetic Animal Models of ASD.
Moreover, the anticonvulsant drug levetiracetam was found to be valuable in
decreasing hyperactivity, impulsivity, aggression, and emotional lability (Rugino &
Samsock, 2002) (Table 1). These clinical observations for several antiepileptic drugs
demonstrate that the prevalence of psychopharmacotherapy and polypharmacy in ASD
patients is considerable, which is directed to the treatment of non-core ASD symptoms
and psychiatric comorbidities, with a lack of pharmacological treatment options for
ASD core symptoms.
1.4.5 Glutamate antagonists
Levels of glutamate have been found to be excessively increased in postmortem brain samples of some ASD individuals (Chez, Burton, Dowling et al., 2007;
Owley, Salt, Guter et al., 2006). Numerous studies have publicized the effectiveness
of several glutamate antagonists, e.g. amantadine and memantine, in ASD patients
(Chez, Burton, et al., 2007; Owley et al., 2006). In a controlled clinical trial,
amantadine showed improving effects on hyperactive behavior and inappropriate
speech in ASD children (Chez, Burton, et al., 2007; Owley et al., 2006). Also, the
clinical use of memantine in the treatment of ASD individuals has shown therapeutic
progress with regard to memory, hyperactivity, irritability, language, social behavior
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and self-stimulatory behavior (Chez, Burton, et al., 2007; Owley et al., 2006) (Table
1).
1.4.6 Acetylcholinesterase inhibitors
Dysfunction of brain cholinergic neurotransmission has been described in
several patients diagnosed with ASD (Chez, Aimonovitch, Buchanan et al., 2004;
Hardan & Handen, 2002; Nicolson, Craven-Thuss, & Smith, 2006; Niederhofer,
Staffen, & Mair, 2002; Perry, Lee, Martin-Ruiz et al., 2001). Therefore,
acetylcholinesterase inhibitor (AChEI) e.g. rivastigmine, donepezil, and galantamine,
have in many studies been investigated for the use in ASD children (Chez et al., 2004;
Hardan et al., 2002; Nicolson et al., 2006; Niederhofer et al., 2002). Interestingly, the
clinical application of rivastigmine in ASD children significantly relieved overall ASD
behaviors, however, several adverse effects including nausea, diarrhoea, hyperactivity
and irritability were reported (Chez et al., 2004; Hardan et al., 2002; Nicolson et al.,
2006; Niederhofer et al., 2002). Among AChEI, donepezil has shown capability to
improve irritability and hyperactivity of ASD children (Chez et al., 2004; Hardan et
al., 2002; Nicolson et al., 2006; Niederhofer et al., 2002). Moreover, galantamine
produced substantial improvements in hyperactivity, irritability, social withdrawal,
inappropriate speech, attention deficiency, and reduction in anger in children
diagnosed with ASD (Chez et al., 2004; Hardan et al., 2002; Nicolson et al., 2006;
Niederhofer et al., 2002) (Table 1). These improvements observed for several AChEI
strongly support the hypothesis that enhancing cholinergic neurotransmission in ASD
results in positive therapeutic effects.
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1.4.7 Psychostimulants
Methylphenidate, the most commonly known CNS stimulant widely used in
the therapeutic management of ADHD and narcolepsy, is commonly indicated for
autistic children and adolescents (Di Martino, Melis, Cianchetti et al., 2004; Handen,
Johnson, & Lubetsky, 2000; Jahromi, Kasari, McCracken et al., 2009; Kim, Shonka,
French et al., 2017). Methylphenidate mainly acts as a norepinephrine-dopamine
reuptake inhibitor. In numerous controlled studies, methylphenidate palliated several
behavior ASD features including impulsivity, attention deficiency, and hyperactivity,
but it correspondingly exhibited some initial adverse effects such as aggression,
anorexia, and increased wakefulness (insomnia) (Di Martino et al., 2004; Handen et
al., 2000; Jahromi et al., 2009; S. J. Kim et al., 2017) (Table 1).
1.4.8 Adrenergic alpha (α)2 receptor agonists
Oral or transdermal administration of selective centrally acting α2 adrenergic
agonist, e.g. clonidine, have revealed to improve mood instability, hyperactive
behavior, , aggressiveness and nervousness in ASD individuals (Fankhauser,
Karumanchi, German et al., 1992; Ming, Gordon, Kang et al., 2008). Clonidine is a
drug used to treat high blood pressure, ADHD, anxiety disorders, tic disorders,
withdrawal (from either alcohol, opioids, or smoking), migraine, and certain pain
conditions, with largely tolerable adverse effects (Fankhauser et al., 1992; Ming et al.,
2008). Also, previous clinical trials carried out with clonidine in ASD subjects have
demonstrated clinical effectiveness and safety profile in ASD and related brain
disorders (Fankhauser et al., 1992; Ming et al., 2008). Moreover, a retrospective study
revealed that the use of guanfacine, a selective α2 adrenergic receptor agonist used in
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the treatment of ADHD, anxiety, and hypertension, was accompanied with
improvements in insomnia, attention deficiency, hyperactivity and tics (Boellner,
Pennick, Fiske et al., 2007; Posey, Puntney, Sasher et al., 2004; Scahill, Aman,
McDougle et al., 2006). However, the most common adverse effects observed with
guanfacine were mood alteration fatigue, blurred vision, and headache (Boellner et al.,
2007; Posey et al., 2004; Scahill et al., 2006) (Table 1).
1.4.9 Opiate antagonists
Based on the reputed role of endogenous opioids such as β-endorphin and
encephalin in the regulation of social behavior, the opiate antagonist naltrexone has
been assessed in ASD (Bouvard, Leboyer, Launay et al., 1995; Clifford, Dissanayake,
Bui et al., 2007; Elchaar, Maisch, Augusto et al., 2006; Kolmen, Feldman, Handen et
al., 1995; Panksepp & Lensing, 1991). The results observed in numerous studies for
naltrexone showed that it might be able to treat behavioral aberrations perceived in
ASD patients and induced by dysfunction of the brain opioid system (Bouvard et al.,
1995; Clifford et al., 2007; Elchaar et al., 2006; Kolmen et al., 1995; Panksepp et al.,
1991). Moreover, numerous studies revealed the significant improvements of various
behavioral symptoms obtained with the use of naltrexone in ASD children (Bouvard
et al., 1995; Clifford et al., 2007; Elchaar et al., 2006; Kolmen et al., 1995; Panksepp
et al., 1991). Furthermore, these studies reported that naltrexone treatment provided
substantial enhancements in self-injurious behavior, hyperactivity, social withdrawal,
agitation and irritability in ASD patients (Bouvard et al., 1995; Clifford et al., 2007;
Elchaar et al., 2006; Kolmen et al., 1995; Panksepp et al., 1991) (Table 1).
The aforementioned described drugs acting at different targets are used to
therapeutically manage the behavioral as well as psychiatric symptoms of ASD.
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However, several brain regions are altered in ASD individuals, resulting in loss of
neuronal function, and behavioral and sensory impairments, including inattention,
hyperactivity, mood fluctuations, aggressiveness, agitation, social deficits and
repetitive and restricted behavior. In the brain, the plasticity of brain tissue, nerve
connections and balance of several neurotransmitters are all implicated in
pathophysiology of ASD individuals. Apart from environmental factors, other
pathological conditions such as autoimmunity, chronic neuroinflammation, oxidative
stress, mitochondrial dysfunction are involved in etiopathogenesis of ASD (Kumar et
al., 2012).
Up until now, there is no approved drug existing in the market, which is
specific for treating symptoms associated with ASD, however, preclinical and clinical
research and development are in progress to find new therapeutic entities. Currently,
there are several candidates that successfully passed different clinical phases of drug
development, with different pharmacological targets to modulate ASD behavioral and
neurological symptoms. Interestingly, 10% of these clinical candidates are currently
in phase 1, 46% have already progressed to phase 2, 27% advanced to phase 3, and
15% reached to phase 4 of clinical development, whereas 2% are currently of
preclinical interest (Ruhela, Prakash, & Medhi, 2015)
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Table 1: Selected medications of different classes that are currently used to manage different symptoms of ASD

Atypical Antipsychotics

Class

Medication
Clozapine

Pharmacological effects
Improves hyperactivity and aggression in ASD
patients

Side effects
Requires patient’s
haematological safety
monitoring and it lowers
seizure threshold

Reference
(Chen et al., 2001; Gobbi
et al., 2001; Sahoo,
Padhy, Singla et al.,
2017; Zuddas et al.,
1996)

Reduces irritability, repetitive behavior, aggression,
anxiety, and depression & nervousness. It shows
neuroprotective activity, modulates astroglia
function, and increases the brain antioxidant activity.

Mild sedation, increased
appetite, fatigue, dizziness,
drowsiness, tremor, and
constipation

(Hara, Ago, Taruta et al.,
2017; McCracken et al.,
2002; McDougle,
Holmes, et al., 1998)

Reduces autistic symptoms in children such as
irritability, stereotypy, and hyperactivity
Reduces stereotyped and repetitive behavior in
children and adolescents with ASD.

Fatigue, vomiting, weight
gain, tremor, and
extrapyramidal symptoms
Hypomania. agitation, and
hyperactivity

(Hirsch et al., 2016;
Marcus et al., 2009;
Owen et al., 2009)
(DeLong et al., 2002;
Fatemi et al., 1998;
Hendriksen, Klinkenberg,
Collin et al., 2016;
Hollander et al., 2005)

Improves compulsive repetitive behaviors,
aggression

Irritability, and increase
risk of suicidal ideas

Risperidone

Aripiprazole

Fluoxetine

Selective Serotonin Reuptake
inhibitor (SSRI)

Structure

Fluvoxamine

(Brown, Eum, Cook et
al., 2017; Howes,
Rogdaki, Findon et al.,
2018; Lee, Kim, Kim et
al., 2018; Martin, Koenig,
Anderson et al., 2003;
McDougle, Naylor,
Cohen et al., 1996)
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Table 1: Selected medications of different classes that are currently used to manage different symptoms of ASD (continued)
Class

Medication

Selective Serotonin Reuptake inhibitor (SSRI) (Continued)

Sertraline

Paroxetine

Structure

Pharmacological effects

Side effects

All SSRIs possess similar effects to fluoxetine and
fluvoxamine. Sertraline shows improvements in
repetitive and disruptive behavior in adults with
ASD, paroxetine reduced aggression, and
escitalopram shows improvements in irritability,
stereotypy, hyperactivity and inappropriate speech.

References
(AlOlaby, Sweha,
Silva et al., 2017;
Hellings et al., 1996;
McDougle, Brodkin, et
al., 1998)

Escitalopram

(Davanzo, Belin,
Widawski et al., 1998;
Hellings, Reed, Cain et
al., 2015)

Venlafaxine

(Brown et al., 2017;
Owley, Walton, Salt et
al., 2005; Viktorin,
Uher, Reichenberg et
al., 2017)

Improves restricted behavior & interest, social and
communication deficits, and hyperactivity

Irritability, and increase
risk of suicidal idea

(Carminati, Deriaz, &
Bertschy, 2006;
Carminati, Gerber,
Darbellay et al., 2016)
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Table 1: Selected medications of different classes that are currently used to manage different symptoms of ASD (continued)

Anticonvulsants

Tricyclic Antidepressant

Class

Medication
Nortriptyline

Structure

Pharmacological effects
Improves hyperactivity and aggressiveness in
autistic children

Side effects
Sedation, increase in aggression,
irritability and hyperactivity

Clomipramine

Improves anger and compulsive and
ritualized behavior

Lamotrigine

Improves overall autistic symptoms

Life-threatening skin reactions,
including Stevens-Johnson
syndrome, drug reaction with
eosinophilia and systemic
symptoms, and toxic epidermal
necrolysis

Valproic acid

Improves receptive language, affective
instability, aggression, and social skills

Irritability, weight gain, anxiety

Levetiracetam

Decreases symptoms such as hyperactivity,
impulsivity, aggression, and affective lability

CNS effects such as somnolence,
decreased energy, headache,
dizziness, mood swings and
coordination difficulties

Reference
(Campbell et al., 1971;
Hong, Lee, Han et al.,
2017; Kurtis, 1966)

(Gordon et al., 1993;
Hong et al., 2017;
Sanchez et al., 1996)

(Jobski et al., 2017;
Uvebrant et al., 1994)

(Anagnostou, Esposito,
Soorya et al., 2006;
Hollander, Chaplin,
Soorya et al., 2010;
Hollander, Soorya,
Wasserman et al., 2006;
Jobski et al., 2017)
(Jobski et al., 2017;
Rugino et al., 2002)
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Table 1: Selected medications of different classes that are currently used to manage different symptoms of ASD (continued)
Class

Medication

Glutamate antagonist

Amantadine

Pharmacological effects
Improves hyperactivity and speech
disturbance

Memantine

Rivastigmine

Acetylcholine esterase inhibitors

Structure

Improves memory, hyperactivity,
irritability, social behavior and
communication, and self-stimulatory
behavior
Improves overall autistic behavior

Improves irritability and hyperactivity
Donepezil

Galantamine

Improves several autistic symptoms in
children such as irritability, hyperactivity,
social interaction deficits, inappropriate
speech, loss of attention, and anger

Side effects

Reference

Nervousness, anxiety,
agitation, insomnia, difficulty
in concentrating, and
exacerbations of pre-existing
seizure disorders and
psychiatric symptoms in
patients with SCH or PD

(King, Wright, Handen et al.,
2001; Naaijen et al., 2017)

Few autistic individuals
experienced worsening of
autistic symptoms
Nausea, diarrhoea,
hyperactivity, and irritability

Nausea and vomiting,
decreased appetite and weight
loss

(Chez, Burton, et al., 2007;
Naaijen et al., 2017; Owley et
al., 2006; Vorstman, Parr,
Moreno-De-Luca et al., 2017)
(Vorstman et al., 2017)

(Hardan et al., 2002;
Vorstman et al., 2017)

(Nicolson et al.,
Niederhofer et al.,
Vorstman et al., 2017)

2006;
2002;
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Table 1: Selected medications of different classes that are currently used to manage different symptoms of ASD (continued)
Structure

Pharmacological effects

Side effects

Reference

Methylphenidate

Improves several autistic behavioral symptoms in
children and adolescents such as hyperactivity,
impulsivity, attention, social communication, and
self-regulation

Anorexia,
aggression, and
insomnia

(Di Martino et al., 2004; Handen et al.,
2000; Jahromi et al., 2009; S. J. Kim et
al., 2017)

Clonidine

Improves hyperactivity, mood fluctuation,
aggressiveness and agitation, sleeping pattern and
night time awakenings

Sedation, dry
mouth, and
hypotension

(Fankhauser et al., 1992; Ming et al.,
2008; Nash & Carter, 2016)

Guanfacine

Improves attention, hyperactivity, and tics

(Boellner et al., 2007; Nash et al., 2016;
Posey et al., 2004; Scahill et al., 2006)

Naltrexone

Improves, hyperactivity, irritability, selfinjuries. However, ineffective in social deficits.

Insomnia, fatigue,
blurred vision,
mood instability,
sedation,
constipation,
irritability, and
aggression.
Gastrointestinal
complaints such as
diarrhoea and
abdominal
cramping.

Opiate
antagonist

Psychostimulant

Medication

Adrenergic α2 receptor agonists

Class

(Bouvard et al., 1995; Clifford et al.,
2007; Elchaar et al., 2006; Kolmen et
al., 1995; Nash et al., 2016; Panksepp et
al., 1991)
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1.5 Animal models of ASD
For the understanding of the aetiology and pathogenesis of any human disease,
e.g. ASD, experimental rodent models are of substantial meaning. Modelling of human
neuropsychiatric diseases with animals is very challenging due to the multifaceted
nature of these disorders, combined with the absence of effective diagnostic
biomarkers and objective tests for accurate diagnosis (Nestler et al., 2010). Moreover,
neuropsychiatric diseases, such as ASD, are multifactorial with genetic, medical and
neurodevelopmental conditions associated with the disease (Masi, DeMayo, Glozier
et al., 2017; Medline Â, 2016). Generally, there are two types of rodent models for
ASD, namely the genetic and non-genetic animal models. Accordingly, ASD genetic
animal models are highly applicable when they reproduce the ASD features that are
existent in an individual human genetic disease such as tuberous sclerosis and fragile
X syndrome. Therefore, the ASD genetic models induced in mice should be
established on an identified genetic cause of a disease, reflect key aspects of the human
symptoms and respond to pharmacotherapies that are operational in the human
diseases (Chadman, Yang, & Crawley, 2009).
1.5.1 Genetic animal models of ASD
A considerable advancement in detecting the genetic basis of several human
diseases has been achieved by geneticists. These achievements include AD,
Huntington's disease, and some forms of breast cancer. However, more difficulties
were associated with the detection of genetic factors for multifaceted diseases such as
SCH, diabetes, bipolar disorder, and also ASD (Fregeac, Colleaux, & Nguyen, 2016;
Hu, Ehli, & Boomsma, 2017; Narahari, Hussain, & Sreeram, 2017; Wei, Yuan, Liu et
al., 2015). In the case of ASD, extensive research efforts elucidated underlying
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mechanisms of the disorder and concluded that these mechanisms might include
dysfunctions of neuronal microRNAs (miRNAs), which are regulators of gene
expression, and which have gained much attention in pathophysiology of various
psychiatric illnesses (Andolina, Di Segni, & Ventura, 2017). Accordingly, about half
of all identified miRNAs in humans are expressed in the CNS and exhibit modulatory
functions crucial for numerous biological processes associated to the development of
the CNS (Hu et al., 2017). Consequently, disruptions in miRNA biogenesis and
miRNA-target interaction have been linked with CNS diseases, including ASD (Hu et
al., 2017). Moreover, three miRNA (miRNA-7, miRNA-9, and miRNA-106b) were
found to be associated with neurodegenerative diseases and only one, namely miRNA9, with intellectual disability (Doxakis, 2010; Y. Hu et al., 2017; Wang, Liu, Zong et
al., 2010; Xu, Zong, Li et al., 2011). Furthermore, it was recognized that the
intellectual disability in Down syndrome which is a neurodevelopmental disorder, was
caused by an extra-copy of chromosome 21 (Lejeune, Gautier, & Turpin, 1959).
However, it is now being firmly established that deletions in the chromosome 21 are
commonly discovered in some patients with intellectual disability including ASD
(Hogart, Wu, LaSalle et al., 2010). Similarly, increased risk of delayed development,
intellectual disability and neurological as well as psychiatric problems associated with
ASD, SCH, epilepsy and hypotonia was found to be the result of micro deletions in
the long (q) arm of the chromosome in a region designated q21.1 (Knight, Regan,
Nicod et al., 1999; Mefford, Cooper, Zerr et al., 2009; Ravnan, Tepperberg,
Papenhausen et al., 2006). Moreover, chromosome 15 has been described to be as one
of several chromosomes enriched in segmental low copy repeats or duplicons (Bailey,
Gu, Clark et al., 2002). These duplicons were revealed to strongly contribute to a
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mechanism in which low copy repeats facilitated misalignment during meiosis I,
leading to unequal recombination of nonallelic homologous and developing a sequence
of common cut-off point along the 15q11.2-q13 region (Christian, Fantes, Mewborn
et al., 1999; Robinson, Bernasconi, Mutirangura et al., 1993; Robinson, Binkert, Gine
et al., 1993; Robinson, Spiegel, & Schinzel, 1993). Previous reports suggested, also,
several cases of ASD with cytogenetic abnormalities in the 15q11–13 region (Cook,
Courchesne, Cox et al., 1998), and the frequency of cytogenetic abnormalities in this
region was found to be around 0-3% in ASD, and in fact, the most frequent cytogenetic
abnormality in this population (Lord, Cook, Leventhal et al., 2000). Moreover, it has
been reported that the paternal inheritance of a cytogenetical abnormality leads to a
normal phenotype; maternal inheritance leads to autism or atypical autism (Tabet,
Verloes, Pilorge et al., 2015). Furthermore, previous efforts revealed that 16p13.1
micro duplication syndrome is caused by interstitial duplications encompassing
16p13.1, which is a risk factor for a range of neuropsychiatric disorders, including
ASD, intellectual disability, SCH, and ADHD (Grozeva, Conrad, Barnes et al., 2012;
Mefford et al., 2009; Ramalingam, Zhou, Fiedler et al., 2011; Ullmann, Turner,
Kirchhoff et al., 2007). There are, also, monogenic diseases that have been associated
with ASD and display its characteristic features:

tuberous

sclerosis, fragile X

syndrome, Rett syndrome and neurofibromatosis 1 (Hulbert & Jiang, 2016; Wetmore
& Garner, 2010). Accordingly, single gene mutation gave rise to several human
syndromes leading to an increase in the risk for developing ASD. Moreover, autistic
traits are also connected to copy-number variants that lead to inheritance of maternal
15q11–13 duplication, resulting in Prader-Willi syndrome (Ogata, Ihara, Murakami et
al., 2014). Furthermore, the developed strategies for the identification of genetic

44
variants has led to the description of novel syndromic forms of ASD and facilitated an
understanding of the relationship between genetic traits and phenotype. Consequently,
these genetic dissimilarities identified so far, along with the newly developed strategies
for genetic engineering, improved the expansion of genetic animal models for ASD.
Accordingly, mice are the major animal model for ASD due to their genetic
manipulability and their capacity to show behavioral deficits associated with ASD
features (Chen et al., 2015). Moreover, construct as well as face validity of mice ASD
animal models together with the availability of well-established techniques to
manipulate their genome and study brain function at numerous levels of analysis
contribute to the overall validity of mouse models (Hulbert et al., 2016). Also, mice as
mammals are genetically and biologically similar to humans, however, their rapid
reproduction and accelerated development allow for the testing of large numbers of
animals at a relatively low cost (Hulbert et al., 2016). Accordingly, animal models for
genes of a syndromic disorder were commonly found to present autistic traits including
Fragile X (FMR1) with social interaction deficits, hyperactivity, and cognitive
impairments (Bhattacharya, Kaphzan, Alvarez-Dieppa et al., 2012; Y. Hu et al., 2017;
Hulbert et al., 2016; Ronesi, Collins, Hays et al., 2012; Willem Verhoeven, 2011), Rett
syndrome and MECP2 mutations with the resulted repetitive and stereotypic/restricted
behaviors, abnormal gait and reduced anxiety, decreased pain and normal olfactory
discrimination (Chao, Chen, Samaco et al., 2010; Samaco, McGraw, Ward et al.,
2013). Other common syndromic disorder with ASD phenotype include tuberous
sclerosis TSC1 or TSC2 with social interaction deficits and repetitive/restricted
behavior or interest (Chao et al., 2010; Willem Verhoeven, 2011), Timothy syndrome
(TS) CACNA1C with impairments in social interactions, repetitive/stereotypic
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behaviors, and increased fear conditioning (Ergaz, Weinstein-Fudim, & Ornoy, 2016)
and Phelan-McDermid syndrome with restricted interest as well as cognitive and
motor deficits (Ergaz et al., 2016; Giza, Urbanski, Prestori et al., 2010) In addition to
PTEN mutations and Cortical dysplasia focal epilepsy with deficits in social
interactions, restricted interest, sensory sensitivity, elevated anxiety, and seizures
(Scott-Van Zeeland, Abrahams, Alvarez-Retuerto et al., 2010)(Cook & Scherer, 2008;
LaSalle, Reiter, & Chamberlain, 2015; Piochon, Kloth, Grasselli et al., 2015). All
behavioral features of the above described syndromes are associated with ASD.
Numerous inbred mouse strains show face validity as ASD models in addition to the
genetically modified animal models of ASD. As such inbred strains display robust and
well-replicated social deficits and repetitive behaviors (Kazdoba, Leach, Yang et al.,
2016). These inbred strains are found to display idiopathic autism, as their ASDrelevant behaviors are not caused by known genetic mutations (Kazdoba et al., 2016).
For instance and while assessing sociability, inbred strains like A/J, BALB/cByJ
(BALB), BTBR T+Itpr3tf/J (BTBR), C58/J (C58), and 129S1/SvImJ mice showed
lack of sociability, as compared to inbred mouse strains with high sociability, such as
C57BL/6J (B6) and FVB/NJ mice (Brodkin, 2007; Y. Hu et al., 2017; Kazdoba et al.,
2016; McFarlane, Kusek, Yang et al., 2008; Moy, Nadler, Poe et al., 2008; Moy,
Nadler, Young et al., 2007). Moreover, it has been shown that several mouse strains,
e.g. BTBR and C58, also demonstrate explicit motoric stereotypies or repetitive
behaviors, such as jumping, digging, and high levels of self-grooming and marble
burying (Kazdoba et al., 2016; Pasciuto, Borrie, Kanellopoulos et al., 2015).
1.5.2 Non-genetic animal models of ASD
Environmental animal models are induced by prenatal exposure of pregnant
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animals to certain chemical compounds, infections, or inflammations. The
environmental inducing factor is only of significance if the chemicals used in the
animal model cause the same effects in humans. Accordingly, the antiepileptic drug,
VPA was found to significantly increase the ASD degree in offspring of treated
mothers (Christianson, Chesler, & Kromberg, 1994; Moore, Turnpenny, Quinn et al.,
2000), and similarly showed to induce ASD-like behaviors in mice and rats (Anshu,
Nair, Kumaresan et al., 2017; Nicolini & Fahnestock, 2017; Rodier, Ingram, Tisdale
et al., 1997). Therefore, the ASD-like animal model induced by in utero exposure to
the anticonvulsant drug VPA has been well established and recognized to study ASD
features (Nicolini et al., 2017). Moreover, the immunomodulatory drug thalidomide,
which was used by pregnant women in the 1950s, was revealed to be associated with
a marked escalation in the incidence of ASD in their offspring (Stromland, Nordin,
Miller et al., 1994). Furthermore, several reports revealed that methylmercury, which
is formed from inorganic mercury by the action of microbes that live in aquatic systems
including lakes, rivers, wetlands, sediments and soils, exposure during childhood
caused a variety of neuropsychological abnormalities, e.g. memory, attention and
language, (Davidson, Cory-Slechta, Thurston et al., 2011; Falluel-Morel, Sokolowski,
Sisti et al., 2007; Grandjean, Budtz-Jorgensen, White et al., 1999). Also, a previous
study has shown that acute systemic administration methylmercury during
developmental phases elicited hippocampal cell death, reductions in neurogenesis, and
severe learning impairments (Grandjean et al., 1999). Thimerosal was a widely used
preservative in numerous biological and drug products since 1930s, including many
vaccines. It is a mercury-containing organic compound which contains ethyl mercury,
a compound supposed to be the cause of several adverse neurodevelopmental deficits,
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including ASD (Hviid, Stellfeld, Wohlfahrt et al., 2003). Also, a previous study in
which 10,000 cases have been examined showed that there is a significant association
between maternal viral infection in the first trimester and ASD in the offspring
(Atladottir, Thorsen, Ostergaard et al., 2010). Indeed, when animals were exposed to
the maternal immune activation with polyinosine: cytosine (poly I:C) at embryonic
day 9.5, the offspring displayed histological and behavioral abnormalities that
resembled ASD (Garay, Hsiao, Patterson et al., 2013; Hsiao, McBride, Chow et al.,
2012; Shi, Smith, Malkova et al., 2009). On behavioral level, these animals
demonstrated impaired sociability, communication differences and increased
repetitive stereotyped behaviors and had smaller brain sizes at birth, followed by
macroencephaly in adulthood. In line with these observations, it has been shown that
viral infections in the mother can prompt substantial changes in the immune system in
both mother and fetus, leading to long-term epigenetic alterations in the offspring
(Kong, Frigge, Masson et al., 2012). Consequently, the timing of immune insults
during developmental phase may be one source of the heterogeneity in the phenotypic
features observed in ASD (Kong et al., 2012). Accordingly, male rats treated with
thalidomide/VPA demonstrated immunological changes such as decreased splenocyte
proliferative response to mitogenic stimulation, lower thymus weight, and decreased
interferon (IFN)-𝛾/IL-10 ratio in peritoneal macrophages, whereas female rats in this
study failed to show many of these behavioral and immunological changes, indicating
that sex-specific responses to some environmental factors might play a significant role
on the phenotypic outcomes of several ASD features (Schneider, Roman, Basta-Kaim
et al., 2008). Also and subsequent to viral infection, the immune response was found
to produce various cytokines, such as (IL)-1, -2 and -6 which modulate the release of
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several monoamines such as 5-HT in the hippocampus and other brain regions
(Libbey, Sweeten, McMahon et al., 2005). Indeed, maternal infection was found to
lead to elevated levels of cytokines and chemokines including IL-1𝛽, IL-6, IL-8, and
IL-12p40 in the plasma of ASD children, and such increases were reported to be
associated with more reduced communication skills and abnormal behaviors
(Patterson, 2012). Also, the offspring of infected animal mothers given poly (I:C)
exhibited both ASD-like behavioral and neuropathological deficits as described above
(Gadad, Hewitson, Young et al., 2013; Garay et al., 2013; Hsiao et al., 2012; Patterson,
2012; Shi et al., 2009). Based on the aforementioned results, environmental influences
both during and after pregnancy can significantly influence the immune system and
the developing nervous system to play a role in constructing several
neurodevelopmental disorders including ASD.
It should be stressed that experimental animal models (genetically manipulated
animal models, animal models obtained by destruction of certain CNS areas, and
animal models obtained by using maternal factors) are indispensable for exploring the
pathophysiologic causes of brain disorders, e.g. ASD, although they do not reflect the
entire state of ASD disease. Moreover, animal models (mostly rodents) are widely
used to study the development of cortical neurocircuit, genetic analysis and molecular
mechanisms underlying ASD, and the palliative effects of newly developed drugs on
core as well as associated symptoms of ASD. Furthermore, genetic as well as nongenetic rodent models have the capability of being the major objects of pharmaceutical
industry in testing drug efficacy, dosage and acute as well as (sub)chronic toxicology.
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1.6 Neuroinflammation and ASD
Neuroinflammation is a response that involves neurons, microglia and
macroglia, which are cells that are present in the CNS (Bradl & Hohlfeld, 2003;
Carson, Doose, Melchior et al., 2006). Neuroinflammation has been reported to be an
important feature of many neurodegenerative disease and neuropsychiatric conditions
such as multiple sclerosis, AD, PD, narcolepsy and ASD (Carson, Thrash, & Walter,
2006; Frick et al., 2016). Implication of the role of inflammation in aetiology of ASD
was based on evidence and medical history of autistic individuals that show signs of
neuroinflammation, altered inflammatory responses and immune abnormalities
throughout life. This is confirmed by increasing clinical and experimental evidence
that links immune and inflammatory alterations with the pathogenesis of ASD
(Lucchina & Depino, 2014). Moreover, post mortem studies have supported this
evidence and have shown neuroinflammation in several brain regions of patients with
ASD (Vargas, Nascimbene, Krishnan et al., 2005). Microglia as the brain’s resident
inflammatory cells have critical role in mediating neuroinflammation and regulation
of brain development and homeostasis. In fact, they play critical role in defence and
tissue repair. Microglia activation is the first sign of neuroinflammation, and
abnormalities in microglia have been implicated in autism (Carson et al., 2006; Frick
et al., 2016). After being activated they may cause neuronal dysfunction and cell death
(neurodegenerative role). Activated microglia roundup, proliferate, migrate,
phagocytes, present antigens to T-cells, release a variety of oxidants such as reactive
oxygen species (ROS), and activate several genes and proteins, such as inducible nitric
oxide synthase (iNOS), cyclooxygenase1 (COX1), cyclooxygenase2 (COX2), and
variety of proinflammatory cytokines including IL-1β, tumor necrosis factor alpha
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(TNF-α) (Figure 6), and that is what is notably observed in autism (Monnet-Tschudi,
Defaux, Braissant et al., 2011). In chronic neuroinflammation, microglia remain
activated for long periods, with continuous release of cytokines and neurotoxic
molecules that contribute to loss of synaptic connections and neuronal death (Lyman,
Lloyd, Ji et al., 2014). Chronic or excessive neuroinflammation is diagnosed in ASD
(Kern et al., 2015), this observed chronic glia activation and altered inflammatory
function maybe partly responsible for the observed behavioral features in ASD, as
chronic peripheral inflammation and abnormal inflammatory responses in the brain
may lead to cognitive dysfunction (Lucchina et al., 2014).

Figure 6: Schematic depiction of microglia activation neuronal cell death.
Neuroinflammatory proteins and cytokines due to microglia activation by genetic and different
environmental activators, leading to neuron dysfunctions and cell death. Adapted from (Shabab,
Khanabdali, Moghadamtousi et al., 2017).

During pregnancy, both environmental and genetic risk factors may affect
inflammatory response of new-borns, hence altering postnatal brain development
(Adams-Chapman & Stoll, 2006). These genetic and environmental factors can
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directly elicit chronic neuroinflammation which in turn may modulate neuronal
function and immune response through glia activation, or directly through affecting
neuronal function (Depino, 2013) (Figure 7). VPA as an environmental risk factor
showed activation in different brain regions, with evidence of long-lasting glia
activation in hippocampus and cerebellum (Lucchina et al., 2014). Hippocampus
(Depino, Lucchina, & Pitossi, 2011) and cerebellum (DeLorey, Sahbaie, Hashemi et
al., 2008; Martin, Goldowitz, & Mittleman, 2010) are two brain regions linked to
autism-related behavior, namely social interaction and repetitive behaviors.
Additionally, several studies showed that cerebellar inflammation may alter social
behavior in adult mice as cerebellum is involved in executive and cognitive functions
(Koziol, Budding, Andreasen et al., 2014; Lucchina et al., 2014; Shi et al., 2009;
Wang, Kloth, & Badura, 2014). Furthermore, evidence suggests that astrocyte and
microglia activation in cortex and cerebellum increase expression of cytokines
including IL-6, TNF-α, MCP-1, TGF-β1, IFNγ, IL-8 and other associated genes
involved with the immune response in different brain regions of autistic subjects
(Chez, Dowling, Patel et al., 2007; Chez & Guido-Estrada, 2010; Garbett, Ebert,
Mitchell et al., 2008; Li, Chauhan, Sheikh et al., 2009; Vargas et al., 2005).
Alternatively, both these environmental and genetic factors, could chronically alter
immune response through increasing production of free radicals, which consequently
activate glia cells, increasing inflammatory response, affecting neurons, mediating
clinical symptoms of autism (Depino, 2013). These findings suggest that
neuroinflammation may contribute to ASD behavioral effect, hence, controlling
microglia activation and inhibiting cytokine and free radical production would be a
therapeutic strategy for treating ASD.
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Figure 7: Effect of genetic and environmental factors on neuronal dysfunction and
immune response modulating ASD symptoms.
All possibilities contributing to ASD through glia activation (grey arrow), or through directly altering
peripheral immune cells (white arrows) which in turn activates glia affecting the neuronal function
(black arrows). Adapted from (Depino, 2013).

The emergence that the HS may be implicated in ASD and may contribute in
ameliorating its core symptoms, necessitates further research to investigate what role
the HS may or may not have in enhanced neuroinflammation in ASD. Possible role of
central histamine as regulator of neuroinflammatory processes has received scant
attention, but lately the potential importance of HA regulation of microglia (Rocha et
al., 2014) was highlighted by the fact that both HA and microglial dysregulation are
implicated in neuropsychiatric disease states such as TS and a range of
neurodegenerative syndromes. Recent finding of microglial abnormalities in the HDC
knockout mouse, a validated model of the pathophysiology of TS (Baldan, Williams,
Gallezot et al., 2014), further emphasizes the importance of understanding HA’s role
in regulating microglial function, especially that TS and ASD have a high degree of
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overlap. An in vitro study demonstrated that all known histamine receptors are
expressed on microglia cells (Ferreira et al., 2012). Another experimental study
suggested a role for histamine in the modulation of microglial inflammatory response,
demonstrating a dual role of histamine in neuroinflammation regulation, mediated by
activated microglia, through modulating cell recruitment and proinflammatory
cytokine release, as IL-1β and TNF-α (Ferreira et al., 2012).
A growing understanding of histamine has shed light on the possibility of
targeting histamine for therapeutic use to treat CNS disorders associated with
microglia-derived inflammation. A very recent study demonstrated the dual role of
histamine in the modulation of microglial responses, suggesting that while histamine
per se can induce microglia injurious effects, oppositely under inflammatory context,
it can inhibit them (Barata-Antunes, Cristovao, Pires et al., 2017a), opening a new
perspective for the therapeutic use of histamine to improve inflammation-associated
processes in disorders associated with microglia- derived inflammation. The role of
H3R antagonist in stimulating the synthesis and release of histamine in brain, as
mentioned earlier, suggest that therapeutic use of H3R antagonists may ameliorate
neuroinflammation and consequently, improve ASD behavioral symptoms. Moreover,
the antioxidant effect of H3R antagonist, as demonstrated by (Mahmood et al., 2012b;
Mani, Jaafar, Azahan et al., 2017) strongly suggest that H3R antagonist may have
therapeutic potential in the management of ASD.
1.7 Aims and Objectives
Based on all aforementioned evidences and results from our lab, H3 receptor
(H3R) antagonists are considered potential therapeutic agents for the management of
different brain disorders associated with cognitive impairments. Accordingly, the
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hypothesis of my PhD research project is that targeting the brain histaminergic system
using H3R antagonists may be new therapeutic agents for reversing core deficits of
ASD, using different mouse models of ASD.
The primary focus of this study is to investigate the effects of sub-chronic
treatment of non-imidazole H3R antagonists (DL77) on autistic-like animal’s
behaviors, mainly sociability and social novelty preference deficits, repetitive/
compulsive-like behaviors, abnormal anxiety, hyperactivity through a battery of
standard behavioral tests. Another objective of the research is to study the role and
implications of the histaminergic system in neuroinflammation and oxidative stress
levels, which have been associated with ASD as mentioned earlier. This is approached
by determining the effects of DL77 on levels of neuroinflammatory and oxidative
stress markers using various experimental approaches in mice brain tissues.
Finally, accumulation of evidence as mentioned above suggested the
implicates a variety of neurotransmitter systems such as ACh, 5-HT, DA, GABA, Glu,
and HA in the onset and progression of ASD. In view of that, recent advances of
developing novel agents with multiple pharmacological effects have become a
promising strategy for treatment of diseases of a multifactorial nature, such as ASD.
Therefore, we were interested to investigate the effects of novel dual-active ligand
E100 with histamine H3 receptor (H3R) antagonist affinity (hH3R Ki = 203 nM) and
acetylcholine esterase inhibitory effect (EeAChE IC50 = 1.93µM and EqBuChE
IC50 = 1.64 µM) on autistic-like behavioral parameters, oxidative stress, and
neuroinflammation in male C57BL/6 mouse model of ASD induced by prenatal
exposure to valproic acid (VPA, 500 mg/kg, i.p.) and in BTBR mice.
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Chapter 2: Methods
2.1 Animals
Three mice strains at 8 weeks of age were used in this study, Tuck-Ordinary
(TO) mice (Harlan, UK), C57BL/6 (C57) and BTBR T+tf/J (BTBR) mice (Jackson
Laboratory, Bar Harbor, USA). BTBR is a genetic animal model of autism. It is an
inbred strain that naturally exhibits several behavioral symptoms of autism. All mice
were bred in the local central animal facility of the College of Medicine and Health
Sciences, United Arab Emirates University (Bastaki, Abdulrazzaq, Shafiullah et al.,
2018). They were housed in plastic cages under a standard light/dark cycle (12 h
dark/light cycle, lights at 6 a.m.) at a constant temperature of 22–25°C, with free access
to tap water and a standard rodent chow diet.
2.2 Establishing VPA animal model of autism
Mice were kept for mating. Female mice were observed daily and placed in a
separate cage when pregnancy was confirmed by the presence of a vaginal plug. This
day was considered embryonic day 0 (E0). On E12.5, pregnant females were i.p.
injected i.p with VPA 500 mg/kg (Sigma-Aldrich, St. Louis, MO, USA) dissolved in
isotonic 0.9% sodium chloride solution, and control mice were injected with saline, as
previously described (Kataoka et al., 2013; Takuma et al., 2014). The day of delivery
was defined as postnatal day 0 (P0). All offspring were weaned, sex-grouped (5–6
mice/cage) at P 21. Pups from VPA-exposed mothers were considered as the VPA
mouse model of autism and were used for experiments at8 weeks of age. On the other
hand, pups for mothers exposed to saline were used as control mice. TO and C57 VPA
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mouse model of autism were developed by this method and all the tests were carried
out on both strains.
2.3 Drugs and chemicals
Two H3R antagonists were used in this study. DL77 [1-(3-(4-tertpentylphenoxy) propyl) piperidine] and E100 [1-(7-(4-chlorophenoxy) heptyl) homopiperidine] (Figure 8). Both compounds were designed and synthesized in the
Department of Technology and Biotechnology of Drugs Krakow, Poland, according
to a previously described procedure (Kuder, Łażewska, Latacz et al., 2016; Lazewska,
Jonczyk, Bajda et al., 2016; Lazewska, Ligneau, Schwartz et al., 2006) and were
provided to us. Sodium valproate (VPA) (500 mg/kg, i.p.), donepezil hydrochloride
(DOZ) (1 mg/kg, i.p.) (reference drug), the H3R agonist R-α methyl histamine (RAM)
(10 mg/kg, i.p.), the brain-penetrant H1R antagonist pyrilamine (PYR) (10 mg/kg,
i.p.), the brain-penetrant H2R antagonist zolantadine (ZOL) (10 mg/kg, i.p.),
Scopolamine hydrochloride (SCO) (0.3 mg/kg, i.p.), LPS (lipopolysaccharide from E.
coli serotype 0111:B4), and the assay kit for reduced glutathione (GSH), rabbit anticyclo-oxygenase2 (COX2), rabbit anti-inducible nitric oxide synthase (iNOS)
antibodies was purchased from Sigma-Aldrich (St. Louis, MO, USA). The lipid
peroxidation assay kit for estimation of malondialdehyde (MDA) was obtained from
North West Life Science (Vancouver, WA, USA). The assay kits for superoxide
dismutase (SOD) and catalase (CAT) were purchased from Cayman chemical (Ann
Arbor, MI, USA). For estimation of levels of proinflammatory cytokines IL-1β, IL-6,
TNF-α and TGF-β commercially available ELISA kits were purchased from R&D
Systems (Minneapolis, MN, USA). Rabbit anti- nuclear transcription factor – kappa B
p65 (NF-κB p65) antibody was purchased from Abcam, (Cambridge, MA, USA).
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Anti-actin antibody was obtained from MERCK (Millipore, USA), while the goat antimouse and goat anti rabbit secondary immunoglobulin G antibodies conjugated to
horseradish peroxidase (HRP) were purchased from Santa Cruz Biotechnology
(Dallas, TX, USA). Anti-ionized calcium-binding adaptor molecule-1 (Iba-1)
polyclonal rabbit was purchased from Wako Chemicals (Richmond, VA, USA). Alexa
Fluor 488- conjugated secondary goat anti-rabbit antibodies were purchased from Life
Technologies (Grand Island, NY, USA). Protease and phosphatase inhibitors were
obtained from Thermo Scientific (Waltham, MA, USA). The Pierce® BCA Protein
Assay Reagent Kit and the SuperSignal® West Pico PLUS chemiluminescence
substrate kit were purchased from Thermo Fisher Scientific Inc. (Rockford, IL, USA).
Mini-Protean TGX® precast electrophoresis gels were obtained from BIO-RAD (BioRad Laboratories Inc, USA). Vectashield®, fluorescent mounting media was procured
from Vector laboratories (Burlingame, CA, USA). Acetylcholinesterase activity
colorimetric assay kit was purchased from BioVision (Milpitas, CA, USA). All the
reagents used in the study were of analytical grade and were purchased from SigmaAldrich (St. Louis, MO, US). Except for E100, which was dissolved in 1% aqueous
solution of Tween 80, all drugs were dissolved in isotonic saline solution. All mice
were i.p. injected at a volume of 10 ml/kg adjusted to body weight, and all doses are
expressed in terms of the free base.
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Figure 8: Chemical structure and in vitro affinities of DL77 and E100 with regard to
hH1R, hH3R, hH4R, in-vivo potency of DL77; and in vitro data of E100 against
EeAChE, and EqBChE.
(a) [125I] Iodoproxyfan binding assay at human H3R stably expressed in CHO-K1 cells, n=3 for DL77
and [3H] Nα-Methylhistamine binding assay performed with cell membrane preparation of HEK-hH3
cells stably expressing the human for H3R, n= 3 for E100, as reported previously (Lazewska et al.,
2006) (b) [3H] Pyrilamine binding assay performed as previously reported, with cell membrane
preparation of CHO-hH1R cells stably expressing the human H1R; n=3 (Schibli & Schubiger, 2002;
Schlotter, Boeckler, Hubner et al., 2005). (c) [3H] Histamine binding assay performed as reported
previously, with cell membrane preparation of Sf9 cells transiently expressing the human H4R and coexpressed with Gαi2 and β1γ2 subunits; n=3 (Meier, Apelt, Reichert et al., 2001). (d) Central histamine
H3R assay in vivo after po administration to mice, n=3 (Lazewska et al., 2006). hH1R: human histamine
H1 receptor; (e and f) E100 comparable inhibitory potency for both cholinesterases (EeAChE, and
EqBChE) in low micromolar range. Abbreviations: CHO: Chinese hamster ovary; Eq: equine; Ee:
electric eel.

2.4 Study design
Pregnant mice (TO and C57) were i.p. injected with either VPA (500 mg/kg)
or saline on embryonic day 12.5 (E12.5) (Moy, Nadler, Perez et al., 2004) and returned
to their home cages. VPA was dissolved in isotonic 0.9% NaCl solution (saline). After
the injection of VPA few pregnant mice died, and some gave still birth or underwent
desorption. From the successfully delivered pups, male offspring only from both VPAexposed mothers and from mothers that received saline were divided into 2 groups
(Group 1: prenatally VPA-exposed offspring; Group 2: prenatally saline-exposed
offspring). Then the mice in each group were further divided into subgroups and i.p.
treated as shown in the schematic experimental design (Figure 9). Group 1 was
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subdivided into eight subgroups of VPA-exposed mice and Group 2 was subdivided
into three subgroups of saline-exposed mice as follows:
Group 1: prenatally VPA-exposed offspring (5-7 mice/group)
Group I: VPA-exposed mice injected with saline
Group II: VPA-exposed mice injected with DL77 (5 mg/kg, i.p.)
Group III: VPA-exposed mice injected with DL77 (10 mg/kg, i.p.)
Group IV: VPA-exposed mice injected with DL77 (15 mg/kg, i.p.)
Group V: VPA-exposed mice injected with DOZ (1 mg/kg, i.p.)
Group VI: DL77 (10 mg/kg, i.p.) was co-administered with RAM (10 mg/kg, i.p.)
Group VII: DL77 (10 mg/kg, i.p.) was co-administered with PYR (10 mg/kg, i.p.)
Group VIII: DL77 (10 mg/kg, i.p.) was co-administered with ZOL (10 mg/kg, i.p.)
Group 2: prenatally saline-exposed offspring (5-7 mice/group)
Group I: saline-exposed mice injected with saline
Group II: saline-exposed mice injected with DL77 (10 mg/kg, i.p.)
Group III: saline-exposed mice injected with DOZ (1 mg/kg, i.p.)
All treatments and vehicle (saline) were injected once daily for 21 days from
P44 onwards. After one week of treatment, the battery of behavioral tests was started
in a sequence shown in Figure 9. Treatments or saline were administered 30–45 min
before each behavioral test. To reduce the number of animals used, the biochemical
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analysis, Western blotting and immunofluorescence staining were performed in the
same groups of animals that were subjected to behavioral tests. The behavioral
experiments of the study were conducted between 9:00 am and 3:00 pm. Before the
behavioral tests animals were habituated in the study place for at least 1 h. All
procedures were approved by the Institutional Animal Ethics Committee of College of
Medicine and Health Sciences/United Arab Emirates University (approval no. ERA2017-5603). All methods were carried out in accordance with relevant guidelines and
regulations.
The same study design (Figure 9) was followed using DL77 and E100 as
treatments on C57 mice prenatally exposed to VPA, and again the offspring were
divided as follows: (Group 1: prenatally VPA-exposed offspring; Group 2: prenatally
saline-exposed offspring). Group 1 was subdivided into fifteen subgroups of VPAexposed mice and Group 2 was subdivided into four subgroups of saline-exposed mice
as follows:
Group 1: prenatally VPA-exposed offspring (8-12 mice/group)
Group I: VPA-exposed mice injected with 1% aqueous solution of Tween 80
Group II: VPA-exposed mice injected with DL77 (5 mg/kg, i.p.)
Group III: VPA-exposed mice injected with DL77 (10 mg/kg, i.p.)
Group IV: VPA-exposed mice injected with DL77 (15 mg/kg, i.p.)
Group V: VPA-exposed mice injected with E100 (5 mg/kg, i.p.)
Group VI: VPA-exposed mice injected with E100 (10 mg/kg, i.p.)
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Group VII: VPA-exposed mice injected with E100 (15 mg/kg, i.p.)
Group VIII: VPA-exposed mice injected with DOZ (1 mg/kg, i.p.)
Group IX: DL77 (15 mg/kg, i.p.) was co-administered with RAM (10 mg/kg, i.p.)
Group X: DL77 (15 mg/kg, i.p.) was co-administered with PYR (10 mg/kg, i.p.)
Group XI: DL77 (15 mg/kg, i.p.) was co-administered with ZOL (10 mg/kg, i.p.)
Group XII: E100 (10 mg/kg, i.p.) was co-administered with RAM (10 mg/kg, i.p.)
Group XIII: E100 (10 mg/kg, i.p.) was co-administered with PYR (10 mg/kg, i.p.)
Group XIV: E100 (10 mg/kg, i.p.) was co-administered with ZOL (10 mg/kg, i.p.)
Group XV: E100 (10 mg/kg, i.p.) was co-administered with SCO (0.3 mg/kg, i.p.)
Group 2: prenatally saline-exposed offspring (8-12 mice/group)
Group I: saline-exposed mice injected with 1% aqueous solution of Tween 80
Group II: saline-exposed mice injected with DL77 (15 mg/kg, i.p.),
Group III: saline-exposed mice injected with E100 (10 mg/kg, i.p.),
Group IV: saline-exposed mice injected with DOZ (1 mg/kg, i.p.)
For further elaboration and authentication, effects of systematic pre-treatment of
E100 was investigated in male BTBR mice following the same sequence of behavioral
tests (Figure 9) and the groups were divided as follows (6-8 mice/group):
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Group I: C57 mice injected with 1% aqueous solution of Tween 80
Group II: BTBR mice injected with 1% aqueous solution of Tween 80
Group III: BTBR mice injected with E100 (5 mg/kg, i.p.)
Group IV: BTBR mice injected with E100 (10 mg/kg, i.p.)
Group V: BTBR mice injected with E100 (15 mg/kg, i.p.)
Group VI: BTBR mice injected with DOZ (1 mg/kg, i.p.)
Group VII: E100 (5 mg/kg, i.p.) was co-administered with RAM (10 mg/kg, i.p.)

Figure 9: Schematic diagram of drug treatments, behavioral studies, and biochemical
assessments with VPA mice.
Pregnant mice were injected with VPA (500 mg/kg, i.p.) at embryonic day 12.5 (E12.5). Treatments
started from postnatal day (P44). Injections (once daily) continued for 21 days until P64. Behavioral
studies was started from P51. All mice were then sacrificed at P64 for biochemical analyses.
Abbreviations: VPA: Valproic acid; i.p.: intraperitoneal; DOZ: Donepezil; RAM: R-alpha methyl
histamine; PYR: Pyrilamine; ZOL: Zolantidine; TCT: Three-chamber test; EPM: Elevated plus-maze;
OFT: Open field test; MBT: Marble Burying test; NST: Nestlet shredding test.
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2.5 Behavioral tests
2.5.1 Three-chamber test (TCT)
TCT assesses cognition in the form of general sociability and social novelty
preference in rodents, identifying rodents with deficits in sociability and/or social
novelty. The TCT of social interaction and social novelty recognition was performed
as described previously (Silverman, Yang, Lord et al., 2010), but with a slight
modification in the apparatus, with one center chamber (40 cm × 20 cm × 22 cm) and
two side chambers (40 cm × 20 cm × 22 cm) separated by two sliding doors under a
light intensity of ~120 lux (Figure 10). The test was composed of four 10-min sessions.
In the first session, a test mouse was habituated to the center chamber with the two
doors closed for 5 min. In the second session, the doors were opened, and a test mouse
was allowed to explore all three chambers for 5 min. Before starting the third session,
a stranger mouse (same age and sex with no previous contact with the test mouse),
referred to as a novel mouse 1, was placed in a small plastic cage in either the left or
right chamber, selected randomly to avoid side preference, while the other cage in the
opposite chamber was kept empty and was referred to as a novel object. In the third
session, the test mouse was allowed to explore all three chambers and cages for 10
min. The time spent exploring (direct contact) the novel mouse 1 was compared with
the time spent exploring the novel object. As previously described, the sociability
index (SI) and social novelty preference index (SNI) were calculated by applying a
mathematical equation to allow the direct comparison of social behavior of the treated
groups (Bambini-Junior, Zanatta, Della Flora Nunes et al., 2014). As the score for SI
became more positive and closer to 1, the more social was the tested animal. The SI
was calculated using the following equation:
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SI = Time exploring novel mouse 1 − Time exploring novel object
Time exploring novel mouse 1 + Time exploring novel object
After the end of the third session a new stranger mouse was added to the empty
cage after which the test mouse was allowed to explore the environment for 10 min,
which made up the fourth session. The new stranger mouse was referred to as novel
mouse 2, while the novel mouse 1 from the previous session was then referred to as
the familiar mouse. The exploratory time was measured as in the previous session to
evaluate the preference of the test mouse to novel mouse over familiar mouse in the
cage. Similarly, SNI was calculated where a value closer to 1 indicated that an animal
was more interested in social novelty. The SNI was calculated as follows:
SNI = Time exploring novel mouse 2 − Time exploring familiar mouse
Time exploring novel mouse 2 + Time exploring familiar mouse
The reason for the first session is that it might increase mouse exploration of side
chambers relative to the center chamber in sessions 3 and 4. Another objective of
habituation in the center chamber before the whole-apparatus habituation was to make
the center chamber a familiar “home base” of the test mouse (Crawley, 2004), as
reported in the original papers (Moy et al., 2004; Nadler, Moy, Dold et al., 2004). In
addition, the time of habituations could be flexible (5–30 min) (Crawley, 2004).
Stranger mice (8–16 weeks old) were habituated to the plastic cage in the threechamber apparatus for 30 minutes 24 h before the test, as described previously (Moy
et al., 2004). The trace movements and sniffing during the experiment were
automatically
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Figure 10: Apparatus used for behavior tests.
Three chamber compartment used for three chamber test (A and B), Elevated Plus-Maze used for
anxiety and locomotor activity chamber test measures (C and D), cage with equidistant 4 × 5
arrangement of black marbles used for marble burying test (E), Open field used for open-field test (E),
and nestlets with specific dimensions used for nestlet shredding test (F). Black and white floorings are
selected to contrast with the colour of mouse used, for accurate detection by the software.

2.5.2 Marble burying test (MBT)
MBT behavior is an accurate reflection of repetitive digging behavior (AngoaPerez, Kane, Briggs et al., 2013; Thomas, Burant, Bui et al., 2009). The test was
performed as previously reported with slight modifications (A. Bahi, J. S. Schwed, M.
Walter et al., 2014; Theoharides et al., 2016; Thomas et al., 2009). Briefly, cages
(26 cm × 48 cm × 20 cm) were filled with fresh, unscented mouse bedding material to
a depth of 5 cm, and the bedding surface was leveled by placing another cage of the
same size onto the surface of the bedding. Each mouse was housed individually for
habituation. After 10-min habituation, the mouse was removed, and 20 glass marbles
(15 mm diameter) were carefully overlaid equidistantly in a 4 × 5 arrangement inside
the cage. Subsequently, each mouse was returned to its designated test cage and
allowed to explore for 30 min. The number of marbles buried (>50% marbles covered
by the bedding) was recorded (Angoa-Perez et al., 2013; Kim, Seung, Kwon et al.,
2014).
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2.5.3 Nestlet shredding test (NST)
NST

is

a

powerful

behavioral

assay

to

assess

repetitive

and

obsessive/compulsive-like behavior. It was performed by placing commercially
available cotton fiber (nestlet) (5 cm × 5 cm, 5 mm thick, ~2.5 g each) after weighing
it on an analytical balance, into a cage (19 cm × 29 cm × 13 cm) filled with fresh,
unscented mouse bedding material to a depth of 0.5 cm (Figure 10). The bedding was
packed by placing another cage of the same size onto the surface of the bedding. Each
nestlet was placed on top of the bedding in one test cage, and the filter-top cover was
placed on the cage. No food and water were provided during the test. One mouse was
added to each cage and left undisturbed with the nestlet for 30 min. The mouse was
then removed and returned to its home cage after test completion. The remaining intact
nestlet was removed from the cage using forceps and allowed to dry overnight. The
remaining un-shredded nestlet was weighed, and the weight difference was divided by
the starting weight to calculate the percentage of nestlet shredded. The remaining
shredded nestlet material and bedding was discarded (Angoa-Perez et al., 2013).
2.5.4 Elevated plus-maze (EPM) test
The EPM test was performed as previously described (Bahi, 2013a, 2013b;
Bahi & Dreyer, 2012, 2014) Briefly, a four-armed apparatus was elevated 40 cm above
the ground. It consisted of two opposite open arms (30 cm × 6 cm) and two closed
arms of the same size with 15 cm high walls. The arms were connected by a central
square (6 cm × 6 cm) (Figure 10). An animal was placed in the center of the maze
facing an open arm. The maze was lighted approximately one meter above the maze.
The amounts of time spent with the head and forepaws in the open arms and closed
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arms of the maze as well as the number of entries into each arm were measured over 5
min using EthoVision® Sofware. The maze was thoroughly cleaned with a tissue
dampened with 70% (volume/volume; v/v) alcohol to remove any odor after each
mouse was tested. The total number of entries into the closed arms is used as an index
of locomotor activity in the test (Bahi, 2013a, 2013b; Bahi et al., 2012; Bahi & Dreyer,
2014).
2.5.5 Open-field test (OFT)
OFT involves exploratory activity performed in a novel environment, assessed
in an open field box (45 cm × 45 cm × 30 cm) (Lucchina et al., 2014) (Figure 10). This
test systematically assesses novel environment exploration, general locomotor
activity, and anxiety-related behavior in rodents. The center was defined as the central
23 cm × 23 cm area. Mice were introduced into the center area of the arena and allowed
5 min for habituation before actual behavioral recording. The total distance moved in
the whole arena, and time spent at the center and periphery were recorded for 10 min
using charged-coupled device camera-assisted motion tracking apparatus and
EthoVision software. After each trial, the apparatus was cleaned using 70% ethanol
and allowed to dry (Kim et al., 2014; Prut & Belzung, 2003). When evaluating the
results, a longer time spent in the center indicated lower levels of anxiety-like
behaviors and the total distance travelled reflected locomotor activity.
2.6 Brain collection and tissue preparation for biochemical studies
After the 21 days of treatment as described above, the animals were injected
with LPS (25 µg/kg, i.p.) two hours before the sacrifice according to previously
published protocols (Lucchina et al., 2014).The animals were deeply anesthetized with
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pentobarbital (40 mg/kg, i.p.), and cardiac perfusion was performed using 1× PBS
(0.01 M phosphate buffer, 0.0027 M potassium chloride and 0.137 M sodium chloride)
at pH 7.4 to wash out the blood. The brains were quickly removed and placed on an
ice plate. The cerebellum and the hippocampus were excised from the brain and snapfrozen in liquid nitrogen for further use in biochemical tests (Ojha, Javed, Azimullah
et al., 2015). On the day of assay, the tissues were homogenized on ice in the extraction
buffer recommended by the manufacturer, RIPA buffer (50 mM Tris HCl, pH 7.4, 140
mM NaCl, 1 mM EDTA, 0.5% Triton X-100 and 0.5% sodium deoxycholate) and
phosphatase and protease inhibitors. The homogenates were sonicated and centrifuged
for 30 min at 14000 rpm at 4°C to remove tissue debris, and the resulting supernatant
was used for the proinflammatory cytokine assessment, oxidative stress and Western
blot analysis. After being transcardially perfused with PBS four animals from
respective groups were further perfused by 4% paraformaldehyde (cold) in 1× PBS.
After removing the brains from the skulls, they were post-fixed in the same fixative
(4% paraformaldehyde) for 48 h at 4°C. The brains were then immersed in 10%
sucrose solution for three consecutive days at 4°C. Finally, the brains were stored in 80°C for cryostat sectioning and immunofluorescence staining analyses (Javed,
Azimullah, Abul Khair et al., 2016; Ojha et al., 2015).
2.6.1 Enzyme-linked Immunosorbent Assay (ELISA)
ELISA was performed to quantify the levels of proinflammatory cytokines, IL1β, IL-6, TNF-α and TGF-β in the cerebellum. The levels of IL-1β, IL-6, TNF-α and
TGF-β were estimated as recommended by the manufacturer’s instructions. For
proinflammatory cytokine analysis, the protein concentrations were determined using
the Pierce® BCA Protein Assay Reagent Kit. Briefly, 96-well plates were coated with
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the diluted capture antibody (100 μl) overnight at room temperature. Each well was
aspirated and washed with wash buffer (0.05% Tween 20 in PBS 0.01 M, pH 7.4). The
plate was blocked by adding reagent diluent (1% bovine serum albumin in PBS [300
μl]) for 1 hour, except for TFG-β the blocking buffer was 5% Tween 20 in PBS, and
the plate was then washed with wash buffer. Samples or standards (100 μl) were added
to the well and incubated for 2 hours, then washed with wash buffer. Each well
received detection antibody (100 μl), was incubated for 2 hours at room temperature,
and was washed with wash buffer. The well then received working solution (1:40) of
streptavidin horseradish peroxidase (100 μl) and was further incubated for 30–40
minutes at room temperature and then washed with wash buffer. The wells received
substrate solution (100 μl) and incubated for 20 minutes (avoid direct light). Finally,
stop solution (2 N H2SO4 [50 μl]) was added and mixed by gentle plate tapping.
Immediately, the optical density of each well was determined at 450nm using a
microplate absorbance reader (Molecular devices Versamax ®, USA). The results are
expressed as pg/mg protein (Ojha et al., 2015; Tyrtyshnaia, Lysenko, Madamba et al.,
2016).
2.6.2 Oxidative stress marker estimations
Lipid peroxidation product: malondialdehyde (MDA): An MDA detection kit
was used to determine the amount of lipid peroxidation using the manufacturer’s
instructions. Briefly, samples or calibrators (250 μl) were added to acid reagent (1 M
Phosphoric acid) (250 μl) and 2-thiobarbituric acid (250 μl). Subsequently, butylated
hydroxytoluene in ethanol (10 μl) was added and vortexed vigorously. Then, the
samples were incubated for 60 min at 60°C and centrifuged at 10,000 × g for 2–3 min.

70
The reaction mixture was transferred to a cuvette and its spectra at 532 nm recorded.
The results are expressed as μM MDA/mg protein.
Glutathione (GSH): For the estimation of GSH, a commercially available GSH
kit was used following the manufacturer’s instructions. Briefly, the samples were first
deproteinized with 5% 5-sulfosalicylic acid solution and centrifuged to remove the
precipitated protein. The supernatant was used to measure the GSH levels. Samples or
standards (10 μl) were incubated at room temperature for 5 minutes with 150 μl of
working mixture (assay buffer + 5,5′-Dithiobis (2-nitrobenzoic acid) + GSH reductase)
in 96-well plates. Diluted NADPH solution (50 μl) was added to each well and mixed
properly. The absorbance of the samples was measured at 412 nm, along with the
kinetics for 5 min by using the microplate reader. The results are expressed as μM
GSH/mg protein.
Superoxide dismutase and Catalase (SOD and CAT): For estimation of the
activity of antioxidant enzymes SOD and CAT, manufacturer’s instructions for the
commercially available kits were followed. Briefly, CAT was estimated by mixing the
samples or different standard concentrations (20 μl) with assay buffer (100 μl) and
methanol (30 μl) in a 96-well plate. To initiate the reaction, H2O2 (20 µl) was added to
each well and incubated on a shaker for 20 min at room temperature. To terminate the
reaction, Potassium hydroxide (30 µl) was added and subsequently followed by the
addition of CAT purpald (30 μl). The plate was covered and incubated for 10 minutes
at room temperature on a shaker. Then CAT potassium periodate (10 µl) was added
and the plate was incubated again for 5 min at room temperature on a shaker and
absorbance was determined using a microplate reader at 540 nm. CAT activity was
expressed as nmol/min/mg protein. For SOD estimation, samples or standard (10 µl)
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were added to diluted radical detector (tetrazolium salt solution) (200 µl) in a 96-well
plate. Xanthine oxidase (20 µl) was added to all wells to initiate the reaction. The plate
was shaken carefully for a few seconds, covered with plate cover and incubated for
30 min at room temperature. Absorbance was determined at 450 nm using a microplate
reader. SOD activity was expressed as units/mg protein (Ojha, Javed, Azimullah et al.,
2016).
2.6.3 Western blot analysis
Western blot analysis was conducted to measure the levels of expression of
COX-2, iNOS, and NF-κB p65 in the cerebellum and hippocampus of different animal
groups, as described previously (Javed, Azimullah, Abul Khair, et al., 2016; Ojha et
al., 2015). As mentioned earlier the prepared cell lysates containing the extracted
protein from the mouse brain tissues were used. The protein content in the sample was
estimated using the Pierce® BCA Protein Assay Reagent Kit. The protein samples
containing equal amounts of protein (30 µg) adjusted with RIPA buffer and 4 ×
Laemmli sample buffer, were loaded and separated in Mini-Protean TGX® precast
electrophoresis gels. The proteins were then transferred onto polyvinylidene difluoride
membranes that were first activated by soaking in 100% methanol. The transfer was
carried in a Trans-blot Turbo semi-dry-transfer system (BIO-RAD, Bio-Rad
laboratories, Inc, USA,) using a transfer buffer (25 mM Tris base, 192 mM glycine,
20% v/v methanol and adjust volume to 1000 ml distilled water, pH 8.3).
Subsequently, the membranes were incubated for 1 h with the blocking buffer (nonfat dry milk) and then washed to avoid non-specific binding. The membranes were
then incubated overnight at 4°C with the specific primary antibody (Table 2). The
second day the membranes were washed and incubated for 1 h with the horseradish
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peroxidase conjugated secondary anti-rabbit antibody, at room temperature. The bands
of proteins detected by the antibodies were visualized using an enhanced
chemiluminescence Pico kit as substrate. Subsequently, the blots were stripped and reprobed for actin (used as loading control) using horseradish peroxidase anti-mouse
secondary antibody (Table 2). The intensity of the band was measured using
densitometry and quantified using the ImageJ software (National Institutes of Health,
Bethesda, MD, USA)
Table 2: Primary and secondary antibodies used in Western blot and their dilutions.
Primary Ab

Dilution

Secondary Ab

Dilution

Rabbit anti-COX-2

1:1000

HRP anti Rabbit

1:20000

Rabbit anti-iNOS

1:5000

HRP anti Rabbit

1:20000

Rabbit anti-NF-κB p65

1:50000

HRP anti Rabbit

1:10000

Mouse anti-actin

1:7000

HRP anti Mouse

1:20000

2.7 Immunofluorescence staining of Iba-1
Brains were collected, post fixed and stored in -80°C as mentioned earlier. On
the day of sectioning, the brains were sliced using a cryostat (Leica, Germany) into 20
µm sections. Immunofluorescence staining was performed with the coronal sections
of the cerebellum to examine the Iba-1 positive microglia (activated). In 24-well plate
brain sections were washed twice with PBS (500 µl/well) and incubated with blocking
reagent (10% normal goat serum in PBS 0.3% Triton-X 100) (250 µl/well) for 1 h at
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room temperature. The sections were then washed and incubated with the primary
polyclonal rabbit antibody against Iba-1 (1:700) (250 µl/well) overnight at 4°C. On
the second day, the sections were washed twice with PBS (500 µl/well) and incubated
with fluorescent anti-rabbit secondary antibody (Alexa Fluor488) (1:1000) (250
µl/well) for 1 h at room temperature. Subsequently, the sections were washed again
and mounted using Vectashield® mounting media. The images were then captured
using the fluorescent microscope (Nikon Eclipse Ni). A minimum of three sections per
brain from four animals were used (three sections per brain) to analyse microglia
activation. From each section the activated microglia were evaluated by measuring the
integrated density of the Iba-1 signal from three different randomly selected fields of
equal areas, using the Image J software. The expression levels of Iba-1 were detected
by the green fluorescence emitted by Alexa Fluor488. The total corrected cellular
fluorescence (TCCF) was then calculated using the following equation: (TCCF) =
integrated density – (area of selected cell × mean fluorescence of the background)
(McCloy, Rogers, Caldon et al., 2014). This TCCF was calculated and normalized
against the mean of the control, with results presented as percentage fold increase from
the control.
2.8. Determination of acetylcholinesterase (AChE) activity in BTBR mice
cerebellum
The acetylcholinesterase assay kit was used, and the procedure followed was
according to the manufacturer. The assay relates the hydrolysis of ACh to choline by
AChE enzyme. Briefly, 5 µl of supernatant of homogenate (cerebellum tissue) was
placed into the plate. Then, 45 µl of working reagent that consists of AChE assay
buffer, and 50 µl reaction mix were added into each well. After incubation for 20-30
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min at 37oC, absorbance was read in a kinetic mode, and choosing two time points in
a linear range to calculate the AChE activity of the sample, using a microplate reader
at 570 nm. AChE activity was expressed as nmol/min/mg protein.
2.9 Statistical analysis
For the SI and SNI, and results of the MBT, NST, OFT and EPM test, statistical
significance was assessed with a group (Control, VPA, BTBR) × drug (SAL, DL77,
E100) analysis of variance. The data were first analyzed for normality by assessing the
sample distribution or skewness (−1.5 to +1.5 considered normally distributed). The
source of the detected significances was determined by Bonferroni’s multiple
comparison post hoc test. P-values less than 0.05 were considered statistically
significant. The number of mice per group is indicated in the figures. Distinct analyses
were performed to enable the calculation of SI and SNI, for the interaction time.
Respective group and chamber were considered independent variables, and their
influence over the dependent variable time was determined. Statistical significance for
biochemical assessments, Western blot, and immunofluorescence analyses was
calculated using one-way analysis of variance followed by post hoc Tukey’s multiple
comparison test. For statistical comparisons, the software package SPSS 25.0 (IBM
Middle East, Dubai, UAE) was used. The results are expressed as the means and
standard errors of the means (SEM). The P-values less than 0.05 were considered
statistically significant.
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Chapter 3: Results
3.1 Effects of DL77 and DOZ on sociability deficits assessed in VPA-exposed TO
mice in TCT
The effect of subchronic systemic injection of DL77 at three different doses (5,
10, and 15 mg/kg, i.p.) and DOZ (1 mg/kg, i.p.) on ASD-like sociability deficits in the
TCT task in VPA-exposed mice are shown in Figure 11A. The results of statistical
analyses revealed that subchronic treatment with DL77 (10 mg/kg, i.p.) prior to TCT
significantly enhanced sociability of VPA-exposed mice by increasing SI when
compared to saline-treated VPA-exposed mice with [F(1,10) = 7.63; P < 0.05].
However, DL77 (5 and 15 mg/kg, i.p.) and DOZ (1 mg/kg, i.p.) failed to enhance
sociability of VPA-exposed mice with p=0.92, p=0.16, and p=0.16, respectively
(Figure 11A). Moreover, no significant difference in the SI was observed for salineexposed mice pretreated with 10 mg/kg of DL77 (10 mg/kg) with p=0.43, indicating
that VPA-exposed mice exhibited enhanced sociability performance when pretreated
with DL77 (10 mg/kg) (Figure 11A). Furthermore, DOZ (1 mg/kg, i.p.) failed to alter
saline-exposed with p=0.19 as compared to saline-treated Saline exposed mice (Figure
11A). Additionally, the observed results for SI values showed that the DL77 (10 mg)provided enhancement in sociability performance was completely abrogated when coadministered with the CNS-penetrant H3R agonist RAM (10 mg/kg, i.p., P<0.05) or
the CNS-penetrant H2R antagonist ZOL (10 mg/kg, i.p.), with [F(1,10) = 30.72; P <
0.001] as compared to DL77 (10 mg)-pretreated VPA-exposed mice (Figure 11B).
However, the CNS-penetrant H1R antagonist PYR (10 mg/kg, i.p.) failed to reverse
the observed effects of DL77 (10 mg/kg) with p=0.71 for the comparison of DL77 (10
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mg)-treated VPA-exposed mice with DL77 (10 mg) + PYR (10 mg)-treated VPAexposed mice (Figure 11B).

Figure 11: Effects of DL77 and DOZ on sociability deficits assessed in VPA-exposed
TO mice in TCT.
After 10 minutes of acclimatization, male subjects were allowed to explore all chambers for 10 min.
The results obtained were Sociability index (SI) A) Abrogation of DL77 (10 mg)-provided effect on SI
(B). Saline-exposed mice were injected with saline in SAL group (gray), DL77 (5, 10, and 15 mg/kg,
i.p. in black), or DOZ (1 mg/kg, i.p. in blue) was administered subchronically for 21 days. Abrogative
studies of subchronic (21 days) systemic co-injection of RAM (10 mg/kg, i.p. for RAM group), PYR
(10 mg/kg, i.p. PYR group), or ZOL (10 mg/kg, i.p., for ZOL group) on the DL77 (10 mg)-provided
improvement of sociability. Saline exposed mice were injected with saline, DL77 (10 mg/kg, i.p.) or
DOZ (1 mg/kg, i.p.). Figures show mean ± SEM (n=6-7). *P<0.05 vs.SI of saline-treated saline-exposed
mice. #P<0.05 vs. SI of saline-treated VPA-exposed mice. $P<0.05, $$$P<0.001 vs. SI of DL77 (10 mg)treated VPA-exposed mice.

3.2 Effects of DL77 and DOZ on social novelty deficits assessed in VPA-exposed
TO mice in TCT
Figure 12 shows the effects of subchronic administration of three different
doses of DL77 (5, 10, and 15 mg/kg, i.p.) and DOZ (1 mg/kg, i.p.) on social novelty
deficits of VPA-exposed mice. The results of post hoc analysis indicated that salineexposed mice exhibited significantly higher SNI when compared to VPA-exposed
mice, with [F(1,10) = 5.87; P < 0.05] (Figure 12A). VPA-exposed mice pretreated with
DL77 (10 or 15 mg/kg, i.p.) showed significant improvement in SNI when compared
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to saline-treated VPA-exposed mice with [F(1,10) = 5.73; P < 0.05] and [F(1,10) = 5.76;
P < 0.05], respectively (Figure 12A). However, DL77 (5 mg/kg, i.p.) and DOZ (1
mg/kg, i.p.) failed to improve the social novelty of VPA-exposed mice, with p=0.93
and p=0.60, respectively (Figure 12A). Furthermore, no significant difference between
saline-treated saline-exposed mice and DL77 (10 mg)-treated saline-exposed mice was
found (p=0.51) (Figure 12B). As depicted in Figure 12B and observed in the post hoc
analysis, the results for SNI values showed that the DL77 (10 mg)-provided
enhancement in social novelty performance was completely counteracted when the
centrally active H3R agonist RAM (10 mg/kg, i.p.) or the CNS-penetrant H2R
antagonist ZOL (10 mg/kg, i.p.) was co-administered (P < 0.05 for both comparisons)
(Figure 12B). However, the CNS-penetrant H1R antagonist PYR (10 mg/kg, i.p.,
P>0.05) failed to reverse the enhancement of DL77-provided social novelty
performance (Figure 12B).
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Figure 12: Effects of DL77 and DOZ on social novelty deficits assessed in VPAexposed TO mice in TCT.
After 10 minutes of exploration, male subjects were allowed to explore all chambers for another 10 min.
The results obtained were Social novelty index (SNI) (A) Abrogation of DL77 (10 mg)-provided effect
on SNI (B). Saline-exposed mice were injected with saline in SAL group (gray), DL77 (5, 10, and 15
mg/kg, i.p. in black), or DOZ (1 mg/kg, i.p. in blue) was administered subchronically for 21 days.
Abrogative studies of subchronic (21 days) systemic co-injection of RAM (10 mg/kg, i.p. for RAM
group), PYR (10 mg/kg, i.p. PYR group), or ZOL (10 mg/kg, i.p., for ZOL group) on the DL77 (10
mg)-provided improvement of social novelty. Saline exposed mice were injected with saline, DL77 10
mg/kg, i.p.) or DOZ (1 mg/kg, i.p.). Figures show mean ± SEM (n=5-7). *P<0.05 vs. SNI of salinetreated saline-exposed mice. #P<0.05 vs. SNI of saline-treated VPA-exposed mice. $P<0.05 vs. SNI of
DL77 (10 mg)-treated VPA-exposed mice.

3.3 Effects of DL77 and DOZ on elevated stereotyped repetitive behavior in VPAexposed TO mice in MBT
The effect of subchronic systemic injection of DL77 (5, 10, or 15 mg/kg, i.p.)
or DOZ (1 mg/kg, i.p.) on the increase in repetitive behavior of VPA-exposed mice in
MBT is shown in Figure 13A and B. The results of statistical analyses showed that
subchronic treatment with either 10 or 15 mg/kg DL77 or 1 mg/kg DOZ prior to MBT
significantly decreased the increased percentage of marbles buried by VPA-exposed
mice, with [F(7,48) = 6.65; P<0.001] (Figure 13A). As observed in the post hoc analysis,
VPA-exposed mice buried significantly more marbles compared to the saline-exposed
animals, with [F(1,12) = 8.03; P<0.05]. However, VPA-exposed mice pretreated with
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DL77 at 10 mg/kg, or 15 mg/kg exhibited significantly decreased percentages of
buried marbles compared to saline-treated VPA-exposed mice, with [F(1,12) = 24.14; P
< 0.001] and [F(1,10) = 27.33; P< 0.001], respectively (Figure 13A). In contrast, DL77
(5 mg/kg, i.p.) failed to significantly decrease the percentage of buried marbles in
VPA-exposed mice, with [F(1,12) = 3.45; p = 0.09] (Figure 13A). Notably, no
significant difference in the DL77-provided effect on percentage of buried marbles
was observed between DL77 10 mg/kg and 15 mg/kg, with p = 0.59. Importantly,
subchronic systemic administration of DOZ (1 mg/kg, i.p.) significantly decreased the
percentage of marbles buried by VPA-exposed mice, with [F(1,12) = 8.62; P < 0.05].
Furthermore, no significant difference in the percentage of buried marbles was
observed in the comparison of saline + saline group vs. saline + DOZ (1 mg) group (p
= 0.88) (Figure 13A). However, there was a significant decrease in the percentage of
buried marbles in saline-exposed mice subchronically treated with DL77 (10 mg/kg,
i.p.) vs. saline + saline group, with [F(1,12) = 16.178; P < 0.05] (Figure 13A). In another
experiment, the DL77 (10 mg)-provided decrease in the percentage of buried marbles
was reversed by RAM, with [F(1,12) = 1.43; p = 0.26] for the comparison of VPAexposed mice vs. VPA-exposed mice + DL77 (10 mg) + RAM (10 mg). However,
PYR and ZOL failed to reverse this DL77 (10 mg)-provided decrease in the percentage
of buried marbles, as they had no significant effect compared to VPA-exposed mice
treated with DL77 (10 mg/kg, i.p.), with [F(1,12) = 2.73; p = 0.12] and [F(1,12) = 0.00; p
= 0.98], respectively (Figure 13B).
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Figure 13: Effects of DL77 and DOZ on elevated stereotyped repetitive behavior in
VPA-exposed TO mice in MBT.
A) Repetitive marble-burying behavior was measured after a 30-minute testing session. VPA-exposed
mice (red) demonstrated elevated stereotyped, repetitive behaviors that were significantly increased
compared to saline-exposed mice (gray). DL77 (at a dose of 5, 10, or 15 mg/kg, i.p. (black)) or DOZ (1
mg/kg, i.p. in blue) was administered subchronically for 21 days. B) Effects of sub-chronic (21 days)
systemic co-administration of RAM (10 mg/kg, i.p.), PYR (10 mg/kg, i.p.), or ZOL (10 mg/kg, i.p.) on
the DL77 (10 mg)-provided attenuation of stereotyped repetitive behavior of VPA-exposed mice
in MBT. Saline-exposed mice were injected with saline in group, DL77 (10 mg/kg, i.p.), or DOZ (1
mg/kg, i.p.). Figures show mean ± SEM (n = 7). *P < 0.05 vs. saline-treated saline-exposed mice. #P <
0.05 vs. saline-treated VPA-exposed mice. #P < 0.05, ###P < 0.001 vs. saline-treated VPA-exposed mice.
&
P < 0.001 vs. saline-treated saline-exposed mice. $P<0.05 vs. DL77 (10 mg)-treated VPA-exposed
mice.

3.4 Effects of DL77 and DOZ on elevated stereotyped repetitive behavior in VPAexposed TO mice in NST
The effect of subchronic systemic injection of DL77 (5, 10, or 15 mg/kg, i.p.)
or DOZ (1 mg/kg, i.p.) on the increase in the percentage of shredded nestlet was
assessed in NST (Figure 14A and B). ANOVA indicated that VPA-exposed mice
shredded significantly more nestlet compared to the saline-exposed mice, with [F(1,12)
= 20.90; P < 0.05]. VPA-exposed mice treated with DL77 (10 mg/kg or 15 mg/kg)
exhibited a significantly lower percentage of shredded nestlet compared to VPAexposed mice treated with saline, with [F(1,12) = 7.34; P < 0.05] and [F(1,12) = 9.63; P <
0.05], respectively (Figure 14A). However, DL77 (5 mg/kg) failed to modulate the
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percentage of shredded nestlet in VPA-exposed mice, with [F(1,12) = 0.39; p = 0.54].
Notably, no significant difference in the DL77-provided effect on percentage of
shredded nestlet was observed between the two doses of 10 and 15 mg/kg, with p =
0.84. Moreover, subchronic systemic administration of DOZ (1 mg/kg, i.p.)
significantly lowered the percentage of shredded nestlet in VPA-exposed mice, with
[F(1,12) = 10.99; P < 0.05]. Furthermore, neither saline + saline group vs. saline + DL77
(10 mg) group nor saline + saline group vs. saline + DOZ (1 mg) group showed
significant differences in shredded nestlet (p = 0.56 and p = 0.53, respectively) (Figure
14A). As depicted in Figure 14B and observed in the post hoc analysis, the DL77 (10
mg)-provided decrease in the percentage of shredded nestlet was reversed following
RAM, with [F(1,12) = 0.002; p = 0.98] compared with saline-treated VPA-exposed mice
(Figure 14B). However, PYR and ZOL failed to reverse this DL77-provided decrease
in the percentage of shredded nestlet, as they had no significant effect compared to
VPA-exposed mice treated with DL77 (10 mg/kg, i.p.), with [F(1,12) = 2.73; p = 0.12]
and [F(1,12) = 0; p = 0.98], respectively (Figure 14B).
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Figure 14: Effects of DL77 and DOZ on elevated stereotyped repetitive behavior in
VPA-exposed TO mice in NST.
(A) Repetitive shredding behavior was measured after a 30-minute testing session. VPA-exposed mice
(red) demonstrated elevated stereotyped, repetitive behaviors that were significantly increased
compared to saline-exposed mice (gray). DL77 (at a dose of 5, 10, or 15 mg/kg, i.p. (black)) or DOZ (1
mg/kg, i.p. in blue) was administered subchronically for 21 days. (B) Effects of sub-chronic (21 days)
systemic co-administration of RAM (10 mg/kg, i.p.), PYR (10 mg/kg, i.p.), or ZOL (10 mg/kg, i.p.) on
the DL77 (10 mg)-provided attenuation of stereotyped repetitive behavior of VPA-exposed mice in
NST. Saline-exposed mice were injected with saline in group, DL77 (10 mg/kg, i.p.), or DOZ (1 mg/kg,
i.p.). Figures show mean ± SEM (n=7). *P < 0.05 vs. saline-treated saline-exposed mice. #P < 0.05 vs.
saline-treated VPA-exposed mice. $P<0.05 vs. DL77 (10 mg)-treated VPA-exposed mice.

3.5 Effects of DL77 and DOZ pretreatment on exploratory behavior in VPAexposed TO mice in EPM test
Figure 15 shows the observed effects of subchronic systemic injection of saline
or the H3R antagonist DL77 (5, 10, or 15 mg/kg, i.p.) on the anxiety parameters of
VPA-exposed mice tested in the EPM, namely, the percentage of time spent in open
arms (Figure 15A), the number of entries into open arms (Figure 15B), and locomotor
activity expressed as the number of entries into closed arms (Figure 15C). Subsequent
post hoc analyses showed that DL77 administered at 5, 10, or 15 mg/kg i.p. did not
alter the percentage of time spent exploring the open arms of the maze during a 5 min
session compared to saline-treated VPA-exposed mice, with [F(1,9) = 0.30; p = 0.59],
[F(1,9) = 0.18; p = 0.68], or [F(1,9) = 0.56; p = 0.47], respectively (Figure 15A). However,
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VPA-exposed mice pretreated with DOZ (1 mg) spent a significantly lesser percentage
of time exploring the open arms compared to saline-treated VPA-exposed mice, with
[F(1,7) = 11.84; P < 0.05] (Figure 15A). Further analyses of data describing the number
of entries and percentage of time in the open arms of the maze yielded for DL77 (5,
10, and 15 mg/kg i.p.) and DOZ (1 mg/kg, i.p.) practically the same results, with [F(1,9)
= 1.75; p = 0.22], [F(1,9) = 1.20; p = 0.30], [F(1,9) = 1.21; p = 0.30], and [F(1,7) = 7.22; P
< 0.05], respectively (Figure 15B). Interestingly, the number of closed arm entries
following subchronic systemic injection of DL77 (5, 10, or 15 mg/kg) was not
significantly different, with [F(1,10) = 0.99; p = 0.34], [F(1,10) = 0.29; p = 0.60], and
[F(1,10) = 0.06; p = 0.81], respectively. However, DOZ (1 mg)-treated VPA-exposed
mice showed fewer closed arm entries compared to saline-treated VPA-exposed mice,
with [F(1,10) = 6.60; P < 0.05] (Figure 15C).
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Figure 15: Effects of DL77 and DOZ pretreatment on exploratory behavior in VPAexposed TO mice in EPM test.
VPA-exposed mice (red) demonstrated elevated impulsive attitude and deficits in cognition behaviors
that were significantly increased compared to saline-exposed mice (gray). DL77 (5, 10, or 15 mg/kg,
i.p. in black) or DOZ (1 mg/kg, i.p., in blue) was administered subchronically for 21 days. DOZ (1
mg/kg, i.p.) attenuated the increased percentage of time spent on the open arms of the EPM (A) the
increased number of entries into the open arms (B) and the increased number of entries into the closed
arms (C) in VPA mice. However, pretreatment with the H3R antagonist DL77 (5, 10, or 15 mg/kg, i.p.)
did not affect any of the three parameters (A-C). Saline-exposed mice were injected with saline or DOZ
(1 mg/kg, i.p.) (A-C). Data are expressed as the mean ± SEM (n=5-7). *P < 0.05 vs. saline-treated salineexposed mice. #P < 0.05 vs. saline-treated VPA-exposed mice.
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3.6 Effects of DL77 and DOZ pretreatment on levels of malondialdehyde (MDA)
and glutathione (GSH) in the cerebellum of VPA-exposed TO mice
The ability of DL77 to reduce oxidative stress in VPA-exposed mice was
evaluated. Two parameters were measured, the MDA and GSH levels in VPA-exposed
mouse cerebellum, which responded in an exacerbated way to the inflammatory
stimulus LPS. The results in Figure 16A and B show that MDA was significantly
elevated (P<0.05), and GSH was significantly decreased (P<0.05) in the brain tissues
of VPA-exposed mice compared to saline-exposed mice (Figure 16A and B).
However, brain tissues of VPA-exposed mice subchronically pretreated with DL77
(10 or 15 mg/kg, i.p.) or DOZ (1 mg/kg, i.p.) showed a significant reduction of MDA
(from 214.88 ± 12.58 μM to 112.77 ± 19.56, 102.24 ± 16.60, and 97.32 ± 16.55 μM
for DL77 (10 and 15 mg/kg) and DOZ (1 mg/kg), respectively) (all P<0.05) (Figure
16A). In addition, subchronic administration of DL77 (10 or 15 mg/kg) or DOZ (1
mg/kg) significantly increased GSH compared to the saline-treated VPA-exposed
animals (all P<0.05) (Figure 16B). Meanwhile, the VPA-exposed mice subchronically
pretreated with 5 mg/kg did not show any significant difference from the saline-treated
VPA-exposed group (Figure 16A and B). Moreover, subchronic systemic coadministration of RAM (10 mg/kg, i.p.) partially abrogated (P< 0.05) the protective
effects of DL77 (10 mg/kg, i.p.) against the VPA-induced decreased level of MDA
(Figure 16A), and it completely reversed the DL77 (10 mg)-provided increase in GSH
in VPA-exposed mice (Figure 16B).
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Figure 16: Effects of DL77 and DOZ pretreatment on levels of malondialdehyde
(MDA) and glutathione (GSH) in the cerebellum of VPA-exposed TO mice.
VPA-exposed mice (red) showed a significant increase in MDA (A) and significant decrease in GSH
(B) compared to saline-exposed mice (gray). DL77 (5, 10, or 15 mg/kg, i.p. in black) or DOZ (1 mg/kg,
i.p. in blue) was administered subchronically for 21 days. DL77 (10 or 15 mg/kg, i.p.) or DOZ (1 mg/kg,
i.p.) significantly decreased MDA and significantly increased GSH. RAM (10 mg/kg, i.p.) when coadministered abrogated the modulating effects provided with DL77 (10 mg/kg, i.p.) on oxidative stress
levels (A, B). Saline-exposed mice were injected with saline. Data are expressed as the mean ± SEM
(n=5-7). *P < 0.05 vs. saline-treated saline-exposed mice. #P < 0.05 vs. saline-treated VPA-exposed
mice. $P < 0.05 vs. DL77 (10 mg)-treated VPA-exposed mice.

3.7 Effects of DL77 and DOZ pretreatment on levels of proinflammatory
cytokines IL-1β, IL-6 and TNF-α in the cerebellum of VPA-exposed TO mice
The effects of DL77 on the levels of proinflammatory cytokines IL-1β, IL-6
and TNF-α in brain tissue of VPA-exposed mice that were exacerbated with LPS
challenge were also assessed (Figure 17A-C). The induction of ASD-like behaviors by
prenatally administered VPA significantly increased IL-1β (Figure 17A), IL-6 (Figure
17B), and TNF-α (Figure 17C) compared to the saline-exposed mice (all P < 0.001),
while subchronic systemic administration of DL77 (5, 10 or 15 mg/kg, i.p.) or DOZ (1
mg/kg) significantly (P < 0.001) attenuated the rise of these proinflammatory
cytokines in VPA-exposed mice (Figure 17A-C). Notably, subchronic systemic coadministration of RAM (10 mg/kg, i.p.) partially abrogated (P < 0.001) the protective
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effects of DL77 (10 mg/kg, i.p.) against VPA-induced elevation of proinflammatory
cytokines (Figure 17A-C).

Figure 17: Effects of DL77 and DOZ pretreatment on levels of proinflammatory
cytokines IL-1β, IL-6 and TNF-α in the cerebellum of VPA-exposed TO mice.
VPA-exposed mice (red) showed significantly increased levels of IL-1β (A) IL-6 (B) and TNF-α (C)
compared to saline-exposed mice (gray) exacerbated by LPS challenge. DL77 (5, 10, or 15 mg/kg, i.p.
in black) or DOZ (1 mg/kg, i.p. in blue) was administered subchronically for 21 days. DL77 (5, 10, or
15 mg/kg, i.p.) or DOZ (1 mg/kg, i.p.) significantly decreased IL-1β (A), IL-6 (B) and TNF-α (C). RAM
(10 mg/kg, i.p.) when co-administered reversed the modulating DL77 (10 mg)-provided effects on
proinflammatory cytokines (A-C). Saline-exposed mice were injected with saline (A-C). Data are
expressed as the mean ± SEM (n = 5-6). ***P < 0.001 vs. saline-exposed mice. ###P < 0.001 vs. VPAexposed mice. $$$P < 0.001 vs. DL77 (10 mg)-treated VPA-exposed mice.
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3.8 Effects of DL77 and E100 on sociability deficits assessed in VPA-exposed
C57BL/6J mice in TCT
The effect of subchronic systemic administration with DL77 (5, 10, or 15
mg/kg, i.p.), E100 (5, 10, or 15 mg/kg, i.p.), and DOZ (1 mg/kg, i.p.) on ASD-like
sociability impairments in the TCT task in VPA-exposed mice are shown in Figure
18A and B. As observed in the post hoc analysis, VPA-exposed mice exhibited
significantly lower sociability expressed in form of SI value when compared to salineexposed animals, with [F(1,12) = 23.38; P<0.05] (Figure 18A). However, DL77 (10 and
15 mg/kg) significantly increased SI of VPA-exposed mice when compared to Saline
treated VPA -exposed group, with [F(1,12) = 9.92; P<0.05] and [F(1,12) = 32.82; P<0.05],
respectively (Figure 18A). Moreover, the results revealed that the enhancement in SI
observed with DL77 (15 mg/kg) was comparable to that shown with DOZ (1 mg/kg),
with [F(1,12) = 0.05; p=0.83], and was significantly higher than the DL77 (5 mg)- and
DL77 (10 mg)-provided effects, with [F(1,12) = 7.22; P<0.05] and [F(1,12) = 5.74;
P<0.05], respectively (Figure 18A). Interestingly, the DL77-provided improvement of
sociability was counteracted following subchronic systemic co-administration with
centrally acting H3R agonist RAM (10 mg/kg, i.p.) with [F(1,12) = 6.42; P<0.05]
compared with DL77 (15 mg)-treated VPA-exposed mice (Figure 18B). However,
CNS-penetrant H1R antagonist PYR (10 mg/kg, i.p.) and H2R antagonist ZOL (10
mg/kg, i.p.) failed to reverse the DL77 (15 mg)-provided sociability enhancement,
with [F(1,12) = 3.64; p=0.08] and [F(1,12) = 1.32; p=0.27], respectively (Figure 18B).
Similarly, the effect of subchronic systemic injection of E100 at three different doses
(5, 10, and 15 mg/kg, i.p.) and DOZ (1 mg/kg, i.p.) on ASD-like sociability
impairments in the TCT task in VPA-exposed mice are shown in Figure 18A. The
results of statistical analyses revealed that subchronic pretreatment with E100 (5, 10,
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and 15 mg/kg, i.p.) and DOZ (1 mg/kg) prior to TCT significantly enhanced sociability
by increasing SI, with [F(8,54) = 4.51; P<0.001] (Figure 18A). As observed in the post
hoc analysis, VPA-exposed mice exhibited significantly lower sociability expressed in
form of SI value when compared to saline-exposed animals, with [F(1,12) = 13.62;
P<0.05] (Figure 18A). However, E100 (5, 10, and 15 mg/kg) significantly increased
SI of VPA-exposed mice when compared to saline-treated VPA-exposed group, with
[F(1,12) = 21.22; P<0.05], [F(1,12) = 23.83; P<0.05], and [F(1,12) = 14.24; P<0.05],
respectively (Figure 18A). Moreover, the results revealed that the enhancement in SI
observed with E100 (10 mg/kg) was comparable to that shown with DOZ (1 mg/kg),
with [F(1,12) = 0.08; p=0.78] as well as with DL77 (15 mg/kg, i.p.) with [F(1,12) = 0.44;
p=0.52], and was significantly higher than the E100 (5 mg)-provided effects, with
[F(1,12) = 5.17; P<0.05] (Figure 18A). Interestingly, the E100-provided improvement
of sociability was counteracted following subchronic systemic co-administration with
centrally acting H3R agonist RAM (10 mg/kg, i.p.), CNS-penetrant H2R antagonist
ZOL (10 mg/kg, i.p.), or muscarinic antagonist SCO (0.3 mg/kg, i.p.), with [F(1,12) =
7.78; P<0.05], [F(1,12) = 8.38; P<0.05], or [F(1,10) = 6.48; P<0.05] respectively, as
compared to the E100 (10 mg)-treated VPA-exposed mice. (Figure 18B). However,
CNS-penetrant H1R antagonist PYR (10 mg/kg, i.p.) failed to reverse the E100 (10
mg)-provided sociability enhancement, with [F(1,12) = 0.06; p=0.82] for SI of E100 (10
mg)-treated VPA-exposed animals vs. PYR (10 mg) + E100 (10 mg)-treated group
(Figure 18B). Notably, neither DL77 (15 mg) nor E100 (10 mg) or DOZ (1 mg) altered
SI of Saline pretreated saline-exposed mice, with [F(1,12) = 0.09; p=0.77], [F(1,12) =
0.12; p=0.73], and [F(1,12) = 1.23; p=0.29], respectively (Figure 18A).
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Figure 18: Effects of DL77 and E100 on sociability deficits assessed in VPAexposed C57BL/6J mice in TCT.
After 10 minutes of acclimatization, male subjects were allowed to explore all chambers for 10 min.
The results obtained were Sociability index (SI) (A) Abrogation of DL77 (15 mg)- and E100 (10 mg)provided effect on SI (B). Saline-exposed mice were injected with saline in SAL group (gray), DL77
(5, 10, and 15 mg/kg, i.p. in black), E100 (5, 10, and 15 mg/kg, i.p. in green), or DOZ (1 mg/kg, i.p. in
blue) was administered subchronically for 21 days. Abrogative studies of subchronic (21 days) systemic
co-injection of RAM (10 mg/kg, i.p.), PYR (10 mg/kg, i.p.), or ZOL (10 mg/kg, i.p.) on the DL77 (15
mg) or E100 (10 mg)-provided improvement of sociability, additionally SCO (0. 3 mg/kg, i.p.) on E100
(10 mg)-provided improvement in SI. Saline-exposed mice were injected with saline in group, DL77
(15 mg/kg, i.p.), E100 (10 mg/kg,i.p.) or DOZ (1 mg/kg, i.p.). Figures show mean ± SEM (n = 7).
*
P<0.05 vs.SI of saline-treated saline-exposed mice. #P<0.05 vs. SI of saline-treated VPA-exposed
mice. &P<0.05 vs. SI of DL77 (5 mg)- or E100 (5 mg)-treated VPA exposed mice. $P<0.05 vs. SI of
DL77 (15 mg)- or E100 (10 mg)-treated VPA-exposed mice.
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3.9 Effects of DL77 and E100 on social novelty deficits assessed in VPA-exposed
C57BL/6J mice in TCT
The effect of subchronic systemic injection of DL77 (5, 10, and 15 mg/kg, i.p.),
E100 (5, 10, or 15 mg/kg, i.p.), and DOZ (1 mg/kg, i.p.) on ASD-like social novelty
impairments in the TCT task in VPA-exposed mice are shown in Figure 19A and B.
As observed in the post hoc analysis, VPA-exposed mice exhibited significantly lower
social novelty expressed in form of SNI value when compared to saline-exposed
animals, with [F(1,12) = 24.64; P<0.05] (Figure 19A). However, DL77 (10 and 15
mg/kg) significantly increased SNI of VPA-exposed mice when compared to Saline
treated VPA-exposed group, with [F(1,12) = 6.36; P<0.05] and [F(1,12) = 17.43; P<0.05],
respectively (Figure 19A). Moreover, the results revealed that the enhancement in SNI
observed with DL77 (15 mg/kg) was comparable to that shown with DL77 (10 mg/kg)
with [F(1,12) = 3.61; p=0.08] and DOZ (1 mg/kg) with [F(1,12) = 0.04; p=0.85], and was
significantly higher than the DL77 (5 mg)-provided effects, with [F(1,12) = 27.43;
P<0.05] (Figure 19A). Interestingly, the DL77 (15 mg)-provided improvement of
social novelty was counteracted following subchronic systemic co-administration with
centrally acting H3R agonist RAM (10 mg/kg, i.p.) and the CNS-penetrant H2R
antagonist ZOL (10 mg/kg, i.p.) with [F(1,12) = 9.09; P<0.05] and [F(1,10) = 18.71;
P<0.05], respectively, and as compared to DL77 (15 mg)-treated VPA-exposed mice
(Figure 19B). However, CNS-penetrant H1R antagonist PYR (10 mg/kg, i.p.) failed to
reverse the DL77 (15 mg)-provided social novelty enhancement, with [F(1,12) = 0.58;
p=0.46] for SNI of DL77 (15 mg)-treated VPA-exposed animals vs. PYR (10 mg) +
DL77 (15 mg)-treated group (Figure 19B). Similarly, improvement in social novelty
preference was achieved following subchronic systemic pretreatment of VPA-exposed
mice with E100 (10 and 15 mg/kg, i.p.) and DOZ (1 mg/kg, i.p.), with [F(1,12) = 15.93;
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P<0.05], [F(1,12) = 15.84; P<0.05], and [F(1,12) = 14.60; P<0.05], respectively (Figure
19A). As depicted in Figure 19B and observed in the post hoc analyses, the E100 (10
mg)-provided improvement of social novelty assessed by SNI was reversed by
systemic co-administration of RAM (10 mg/kg, i.p.), ZOL (10 mg/kg, i.p.), or SCO
(0.3 mg/kg, i.p.), with [F(1,12) = 6.77; P<0.05], [F(1,12) = 14.75; P<0.05], or [F(1,10) =
25.29; P<0.05], respectively, and as compared to the E100 (10 mg)-treated animals
(Figure 19B). However, PYR failed to counteract the improved social novelty
provided with E100 (10 mg/kg, i.p.) in treated VPA-exposed mice, since SNI remained
not significant following subchronic co-administration of PYR (10 mg/kg, i.p.) and
E100 (10 mg/kg, i.p.) with [F(1,12) = 0.39; p=0.55] for SNI of E100 (10 mg)-treated
VPA-exposed animals vs. PYR (10 mg) + E100 (10 mg)-treated group (Figure 19B).
Interestingly, the E100 (10 mg)-provided improvement of social novelty assessed by
SNI was comparable to the effects provided by DOZ (1 mg/kg) and DL77 (15 mg/kg),
with [F(1,12) = 0.52; p=0.49] and [F(1,12) = 0.04; p=0.85], respectively (Figure 19A).
Notably, neither DL77 (15 mg) nor E100 (10 mg) or DOZ (1 mg) altered SNI of saline
pretreated saline-exposed mice, with [F(1,12) = 0.19; p=0.67], [F(1,12) = 0.60; p=0.46],
and [F(1,12) = 0.86; p=0.37], respectively (Figure 19A).
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Figure 19: Effects of DL77 and E100 on social novelty deficits assessed in VPAexposed C57BL/6J mice in TCT.
After 10 minutes of exploration, male subjects were allowed to explore all chambers for another 10 min.
The results obtained were Social novelty index (SNI) (A) Abrogation of DL77 (15 mg)- and E100 (10
mg)-provided effect on SNI (B). Saline-exposed mice were injected with saline in SAL group (gray),
DL77 (5, 10, and 15 mg/kg, i.p. in black), E100 (5, 10, and 15 mg/kg, i.p. in green), or DOZ (1 mg/kg,
i.p. in blue) was administered subchronically for 21 days. Abrogative studies of subchronic (21 days)
systemic co-injection of RAM (10 mg/kg, i.p.), PYR (10 mg/kg, i.p.), or ZOL (10 mg/kg, i.p.) on the
DL77 (15 mg) or E100 (10 mg)-provided improvement of social novelty, additionally SCO (0.3 mg/kg,
i.p.) on E100 (10 mg)-provided improvement in SNI. Saline-exposed mice were injected with saline in
group, DL77 (15 mg/kg, i.p.), E100 (10 mg/kg,i.p.) or DOZ (1 mg/kg, i.p.). Figures show mean ± SEM
(n = 7). *P<0.05 vs. SNI of saline-treated saline-exposed mice. #P<0.05 vs. SNI of saline-treated VPAexposed mice. &P<0.05 vs. SI of DL77 (5 mg)- or E100 (5 mg)-treated VPA exposed mice. $P<0.05 vs.
SNI of DL77 (15 mg)- or E100 (10 mg)-treated VPA-exposed mice.
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3.10 Effects of DL77 and E100 on elevated stereotyped repetitive behavior in
VPA-exposed C57BL/6J mice in MBT
The effect of subchronic systemic administration with DL77 (5, 10, or 15
mg/kg, i.p.), E100 (5, 10, or 15 mg/kg, i.p.), and DOZ (1 mg/kg, i.p.) on the elevated
repetitive behavior of VPA-exposed mice in MBT is shown in Figure 20A and B. The
results of statistical analyses showed that VPA-exposed mice buried significantly more
marbles compared to the saline-exposed animals, with [F(1,8) = 18.62; P<0.05].
However, DL77 (10 or 15 mg/kg, i.p.) and DOZ (1 mg/kg, i.p.) significantly
obliterated the increased percentage of marbles buried by VPA-exposed mice
pretreated when compared to saline-treated VPA-exposed mice, with [F(1,9) = 10.56;
P<0.05], [F(1,10) = 14.30; P<0.05], and [F(1,8) = 8.32; P<0.05], respectively (Figure
20A). Noticeably, subchronic systemic administration of DL77 (5 mg/kg, i.p.) failed
to significantly modify the percentage of buried marbles in VPA-exposed mice, with
[F(1,8) = 2.60; p=0.14] (Figure 20A). Moreover, the DL77 (15 mg)-provided decrease
in the percentage of buried marbles was entirely abrogated by RAM and ZOL, with
[F(1,11) = 10.18; P<0.05] and [F(1,12) = 4.80; P<0.05], respectively, and as compared
with DL77 (15 mg)-treated VPA-exposed mice (Figure 20B). However, PYR failed to
counteract this DL77 (15 mg)-provided decrease in the percentage of buried marbles,
as PYR had no significant effect compared to VPA-exposed mice treated with DL77
(15 mg/kg, i.p.), with [F(1,11) = 0.14; p= 0.71] (Figure 20B). Similarly, the effect of
subchronic systemic administration with E100 (5, 10, or 15 mg/kg, i.p.) on the elevated
repetitive behavior of VPA-exposed mice in MBT is shown in Figure 20A. The results
of statistical analyses showed that E100 (10 or 15 mg/kg, i.p.) significantly obliterated
the increased percentage of marbles buried by VPA-exposed mice pretreated when
compared to saline-treated VPA-exposed mice, with [F(1,8) = 17.32; P<0.05] and [F(1,8)
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= 22.35; P<0.05], respectively (Figure 20A). Noticeably, subchronic systemic
administration of E100 (5 mg/kg, i.p.) failed to significantly modify the percentage of
buried marbles in VPA-exposed mice, with [F(1,8) = 0.52; p=0.49] (Figure 20A).
Moreover, the E100 (10 mg)-provided decrease in the percentage of buried marbles
was entirely abrogated by RAM, ZOL, and SCO, with [F(1,8) = 17.71; P<0.05], [F(1,8)
= 5.98; P<0.05], and [F(1,8) = 5.92; P<0.05], respectively, and as compared with E100
(10 mg)-treated VPA-exposed mice (Figure 20B). However, PYR failed to counteract
this E100 (10 mg)-provided decrease in the percentage of buried marbles, as PYR had
no significant effect compared to VPA-exposed mice treated with E100 (10 mg/kg,
i.p.), with [F(1,8) = 0.09; p= 0.77] (Figure 20B). Interestingly, the E100 (10 mg)provided mitigation of repetitive behavior assessed by percentage of buried marbles
was comparable to the effects provided by DOZ (1 mg/kg) and DL77 (15 mg/kg), with
[F(1,10) = 0.10; p=0.75] and [F(1,8) = 3.95; p=0.08], respectively (Figure 20A). Notably,
neither DL77 (15 mg) nor E100 (10 mg) or DOZ (1 mg) altered percentage of buried
marbles of Saline pretreated saline-exposed mice, with [F(1,8) = 0.30; p=0.60], [F(1,8) =
0.11; p=0.75], , and [F(1,8) = 0.02; p=0.89], respectively (Figure 20A).
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Figure 20: Effects of DL77 and E100 on elevated stereotyped repetitive behavior in
VPA-exposed C57BL/6J mice in MBT.
(A) Repetitive marble-burying behavior was measured after a 30-minute testing session. VPA-exposed
mice (red) demonstrated elevated stereotyped, repetitive behaviors that were significantly increased
compared to saline-exposed mice (gray). DL77 (5, 10, or 15 mg/kg, i.p., in black), E100 (5, 10, or 15
mg/kg, i.p., in green), or DOZ (1 mg/kg, i.p. in blue) was administered subchronically for 21 days. (B)
Effects of subchronic (21 days) systemic co-administration of RAM (10 mg/kg, i.p.), PYR (10 mg/kg,
i.p.), or ZOL (10 mg/kg, i.p.) on the DL77 (15 mg)- or E100 (10mg)-provided attenuation of stereotyped
repetitive behavior and additionally SCO (0.3 mg/kg, i.p.) on E100 (10 mg)-provided improvement of
VPA-exposed mice in MBT. Saline-exposed mice were injected with saline, DL77 (15 mg/kg, i.p.),
E100 (10 mg/kg, i.p.), or DOZ (1 mg/kg, i.p.). Figures show mean ± SEM (n = 7). *P < 0.05 vs. salineexposed mice. #P < 0.05 vs. VPA-exposed mice. &P<0.05 vs. DL77 (5 mg)- or E100 (5 mg)-treated
VPA-exposed mice. $P<0.05 vs. DL77 (15 mg)- or E100 (10 mg)-treated VPA-exposed mice.
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3.11 Effects of DL77 and E100 on elevated repetitive and compulsive-like
behaviors in VPA-exposed C57BL/6J mice in NST
The effect of subchronic systemic administration with DL77 (5, 10, or 15
mg/kg, i.p.), E100 (5, 10, or 15 mg/kg, i.p.), and DOZ (1 mg/kg, i.p.) on the percentage
escalation of shredded nestlet was evaluated in NST (Figure 21A and B). Post hoc
analyses showed that VPA-exposed mice shredded significantly more nestlet
compared to the saline-exposed mice, with [F(1,8) = 20.31; P<0.05]. However, VPAexposed mice pretreated with DL77 (10 or 15 mg/kg, i.p.) and DOZ (1 mg/kg, i.p.)
exhibited a significantly lower percentage of shredded nestlet compared to VPAexposed mice treated with saline, with [F(1,8) = 5.65; P<0.05], [F(1,8) = 17.75; P<0.05],
and [F(1,8) = 19.42; P<0.05], respectively (Figure 21A). Moreover, subchronic
systemic administration of DL77 (5 mg/kg, i.p.) failed to significantly modify the
percentage of shredded nestlet in VPA-exposed mice, with [F(1,8) = 0.06; p=0.82]
(Figure 21A). Notably, there was a significant difference in the DL77-provided effect
on percentage of shredded nestlet detected between the two doses of 10 mg/kg and 15
mg/kg, with [F(1,8) = 13.72; P<0.05] (Figure 21A). As shown in Figure 21B and
observed in the post hoc analyses, the DL77 (15 mg)-provided decrease in the
percentage of shredded nestlet was countered following subchronic systemic coadministration of RAM (10 mg/kg, i.p.) and ZOL (10 mg/kg, i.p.), with [F(1,8) = 18.45;
P<0.05] and [F(1,8) = 6.08; P<0.05], respectively, and compared with DL77 (15 mg)treated VPA-exposed mice (Figure 21B). However, PYR failed to reverse this DL77provided decrease in the percentage of shredded nestlet, as it had no significant effect
compared to VPA-exposed mice treated with DL77 (15 mg/kg, i.p.), with [F(1,8) = 0.02;
p=0.90] (Figure 21B). Similarly, the effect of subchronic systemic administration of
E100 (5, 10, or 15 mg/kg, i.p.) on the percentage escalation of shredded nestlet was
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evaluated in NSB (Figure 21B). Post hoc analyses showed that VPA-exposed mice
pretreated with E100 (5 mg, 10 mg or 15 mg/kg, i.p.) exhibited a significantly lower
percentage of shredded nestlet compared to VPA-exposed mice treated with saline,
with [F(1,8) = 20.92; P<0.05], [F(1,8) = 33.26; P<0.05], and [F(1,8) = 38.78; P<0.05],
respectively (Figure 21A). Moreover, the effects observed with 10 or 15 mg/kg were
significantly higher than that witnessed with 5 mg/kg, with [F(1,8) = 6.62; P<0.05] and
[F(1,8) = 9.60; P<0.05], respectively. Notably, no significant difference in the E100provided effect on percentage of shredded nestlet was detected between the two doses
of 10 mg/kg and 15 mg/kg, with p=0.93 (Figure 21A). As shown in Figure 21B and
observed in the post hoc analyses, the E100 (10 mg)-provided decrease in the
percentage of shredded nestlet was countered following subchronic systemic coadministration of RAM (10 mg/kg, i.p.), with [F(1,8) = 11.45; P<0.05] compared with
E100 (10 mg)-treated VPA-exposed mice (Figure 21B). However, PYR, ZOL and
SCO failed to reverse this E100-provided decrease in the percentage of shredded
nestlet, as they had no significant effect compared to VPA-exposed mice treated with
E100 (10 mg/kg, i.p.), with [F(1,8) = 0.003; p=0.96], [F(1,8) = 0.74; p= 0.41], and [F(1,8)
= 0.11; p=0.75], respectively (Figure 21B). Interestingly, the E100 (10 mg)-provided
mitigation of repetitive behavior assessed by percentage of shredded nestlet was
comparable to the effects provided by DOZ (1 mg/kg) and DL77 (15 mg/kg), with
[F(1,8) = 0.003; p=0.96] and [F(1,8) = 0.009; p=0.93], respectively (Figure 21A).
Notably, neither DL77 (15 mg) nor E100 (10 mg) or DOZ (1 mg) altered percentage
of shredded nestlet of saline-treated saline-exposed mice, with [F(1,8) = 0.22; p=0.65],
[F(1,8) = 1.14; p=0.99], , and [F(1,8) = 0.30; p=0.60], respectively (Figure 21A).
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Figure 21: Effects of DL77 and E100 on elevated repetitive and compulsive-like
behaviors in VPA-exposed C57BL/6J mice in NST.
(A) Repetitive shredding behavior was measured after a 30-minute testing session. VPA-exposed mice
(red) demonstrated elevated stereotyped, repetitive behaviors that were significantly increased
compared to saline-exposed mice (gray). DL77 (5, 10, or 15 mg/kg, i.p., in black), E100 (5, 10, or 15
mg/kg, i.p., in olive), or DOZ (1 mg/kg, i.p. in blue) was administered subchronically for 21 days. (B)
Effects of subchronic (21 days) systemic co-administration of RAM (10 mg/kg, i.p.), PYR (10 mg/kg,
i.p.), or ZOL (10 mg/kg, i.p.) on the DL77 (15 mg)- or E100 (10 mg)-provided attenuation of stereotyped
repetitive behavior and additionally SCO (0.3 mg/kg, i.p.) on E100 (10 mg)-provided improvement of
VPA-exposed mice in NST. Saline-exposed mice were injected with saline, DL77 (15 mg/kg, i.p.),
E100 (10 mg/kg, i.p.), or DOZ (1 mg/kg, i.p.). Figures show mean ± SEM (n = 7). *P < 0.05 vs. salineexposed mice. #P < 0.05 vs. VPA-exposed mice. &P<0.05 vs. DL77 (5 mg)- or E100 (5 mg)-treated
VPA-exposed mice. $P<0.05 vs. DL77 (15 mg)- or E100 (10 mg)-treated VPA-exposed mice.
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3.12 Effects of DL77 and E100 pretreatment on anxiety responses and locomotor
activity in VPA-exposed C57BL/6J mice in EPM test
Figure 22A-C shows the observed effects of subchronic systemic injection of
DL77 (5, 10, or 15 mg/kg, i.p.), E100 (5, 10, or 15 mg/kg, i.p.), and DOZ (1 mg/kg,
i.p.) on the anxiety parameters of VPA-exposed mice tested in the EPM, namely, the
percentage of time spent in open arms (Figure 22A), the number of entries into open
arms (Figure 22B), and locomotor activity expressed as the number of entries into
closed arms (Figure 22C). The results observed showed that VPA-exposed mice spent
significantly less time as well as lower number of entries in open arms when compared
to saline-exposed mice, with [F(1,10) = 20.56; P<0.05] and [F(1,10) = 19.84; P<0.05],
respectively (Figure 22A and B). However, subsequent post hoc analyses revealed that
DL77 when administered at 15 mg/kg, i.p. significantly altered the percentage of time
spent exploring the open arms of the maze during a 5 min session compared to salinetreated VPA-exposed mice, with [F(1,10) = 5.37; P<0.05] (Figure 22A). Moreover,
DL77 when administered at three different doses (5, 10, and 15 mg/kg, i.p.) failed to
significantly increase the number of entries the open arms of the maze during a 5 min
session compared to saline-treated VPA-exposed mice, with p = 0.25, p = 0.99, and p
= 0.77, respectively (Figure 22B). Interestingly, VPA-exposed mice pretreated with
DOZ (1 mg) spent a significantly higher percentage of time exploring the open arms
compared to saline-treated VPA-exposed mice, with [F(1,10) = 12.99; P<0.05] (Figure
22A). Further analyses of data describing the number of entries into the open arms of
the maze yielded for DOZ (1 mg/kg, i.p.) practically the same results, with [F(1,10) =
9.97; P<0.05] (Figure 22B). Notably, the number of closed arm entries following
subchronic systemic injection of DL77 (5, 10, or 15 mg/kg) and DOZ (1 mg/kg, i.p.)
was not significantly different, with [F(1,10) = 2.14; p=0.17], [F(1,10) = 2.84; p=0.12],
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[F(1,10) = 2.08; p=0.18], and [F(1,10) = 4.40; p=0.06], receptively (Figure 22C).
Similarly, the effects of subchronic systemic injection of E100 (5, 10, or 15 mg/kg,
i.p.) on the anxiety parameters of VPA-exposed mice in the EPM, namely, the
percentage of time spent in open arms (Figure 22A), the number of entries into open
arms (Figure 22B), and locomotor activity expressed as the number of entries into
closed arms were evaluated (Figure 22C). The results observed revealed that E100
when administered at 10 or 15 mg/kg, i.p. significantly altered the percentage of time
spent exploring the open arms of the maze during a 5 min session compared to salinetreated VPA-exposed mice, with [F(1,10) = 21.54; P<0.05] and [F(1,10) = 12.64; P<0.05],
respectively (Figure 22A). Moreover, post hoc evaluation revealed that, compared
with saline-exposed mice, the VPA-exposed mice displayed similar closed arm entries,
with [F(1.10) = 3.76; p=0.08] (Figure 22C). However, E100 when administered at 10 or
15 mg/kg, i.p. significantly increased the number of entries the open arms of the maze
during a 5 min session compared to saline-treated VPA-exposed mice, with [F(1,10) =
8.29; P<0.05] and [F(1,10) = 13.24; P<0.05], respectively (Figure 22B). Interestingly,
VPA-exposed mice pretreated with DOZ (1 mg) spent a significantly higher
percentage of time exploring the open arms compared to saline-treated VPA-exposed
mice, with [F(1,10) = 13.74; P<0.05] (Figure 22A). Notably, the number of closed arm
entries following subchronic systemic injection of E100 (5, 10, or 15 mg/kg) was not
significantly different, with [F(1,10) = 0.51; p=0.49], [F(1,10) = 2.14; p=0.17], and [F(1,10)
= 0.47; p=0.51], receptively (Figure 22C). Interestingly, the E100 (10 mg)-provided
alteration of time spent in open arms or number of entries into open arms was
significantly higher than those provided with DL77 (15 mg/kg), with [F(1,10) = 6.59;
P<0.05] and [F(1,10) = 6.43; P<0.05], respectively (Figure 22A and B). As shown in
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Figure 22D and observed in the post hoc analyses, the DL77 (15 mg)- or E100 (10
mg)-provided increase in the time spent in open arms was abrogated following
subchronic systemic co-administration of RAM (10 mg/kg, i.p.), with [F(1,10) = 8.63;
P<0.05] and [F(1,8) = 28.93; P<0.001], respectively, and as compared with DL77 (15
mg)- or E100 (10 mg)-treated VPA-exposed mice (Figure 22D). However, PYR and
ZOL failed to abrogate the DL77-provided increase in time spent in open arm, as they
had no significant effect compared to VPA-exposed mice treated with DL77 (15
mg/kg, i.p.), with [F(1,10) = 0.08; p=0.79] and [F(1,10) = 0.40; p=0.54], respectively
(Figure 22D). However, SCO reversed the E100-provided effects on time spent in open
arm and as compared to VPA-exposed mice treated with E100 (10 mg/kg, i.p.), with
[F(1,10) = 8.16; P<0.05], while ZOL and PYR failed to nullify the E100 (10 mg)provided effect, with [F(1,11) = 0.32; p=0.59] and [F(1,11) = 0.60; p=0.45], respectively
(Figure 22D). Statistical analyses of number of entries into open arms yielded
practically the same results for E100 (10 mg)-provide effect (Figure 22B) and its
abrogation with RAM (Figure 22E). Notably, neither DL77 (15 mg) nor E100 (10 mg)
or DOZ (1 mg) altered percentage of time spent in open arms of saline-treated salineexposed mice, with [F(1,10) = 2.34; p=0.16], [F(1,10) = 0.70; p=0.42], , and [F(1,10) = 0.03;
p=0.87], respectively (Figure 22A). Similarly, neither DL77 (15 mg) nor E100 (10 mg)
or DOZ (1 mg) altered number of entries into open arms of Saline pretreated salineexposed mice (all P>0.05) (Figure 22B).
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Figure 22: Effects of DL77 and E100 pretreatment on anxiety responses and
locomotor activity in VPA-exposed C57BL/6J mice in EPM test.
VPA-exposed mice (red) demonstrated elevated innate anxiety and risk assessment that were
significantly increased compared to saline-exposed mice (gray). DL77 (5, 10, or 15 mg/kg, i.p. in black),
E100 (5, 10, or 15 mg/kg, i.p., in green), or DOZ (1 mg/kg, i.p., in blue) was administered subchronically
for 21 days. DOZ (1 mg/kg, i.p.) attenuated the decreased percentage of time spent on the open arms of
the EPM (A) the decreased number of entries into the open arms (B) and the increased number of entries
into the closed arms (C) in VPA exposed mice. Abrogation of subchronic (21 days) systemic coadministration of RAM (10 mg/kg, i.p.), PYR (10 mg/kg, i.p.), or ZOL (10 mg/kg, i.p.) on the DL77
(15 mg)- or E100 (10 mg)-provided effects and additionally SCO (0.3 mg/kg, i.p.) on E100 (10 mg)provided modulation on time spent in the open arms (D) and number of entries into the open arms (E).
attenuation of anxiety of VPA-exposed mice in EPM. Saline-exposed mice were injected with saline,
DL77 (15 mg/kg, i.p.), E100 (10 mg/kg, i.p.), or DOZ (1 mg/kg, i.p.) (A-C). Data are expressed as the
mean ± SEM (n = 6). *P < 0.05 vs. saline-exposed mice. #P < 0.05 vs. VPA-exposed mice. &P<0.05 vs.
DL77 (5 mg)- or E100 (5 mg)-treated VPA-exposed mice. $P<0.05 vs. DL77 (15 mg)- or E100 (10 mg)treated VPA-exposed mice.
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Figure 22: Effects of DL77 and E100 pretreatment on anxiety responses and
locomotor activity in VPA-exposed C57BL/6J mice in EPM test (continued).

3.13 Effects of DL77 and E100 pretreatment on exploratory and anxiety-like
behaviors in VPA-exposed C57BL/6J mice in OFT
Figure 23 A-D shows the observed effects of subchronic systemic injection of
DL77 (5, 10, or 15 mg/kg, i.p.), E100 (5, 10, or 15 mg/kg, i.p.), and DOZ (1 mg/kg,
i.p.) on the anxiety parameters of VPA-exposed mice tested in the OFT. As seen in
Figure 23 A-D, there were no significant effects of subchronic systemic exposure of
VPA-exposed mice to DL77 (5, 10, and 15 mg/kg, i.p.) on time spent in the central
arena, time spent in the periphery and total distance travelled (all P values >0.05)
(Figure 23A-D). In contrast, analysis of variance demonstrated that VPA-exposed
mice pretreated with E100 (10 and 15 mg/kg, i.p.) spent a significantly higher
percentage of time in the center of the arena, with [F(1,8) = 19.95; P<0.05] and [F(1,8) =
10.31; P<0.05], respectively (Figure 23A). As shown in Figure 23B and observed in
the post hoc analyses, the E100 (10 mg)-provided increase in the time spent in the
center of arena was abrogated following subchronic systemic co-administration of
RAM (10 mg/kg, i.p.), with [F(1,8) = 28.93; P<0.05] compared with E100 (10 mg)-
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treated VPA-exposed mice (Figure 23B). However, PYR, ZOL, and SCO failed to
abrogate this E100-provided increase in time spent in central arena, as they had no
significant effect compared to VPA-exposed mice treated with E100 (10 mg/kg, i.p.),
with [F(1,8) = 0.054; p=0.82], [F(1,8) = 0.18; p= 0.69], and [F(1,8) = 0.33; p=0.86],
respectively (Figure 23B). In addition, there were no significant effects of subchronic
systemic exposure of VPA-exposed mice to E100 (5, 10, and 15 mg/kg, i.p.) on
increased total distance travelled in the test arena neither on increased time spent in
the periphery (all P values >0.05) (Figure 23C and D). Notably, subchronic treatment
of saline-exposed mice with E100 (10 mg/kg, i.p.) had no significant influence on time
spent in the central arena compared to saline-pretreated saline-exposed mice, with
[F(1,8) = 0.01; p=0.92] (Figure 23A).
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Figure 23: Effects of DL77 and E100 pretreatment on exploratory and anxiety-like
behaviors in VPA-exposed C57BL/6J mice in OFT.
VPA-exposed mice (red) demonstrated general locomotor activity and anxiety-related emotional
behaviors that were significantly increased compared to saline-exposed mice (gray). DL77 (5, 10, or 15
mg/kg, i.p. in black), E100 (5, 10, or 15 mg/kg, i.p. in green) or DOZ (1 mg/kg, i.p. in blue) was
administered subchronically for 21 days. E100 (10 and 15 mg/kg, i.p.) and DOZ (1 mg/kg, i.p.)
increased the decreased time spent in the central arena (A) but failed to modulate the increased time
spent in the periphery (C) as well as the increased total distance travelled (D) in VPA-exposed mice in
the OFT. Effects of subchronic (21 days) systemic co-injection of RAM (10 mg/kg, i.p.), PYR (10
mg/kg, i.p.), ZOL (10 mg/kg, i.p.), or SCO (0.3 mg/kg, i.p.) on the E100 (10 mg)-provided amelioration
of time spent in the center of VPA-exposed mice in OFT (B). Data are expressed as the mean ± SEM
(n = 5). #P<0.05 vs. saline-exposed mice. *P<0.05 vs. saline-treated VPA-exposed mice. $P<0.05 vs.
E100 (10 mg)-treated VPA-exposed mice.

3.14 DL77 and E100 restored levels of proinflammatory cytokines in the
cerebellum of VPA-exposed C57BL/6J mice
The effects of subchronic systemic treatment of DL77 (5, 10, or 15 mg/kg, i.p.),
E100 (5, 10, or 15 mg/kg, i.p.), and DOZ (1 mg/kg, i.p.) on the levels of
proinflammatory cytokines IL-1β (Figure 24A), IL-6 (Figure 24C), TNF-α (Figure
24E), and TGF-β (Figure 24G) exacerbated with LPS challenge in cerebellum tissue
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of VPA-exposed mice were evaluated. The results observed revealed that systemic
prenatal injection of VPA (500 mg/kg, i.p.) induced ASD-like behaviors in VPAexposed mice and significantly increased IL-1β (Figure 24A), IL-6 (Figure 24C), TNFα (Figure 24E), and TGF-β (Figure 24G) compared to the saline-exposed mice (all
P<0.05). However, subchronic systemic administration of DL77 (10 and 15 mg/kg,
i.p.) or DOZ (1 mg/kg) significantly (all P<0.05) mitigated the rise of these
proinflammatory cytokines in VPA-exposed mice (Figures 24A, C, E, and G).
Notably, subchronic systemic co-administration of RAM (10 mg/kg, i.p.) abrogated
(all P<0.05) the protective effects of DL77 (15 mg/kg, i.p.) against VPA-induced
elevation of IL-1β (Figure 24B), IL-6 (Figure 24D), TNF-α (Figure 24F), and TGF- β
(Figure 24H). Similarly, the effects of E100 (5,10 and 15 mg/kg, i.p.) on the levels of
proinflammatory cytokines IL-1β (Figure 24A), IL-6 (Figure 24C), TNF-α (Figure
24E), and TGF-β (Figure 24G) in the cerebellum tissue of VPA-exposed mice were
evaluated. The results observed revealed that subchronic systemic administration of
E100 (5, 10, and 15 mg/kg, i.p.) significantly (all P<0.05) alleviated the rise of these
proinflammatory cytokines in VPA-exposed mice. Also, subchronic systemic coadministration of RAM (10 mg/kg, i.p.) nullified (all P<0.05) the protective effects of
E100 (10 mg/kg, i.p.) against VPA-induced elevation of IL-1β (Figure 24B), IL-6
(Figure 24D), TNF-α (Figure 24F), and TGF- β (Figure 24H).
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Figure 24: DL77 and E100 restored levels of proinflammatory cytokines in the
cerebellum of VPA-exposed C57BL/6J mice.
VPA-exposed mice (red) showed a significant increase in IL-1β (A), IL-6 (C), TNF-α (E), and TGF-β
(G) compared to saline-exposed mice (gray). DL77 (5, 10, or 15 mg/kg, i.p. in black), E100 (5, 10, or
15 mg/kg, i.p. in green), or DOZ (1 mg/kg, i.p. in blue) was administered subchronically for 21 days.
DL77 (10 or 15 mg/kg, i.p.), E100 (5, 10, or 15 mg/kg, i.p.), or DOZ (1 mg/kg, i.p.) significantly
decreased the elevated levels of these cytokines. RAM (10 mg/kg, i.p.), PYR (10 mg/kg, i.p.), and ZOL
(10 mg/kg, i.p.) were co-administered for abrogative studies of the modulating DL77 (15 mg)-, or E100
(10 mg)-provided effects on cytokines levels (B, D, F, and H). Data are expressed as the mean ± SEM
(n = 5). *P< 0.05 vs. saline-exposed mice. #P<0.05, ##P<0.01 vs. VPA-exposed mice. &P<0.05 vs. DL77
(5 mg)- or E100 (5 mg)-provided improvement. $P<0.05 vs. DL77 (15 mg)-, or E100 (10 mg)-treated
VPA-exposed mice.
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Figure 24: DL77 and E100 restored levels of proinflammatory cytokines in the
cerebellum of VPA-exposed C57BL/6J mice (continued).

3.15 DL77 and E100 restored levels of oxidative stress markers in the cerebellum
of VPA-exposed C57BL/6J mice
The ability of subchronic systemic administration with DL77 (5, 10, or 15
mg/kg, i.p.), E100 (5, 10, or 25 mg/kg, i.p.), and DOZ (1 mg/kg, i.p.) to decrease
oxidative stress in VPA-exposed mice was assessed (Figure 25A-H). Four parameters
were measured, namely the levels of MDA, GSH, SOD, and CAT in VPA-exposed
mouse cerebellum. The results show that MDA was significantly raised (P<0.05) and
GSH, SOD, and CAT were significantly reduced (P<0.05) in the brain tissues of VPAexposed mice compared to saline-exposed mice (Figure 25A, C, E, and G). However,
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brain tissues of VPA-exposed mice subchronically pretreated with DL77 (15 mg/kg,
i.p.) or DOZ (1 mg/kg, i.p.) displayed a significant reduction of MDA as well as
significant elevation of GSH, SOD, and CAT (P<0.05) (Figure 25A, C, E, and G).
Moreover, subchronic systemic co-administration of RAM (10 mg/kg, i.p.) reversed
(P<0.05) the protective effects of DL77 (15 mg/kg, i.p.) against the VPA-induced
increased level of MDA (Figure 25B), and it also reversed (all P<0.05) the DL77 (15
mg)-provided increase in GSH, SOD, and CAT in VPA-exposed mice (Figure 25D, F
and H). Similarly, brain tissues of VPA-exposed mice subchronically pretreated with
E100 (, 10, and 15 mg/kg, i.p.) displayed a significant reduction of MDA (Figure 25A)
as well as significant elevation of GSH (Figure 25C), SOD (Figure 25E), and CAT
(Figure 25G) (all P<0.05). Moreover, subchronic systemic co-administration of RAM
(10 mg/kg, i.p.) partially abrogated (P<0.05) the protective effects of E100 (10 mg/kg,
i.p.) against the VPA-induced increased level of MDA (Figure 25B), and it also
partially reversed (P<0.05) the E100 (10 mg)-provided increase in GSH, SOD, and
CAT in VPA-exposed mice (Figure 25D, F and H).
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Figure 25: DL77 and E100 restored levels of oxidative stress markers in the
cerebellum of VPA-exposed C57BL/6J mice.
VPA-exposed mice (red) showed a significant increase in MDA (A) and decrease in GSH (C), SOD
(E), and CAT (G) compared to saline-exposed mice (gray). DL77 (5, 10, or 15 mg/kg, i.p. in black),
E100 (5, 10, or 15 mg/kg, i.p. in green), or DOZ (1 mg/kg, i.p. in blue) was administered subchronically
for 21 days. DL77 (5, 10, or 15 mg/kg, i.p.), E100 (5, 10, or 15 mg/kg, i.p.), or DOZ (1 mg/kg, i.p.)
significantly modulated the levels of these markers. RAM (10 mg/kg, i.p.), PYR (10 mg/kg, i.p.), and
ZOL (10 mg/kg, i.p.) were co-administered for abrogative studies of the modulating DL77 (15 mg)-, or
E100 (10 mg)-provided effects on oxidative stress levels (B, D, F, and H). Data are expressed as the
mean ±SEM (n = 5). *P< 0.05 vs. saline-exposed mice. #P<0.05 vs. VPA-exposed mice. &P<0.05 vs.
DL77 (5 mg)- or E100 (5 mg)-provided effects. $P<0.05 vs. DL77 (15 mg)-, or E100 (10 mg)-treated
VPA-exposed mice.
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Figure 25: DL77 and E100 restored levels of oxidative stress markers in the
cerebellum of VPA-exposed C57BL/6J mice (continued).

3.16 Effects of E100 on expression of NF-κB p65, iNOS & COX-2 in cerebellum
and hippocampus of VPA-exposed C57BL/6J mice
The expressions of NF-κBp65, iNOS, and COX-2 were also tested using
Western blot in tissue lysates that were isolated from cerebellum (Figure 26A) and
hippocampus regions (Figure 26B). A significant increase in expression of NF-κBp65,
iNOS, and COX-2 (Figure 26A) was observed in the cerebellum of VPA-exposed mice
when compared to the saline-exposed control group of mice (all P<0.05). However,
following subchronic systemic pretreatment of VPA-exposed mice with E100 (10
mg/kg), a remarkable reduction in the level of NF-κBp65, iNOS, and COX-2 (all
P<0.05) was observed when compared to the VPA-exposed mice (Figure 26A).
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Similarly, hippocampal tissues of VPA-exposed mice also showed a significant
increase (P< 0.05) in expression of NF-κBp65, iNOS, and COX-2 (Figure 26B) when
compared to the saline-exposed mice, however, subchronic systemic pretreatment of
VPA-exposed mice with E100 (10 mg/kg) resulted in a remarkable decrease in
expression of NF-κBp65, iNOS, and COX-2 (all P<0.05) when compared to the VPAexposed mice (Figure 26B). Interestingly, subchronic systemic co-administration of
RAM (10 mg/kg, i.p.) entirely nullified the mitigating effects of E100 (10 mg/kg, i.p.)
on expression of NF-κBp65 and COX-2 in cerebellum and hippocampus tissues (all
P<0.05), and it also partly counteracted the E100 (10 mg)-provided effects on iNOS
in VPA-exposed mice (all P<0.05) (Figure 26A and B).
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Figure 26: Effects of E100 on expression of NF-κB p65, iNOS & COX-2 in cerebellum
and hippocampus of VPA-exposed C57BL/6J mice.
NF-κBp65, iNOS and COX-2 are modulated by subchronic treatment with E100 (10 mg/kg, i.p.) in
cerebellum and hippocampus of prenatally VPA treated mice (red). Representative immunoblots of
cerebellum tissues of VPA-exposed group subjected to immunoreactions with anti-NF-κB p65, antiiNOS and anti-COX2 (A). Representative immunoblots of hippocampal tissues of VPA-exposed group
subjected to immunoreactions with anti-NF-κB p65, anti-iNOS and anti-COX2 (B). Blots were
quantified using Image J and corresponding results were represented as fold change of control. Data are
expressed as mean ± SEM (n=3). *P<0.05, **P<0.01, ***P<0.001 vs saline-exposed mice; #P<0.05,
##
P<0.01, ###P< 0.001 vs. VPA-exposed mice and $P<0.05, $$P<0.01, $$$P<0.001 vs. E100 (10 mg)pretreated group VPA exposed mice.
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3.17 Effects of E100 on iba-1 positive microglia in cerebellum tissues of VPAexposed C57BL/6J mice
Activation of glial cell (microglia) in VPA-exposed mice has been observed
and is considered to be an index of the inflammatory responses (Figure 27A and B).
The observed results showed that VPA-exposed mice exhibited a significant increase
in the expression of Iba-1, which is a marker of activated microglia (P<0.05) (Figure
27A and B). Immunofluorescence staining revealed a significant increase (P<0.05) in
the number of activated microglia in VPA-exposed mice compared to the salineexposed control mice (Figure 27A and B). However, subchronic systemic treatment of
VPA-exposed mice with E100 (10 mg/kg, i.p.) significantly decreased the number of
activated microglia compared to the saline-exposed control mice (P< 0.05) (Figure
27C). Moreover, subchronic systemic co-administration of RAM (10 mg/kg, i.p.)
entirely reversed the effects of E100 (10 mg/kg, i.p.) on the number of activated
microglia compared to the E100 (10 mg)-treated VPA-exposed animals (P< 0.05)
(Figure 27D).
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Figure 27: Effects of E100 on iba-1 positive microglia in cerebellum tissues of VPAexposed C57BL/6J mice.
Profound expression of iba-1-positive microglia was found in the VPA-exposed mice (B) compared to
the saline-exposed mice (A). In contrast, subchronic treatment with E100 to the VPA-exposed mice
showed significantly lower staining of Iba-1 compared to the VPA-exposed mice (C). Subchronic (21
days) systemic co-injection of RAM (10 mg/kg, i.p) counteracted the E100 (10 mg)-provided
amelioration of iba-expression of VPA-exposed mice ($P < 0.05) (D). Quantitative analysis of activated
microglia (E) revealed a significant increase (*P<0.05) in the number of activated microglia in
cerebellum of VPA-exposed mice compared to the saline-exposed mice. However, subchronic treatment
with E100 (10 mg/kg, i.p.) to the VPA-exposed mice significantly reduced (#P<0.05) the number of
activated microglia in the E100-treated VPA-exposed mice compared to the saline-treated VPAexposed mice group. Values are expressed as the percent mean ± SEM (n = 3).
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3.18 Effects of E100 on sociability and social novelty impairments of BTBR mouse
model of ASD
The effect of subchronic systemic injection of E100 at three different doses (5,
10, and 15 mg/kg, i.p.) and DOZ (1 mg/kg, i.p.) on ASD-like sociability and social
novelty impairments in the TCT task in BTBR mice are shown in Figure 28 A and B.
The results of statistical analyses revealed that subchronic pretreatment with E100 (5,
10, and 15 mg/kg, i.p.) and DOZ (1 mg/kg) prior to TCT significantly enhanced
sociability by increasing SI, with [F(5,24) = 5.79; P<0.05] (Figure 28A). As observed in
the post hoc analysis, BTBR mice exhibited significantly lower sociability expressed
in form of SI value when compared to control animals, with [F(1,8) = 13.66; P<0.05]
(Figure 28A). However, E100 (5 and 10 mg/kg) and DOZ (1 mg/kg) significantly
increased SI of BTBR mice when compared to saline treated BTBR mice group, with
[F(1,8) = 9.36; P<0.05], [F(1,8) = 8.74; P<0.05], and [F(1,8) = 6.21; P<0.05], respectively
(Figure 28A). Moreover, the results revealed that the enhancement in SI observed with
E100 (5 mg/kg) was comparable to that shown with DOZ (1 mg/kg) and E100 (10
mg/kg), with [F(1,8) = 0.46; p=0.52] and [F(1,8) = 0.26; p=0.63], respectively (Figure
28A). Notably, E100 (15 mg/kg) failed to restore sociability deficits of BTBR mice,
with [F(1,8) = 4.21; p=0.07] (Figure 28A). Interestingly, the E100 (5 mg)-provided
improvement of sociability was counteracted following subchronic systemic coadministration with centrally acting H3R agonist RAM (10 mg/kg, i.p.), with [F(1,8) =
10.90; P<0.05] (Figure 28A). Similarly, the results of post hoc analyses indicated that
BTBR mice demonstrated significantly impaired social novelty preference when
compared to the control mice, with [F(1,8) = 6.69; P<0.05] (Figure 28B). However,
improvement in social novelty preference was achieved following subchronic systemic
pretreatment of BTBR mice with E100 (5 and 10 mg/kg, i.p.) and DOZ (1 mg/kg, i.p.),
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with [F(1,8) = 8.65; P<0.05], [F(1,8) = 5.47; P<0.05], and [F(1,8) = 5.37; P<0.05],
respectively (Figure 28B). E100 (15 mg/kg) failed to restore social novelty deficits of
BTBR mice, with [F(1,8) = 1.83; p=0.21] (Figure 28B). As depicted in Figure 28B and
observed in the post hoc analyses, the E100 (5 mg)-provided improvement of social
novelty assessed by SNI was nullified by RAM (10 mg/kg, i.p.), with [F(1,8) = 7.08;
P<0.05], and as compared to the E100 (5 mg)-treated BTBR mice (Figure 28B).
Interestingly, subchronic systemic pretreatment of control mice with the most
promising dose of E100 (5 mg/kg, i.p.) did not alter SI or SNI as compared to salinetreated control mice (P>0.05).

Figure 28: E100 improved sociability and social novelty deficits of BTBR mouse
model of ASD.
After 10 minutes of acclimatization, male subjects were allowed to explore all chambers for two 10 min
sessions. The results obtained were Sociability index (SI) (A) and Social novelty index (SNI) (B).
C57BL/6J (gray) were injected with saline in Ctrl group, E100 (5,10 or 15 mg/kg, i.p.) or DOZ (1 mg/kg,
i.p.) were administered subchronically for 21 days. Abrogative study of subchronic (21 days) systemic
co-injection of RAM (10 mg/kg, i.p.) on the E100 (5 mg)-provided improvement of sociability (A) and
social novelty (B). Figures show mean ± SEM (n = 5). *P<0.05 vs. SI or SNI of saline-treated Ctrl mice.
#
P<0.05 vs. SI or SNI of saline-treated BTBR mice. $P<0.05 vs. E100 (5 mg)-treated BTBR mice.

3.19 Effects of E100 on acetylcholine esterase activity in cerebellum tissues of
BTBR mice
Acetylcholine esterase activity in BTBR mice has been assessed (Figure 29).
The observed results showed that BTBR mice exhibited a significant increase in the
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activity of acetylcholine esterase enzyme in cerebellum tissues of BTBR mice as
compared to control mice (P<0.05) (Figure 29). However, subchronic systemic
treatment of BTBR mice with E100 (5 mg/kg, i.p.) significantly decreased the
acetylcholine activity of BTBR mice when compared with the saline-treated BTBR
mice (P< 0.01) (Figure 29). Similarly, subchronic systemic pretreatment with the
reference drug DOZ (1 mg/kg, i.p.) significantly decreased the acetylcholine activity
of BTBR mice when compared with the saline-treated BTBR mice (P< 0.01) (Figure
29).

Figure 29: Effects of E100 on acetylcholine esterase activity in cerebellum tissues of
BTBR mice.
Inhibitory effects of E100 (5 mg/kg, i.p.) on acetylcholine esterase enzyme in the cerebellum of BTBR
mice. Quantitative analysis revealed a significant increase (**P<0.01) in the acetylcholine esterase
enzyme activity in cerebellum of BTBR mice compared to the control mice. However, subchronic
treatment with E100 (5 mg/kg, i.p.) or DOZ (1 mg/kg, i.p.) to the BTBR mice significantly reduced
(##P<0.01) this activity compared to the saline-treated BTBR mice. Values are expressed as the
percent mean ± SEM (n = 3-5).
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3.20 Effects E100 on stereotyped repetitive and obsessive-compulsive behaviors
of BTBR mouse model of ASD in MBT and NST
The effect of subchronic systemic administration with E100 (5, 10, or 15
mg/kg, i.p.) or DOZ (1 mg/kg, i.p.) on the elevated repetitive behavior of BTBR mice
in MBT is shown in Figure 30A. The results of statistical analyses showed that
subchronic pretreatment with 5, 10 or 15 mg/kg of E100 or 1 mg/kg DOZ prior to
MBT significantly reduced the elevated percentage of marbles buried by BTBR mice,
with [F(5,30) = 14.22; P<0.05] (Figure 30A). BTBR mice buried significantly more
marbles compared to the control mice, with [F(1,10) = 34.37; P<0.05]. However,
pretreatment with E100 (5, 10 or 15 mg/kg, i.p.) and DOZ (1 mg/kg, i.p.) significantly
obliterated the increased percentage of marbles buried by BTBR mice when compared
to saline-treated BTBR mice, with [F(1,10) = 29.41; P<0.05], [F(1,10) = 19.61; P<0.05],
[F(1,10) = 13.24; P<0.05], and [F(1,10) = 22.85; P<0.05], respectively (Figure 30A).
Moreover, the E100 (5 mg)-provided decrease in the percentage of buried marbles was
comparable to the DOZ-provided effect, with [F(1,10) = 0.12; p=0.73], and was entirely
abrogated by RAM, with [F(1,10) = 2.08; p=0.18] and as compared with slaine-treated
BTBR mice (Figure 30A). Notably, subchronic systemic pretreatment of control mice
with the most promising dose of E100 (5 mg/kg, i.p.) did not alter percentage of buried
marbles in MBT as compared to saline-treated control mice (P>0.05). Similarly, the
effect of subchronic systemic administration of E100 (5, 10, or 15 mg/kg, i.p.) or DOZ
(1 mg/kg, i.p.) on the percentage escalation of shredded nestlet was evaluated in NST
(Figure 30B). Post hoc analyses showed that BTBR mice shredded significantly more
nestlet compared to the control mice, with [F(1,10) = 27.94; P<0.05]. However, BTBR
mice pretreated with E100 (5 or 10 mg/kg, i.p.) exhibited a significantly lower
percentage of shredded nestlet compared to BTBR mice treated with saline, with
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[F(1,10) = 12.72; P<0.05] and [F(1,10) = 6.63; P<0.05], respectively (Figure 30B).
Moreover, the effect observed with 5 mg/kg was comparable to that witnessed with 10
mg/kg, with [F(1,10) = 0.54; p = 0.48], and was significantly higher than that witnessed
with 15 mg/kg, with [F(1,10) = 6.11; P<0.05] (Figure 30B). Notably, no significant
difference in the E100-provided effect on percentage of shredded nestlet was detected
between the two doses of 10 mg/kg and 15 mg/kg, with p=0.17 (Figure 30B).
Moreover, subchronic systemic administration of DOZ (1 mg/kg, i.p.) significantly
lowered the percentage of shredded nestlet in BTBR mice, with [F(1,10) = 7.79;
P<0.05]. As shown in Figure 30B and observed in the post hoc analyses, the E100 (5
mg)-provided decrease in the percentage of shredded nestlet was countered following
subchronic systemic co-administration of RAM (10 mg/kg, i.p.), with [F(1,10) = 6.05;
P<0.05] and as compared with E100 (5 mg)-treated BTBR mice (Figure 30B).
Notably, subchronic systemic pretreatment of control mice with the most promising
dose of E100 (5 mg/kg, i.p.) did not alter percentage of shredded nestlets in NST as
compared to saline-treated control mice (P>0.05).
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Figure 30: E100 mitigated stereotyped repetitive behavior in MBT and attenuated
increased obsessive-compulsive features in NST.
Repetitive marble-burying (A) and obsessive compulsive nestlet shredding (B) behavior were measured
after a 30-minute testing session. BTBR mice (red) demonstrated elevated stereotyped, repetitive and
compulsive behaviors that were significantly increased compared to Ctrl mice (gray). E100 (at a dose
of 5, 10, or 15 mg/kg, i.p in green) or DOZ (1 mg/kg, i.p. in blue) was administered subchronically for
21 days. Effects of subchronic (21 days) systemic co-injection of RAM (10 mg/kg, i.p.) on the E100 (5
mg)-provided attenuation of stereotyped repetitive and compulsive behaviors of BTBR mice were
assessed in MBT (A) and NST (B). Figures show mean ± SEM (n = 6). *P<0.05 vs. saline-treated Ctrl
mice. #P<0.05 vs. saline-treated BTBR mice. &P<0.05 vs. E100 (10 or 15 mg)-treated BTBR mice.
$
P<0.05 vs. E100 (5 mg)-treated BTBR mice.

3.21 Effects of E100 on anxiety levels and locomotor activity of BTBR model of
ASD in EPM
Figure 31A-C shows the observed effects of subchronic systemic injection of
saline or E100 (5, 10, or 15 mg/kg, i.p.) on the anxiety parameters of BTBR mice tested
in the EPM, namely, the percentage of time spent in open arms (Figure 31A), the
number of entries into open arms (Figure 31B), and locomotor activity expressed as
the number of entries into closed arms (Figure 31C). The results observed showed that
BTBR mice spent significantly less time and lower number of entries in open arms
when compared to control mice, with [F(1,10) = 36.82; P<0.05] and [F(1,10) = 8.83;
P<0.05], respectively (Figure 31A and B). However, subsequent post hoc analyses
revealed that E100 when administered at 5, 10, or 15 mg/kg, i.p. significantly altered
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the percentage of time spent exploring the open arms of the maze during a 5 min
session compared to saline-treated BTBR mice, with [F(1,10) = 23.99; P<0.05], [F(1,10)
= 5.33; P<0.05], and [F(1,10) = 17.91; P<0.05], respectively (Figure 31A). Moreover,
post hoc evaluation revealed that, compared with control mice, the BTBR mice
displayed a lower number of entries into the open arms, with [F(1.10) = 8.83; P<0.05]
(Figure 31B). However, E100 when administered at 5, 10 or 15 mg/kg, i.p.
significantly increased the number of entries the open arms of the maze during a 5 min
session compared to saline-treated BTBR mice, with [F(1,10) = 13.24; P<0.05], [F(1,10)
= 12.31; P<0.05], and [F(1,10) = 18.85; P<0.05], respectively (Figure 31B).
Interestingly, BTBR mice pretreated with DOZ (1 mg) spent a significantly lower
percentage of time exploring the open arms compared to saline-treated BTBR mice,
with [F(1,10) = 14.28; P<0.05] (Figure 31A). Further analyses of data describing the
number of entries into the open arms of the maze yielded for DOZ (1 mg/kg, i.p.)
higher number of entries into open arms when compared to saline-treated BTBR mice,
with [F(1,10) = 8.42; P<0.05] (Figure 31B). As shown in Figure 31A and B, the E100
(5 mg)-provided improvement in anxiety levels was abrogated by RAM (10 mg/kg,
i.p.) with [F(1,10) = 10.74; P<0.05] and [F(1,10) = 6.17; P<0.05], for time spent in open
arms and number of open arm entries, respectively, and as compared to E100 (5 mg)treated BTBR mice. Notably, the number of closed arm entries following subchronic
systemic injection of E100 (5, 10, or 15 mg/kg) and DOZ (1 mg/kg, i.p.) was not
significantly different as compared to saline treated BTBR mice, with [F(1,10) = 1.90;
p=0.20], [F(1,10) = 0.34; p=0.57], [F(1,10) = 2.46; p=0.15], and [F(1,10) = 2.73; p=0.13],
receptively (Figure 31C). Interestingly, subchronic systemic pretreatment of control
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mice with the most promising dose of E100 (5 mg/kg, i.p.) did not alter any of the
tested parameters in EPM and as compared to saline-treated control mice (all P>0.05).

Figure 31: Effects of E100 and DOZ pretreatment on anxiety levels and locomotor
activity in BTBR mice in EPM test.
BTBR mice (red) demonstrated elevated anxiety-related behavior and hyperactivity that were
significantly increased compared to Ctrl mice (gray). E100 (5, 10, or 15 mg/kg, i.p. in green) or DOZ
(1 mg/kg, i.p., in blue) was administered subchronically for 21 days. E100 (5, 10, or 15 mg/kg, i.p.) and
DOZ (1 mg/kg, i.p.) attenuated the decreased percentage of time spent on the open arms of the EPM
(A) the decreased number of entries into the open arms (B) and the increased number of entries into the
closed arms (C) in BTBR mice. Effects of subchronic (21 days) systemic co-injection of RAM (10
mg/kg, i.p.) on the E100 (5 mg)-provided elevation of time spent in open arms (A) or number of entries
into open arms (B) of BTBR mice were assessed in EPM test. Data are expressed as the mean ± SEM
(n = 6). *P < 0.05 vs. Saline treated Ctrl mice. #P < 0.05 vs. Saline treated BTBR mice. &P<0.05 vs.
E100 (10 or 15 mg)-treated BTBR mice. $P<0.05 vs. E100 (5 mg)-treated BTBR mice.
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3.22 Effects of E100 on anxiety levels and locomotor activity of BTBR model of
ASD in OFT
In addition to EPM, the OFT was used to test anxiety-like behavior and
locomotion. As seen in Figure 32A-C, there were no significant effects of subchronic
systemic exposure of BTBR mice to E100 (5, 10, and 15 mg/kg, i.p.) on time spent in
the periphery (all P>0.05) (Figure 32B). In contrast, analysis of variance demonstrated
that BTBR mice pretreated with E100 (5, 10, and 15 mg/kg, i.p.) spent a significantly
lower percentage of time in the center of the arena, with [F(1,6) = 6.96; P<0.05], [F(1,6)
= 15.25; P<0.05], and [F(1,6) = 14.56; P<0.05], respectively (Figure 32A). As shown
in Figure 32A and observed in the post hoc analyses, the E100 (5 mg)-provided
decrease in the time spent in the center of arena was abrogated following subchronic
systemic co-administration of RAM (10 mg/kg, i.p.), with [F(1,6) = 6.42; P<0.05]
compared with E100 (5 mg)-treated BTBR mice (Figure 32A). Moreover, BTBR mice
pretreated with E100 (5, 10, and 15 mg/kg, i.p.) and DOZ (1 mg/kg, i.p.) demonstrated
significantly lower travelled distance when compared to saline-treated BTBR mice,
with [F(1,6) = 10.60; P<0.05], [F(1,6) = 10.57; P<0.05], [F(1,6) = 8.84; P<0.05], and [F(1,6)
= 7.76; P<0.05], respectively (Figure 32C). Notably, subchronic treatment of control
mice with E100 (5 mg/kg, i.p.) had no significant influence on time spent in the central
arena, time spent in the periphery, or total distance travelled as compared to salinepretreated control mice (all P>0.05) (Figure 32A-C).
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Figure 32: Effects of E100 and DOZ pretreatment on anxiety levels and locomotor
activity in BTBR mice in OFT.
BTBR mice (red) demonstrated elevated impulsive attitude and deficits in cognition as well as
locomotor activity behaviors that were significantly increased compared to Ctrl mice (gray). E100 (5,
10, or 15 mg/kg, i.p. in green) or DOZ (1 mg/kg, i.p. in blue) was administered subchronically for 21
days. E100 (5 and 15 mg/kg, i.p.) and DOZ (1 mg/kg, i.p.) attenuated the increased time spent in the
central arena (A) as well as the increased total distance travelled (C) but failed to modulate the time
spent in the periphery (B) in BTBR mice in the OFT. Effects of subchronic (21 days) systemic coinjection of RAM (10 mg/kg, i.p.) on the E100 (5 mg)-provided amelioration of time spent in the center
and increased distance travelled (C) of BTBR mice in OFT. Data are expressed as the mean ±SEM (n
= 4). *P<0.05 vs. Saline treated Ctrl mice. #P<0.05 vs. Saline treated BTBR mice. $P<0.05 vs. E100 (5
mg)-treated BTBR mice.

3.23 Effects of E100 on activated microglia in cerebellum tissues of BTBR mice
Activation of glial cell (microglia) in BTBR mice has been observed (Figure
33). The observed results showed that BTBR mice exhibited a significant increase in
the expression of iba-1, which is a marker of activated microglia (P<0.05) (Figure 33).
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However, subchronic systemic treatment of BTBR mice with E100 (5 mg/kg, i.p.)
significantly decreased the number of activated microglia compared to the salinetreated BTBR mice (P<0.05) (Figure 33). Moreover, subchronic systemic coadministration of RAM (10 mg/kg, i.p.) entirely reversed the effects of E100 (5 mg/kg,
i.p.) on the number of activated microglia compared to the E100 (5 mg)-treated BTBR
animals (P< 0.05) (Figure 33).

Figure 33: Effects of E100 on iba-1 positive microglia in cerebellum tissues of
BTBR mice.
Quantitative analysis of activated microglia revealed a significant increase ( *P<0.05) in the number of
activated microglia in cerebellum of BTBR mice compared to control mice. However, subchronic
treatment with E100 (5 mg/kg, i.p.) to the BTBR mice significantly reduced ( #P<0.05) the number of
activated microglia compared to the saline-treated BTBR mice. Effects of subchronic (21 days) systemic
co-injection of RAM (10 mg/kg, i.p.) on the E100 (5 mg)-provided mitigation of activated microglia in
BTBR mice $P<0.05. Values are expressed as the percent mean ± SEM (n = 3).
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Chapter 4: Discussion
Antagonists targeting H3Rs are considered promising alternative treatments
for different brain disorders, such as SCH, AD and narcolepsy (Passani et al., 2011;
Sadek et al., 2016c). In the current study we investigated, for the first time, the effects
of the H3R antagonist DL77 on a mouse model of ASD-like behaviors induced by
prenatal exposure to VPA. DL77 was chosen for the current study because it belongs
to the class of non-imidazole H3R antagonists with improved selectivity and safety
profile compared to the imidazole-based H3R antagonists, e.g., ciproxifan, which have
several limitations as clinical candidates due to the presence of an imidazole
heterocycle, which is responsible for numerous possible pharmacokinetic drawbacks,
such as CYP450 inhibition, off-target activity, or lack of subtype selectivity, especially
over H4R (Passani et al., 2011).
Subchronic systemic administration of DL77 demonstrated ameliorating
effects on social interaction deficits and stereotypies in VPA-exposed mice. In the TCT
paradigm, sociability or social novelty is the tendency to spend time exploring an
unfamiliar animal, compared to time spent exploring an object or a familiar animal,
respectively. Systemic subchronic pretreatment with DL77 normalized the impairment
in sociability demonstrated by VPA-exposed mice, since these animals, when
pretreated with DL77, presented increased sociability index (improved sociability,
Figure 11A) and social novelty index (improved social novelty, Figure 12A), to levels
similar to the saline-exposed mice. Numerous previous studies have focused on the
procognitive effects of several H3R antagonists on social memory (Alachkar,
Lazewska, Kiec-Kononowicz et al., 2017; Fox, Esbenshade, Pan et al., 2005; Fox, Pan,
Esbenshade, Bennani et al., 2002; Fox, Pan, Esbenshade, Bitner et al., 2002; Fox, Pan,
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Lewis et al., 2004; Fox, Pan, Radek et al., 2003; Sadek et al., 2016d), a behavioral
feature that is also altered in ASD (Noland, Steven Reznick, Stone et al., 2010), but
our study is the first one to assess the effects on of a non-imidazole based H3R
antagonist on sociability deficits as ASD-like behaviors in VPA-exposed mice.
Importantly, the sociability- and social novelty-enhancing effect observed for DL77
was dose-dependent, since DL77 (5 mg/kg) failed to improve sociability (Figure 11A)
or social novelty preference (Figure 12A), while a dose of 10 mg/kg or 15 mg/kg
provided significant enhancement in sociability as well as social novelty behavior. An
optimum effect was observed when the H3R antagonist DL77 was applied at a dose of
10 mg/kg, and a dose of 15 mg/kg DL77 did not significantly improve upon the DL77
(10 mg)-provided sociability or social novelty enhancement (Figures 11A and 12A).
Interestingly, the observations for the dose-dependent effects of DL77 are in line with
those previously observed for numerous H3R antagonists in preclinical experiments in
different rodents (Benetti and Izquierdo, 2013; Benetti et al., 2013; Sadek et al.,
2016c). In addition, the observed results with regard to dose dependency strongly
support previous procognitive effects observed for the H3R antagonist DL77 (2.5, 5,
or 10 mg/kg, i.p.) on different memory stages, namely, acquisition, consolidation, and
retrieval in rats (Sadek et al., 2016c). Notably, the observations of sociability- and
social novelty-enhancing effects for DL77 are in agreement with earlier experimental
results observed with the imidazole-based H3R antagonist ciproxifan in Swiss mice
(Baronio et al., 2015). In that study, ciproxifan (3 mg/kg, i.p.) attenuated sociability
deficits in the VPA-induced ASD-like behaviors (Baronio et. al 2015).
Interestingly, the DL77 (10 mg)-provided enhancing effects on sociability and
social novelty were completely reversed when mice were co-administered the CNS-
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penetrant H3R agonist RAM or with the CNS-penetrant H2R antagonist ZOL, but not
with the centrally acting H1R antagonist PYR (Figures 11B and 12B). The latter
observations indicate that brain histaminergic neurotransmission appears to be
involved in the capacity of the H3R antagonist DL77 to facilitate the release brain
histamine in specific brain areas (Brioni, Esbenshade, Garrison et al., 2011; Panula et
al., 2015; Sadek et al., 2016c; Sadek & Stark, 2016e). The current results further
indicate that histaminergic pathways, through activation of H2Rs, fundamentally
contribute to neuronal pathways important for alteration of sociability and social
novelty processes in the TCT paradigm in VPA-exposed mice. Notably, the reference
drug DOZ failed to improve both social impairment parameters of VPA exposed mice
following subchronic systemic treatment (Figure 11A and 12A). These observations
could be explained by the results of a previous study in which the integrity of the
central histaminergic system was found to be a crucial requirement for the biochemical
and behavioral effects elicited by two procognitive compounds, namely, the H3R
antagonist ABT-239 and the acetylcholine esterase inhibitor DOZ (Provensi, Costa,
Passani et al., 2016). Consequently, further investigations are necessary to assess the
functionality of the central histaminergic system in VPA-exposed mice to further
explain the behavioral results observed for DOZ in sociability as well as social novelty
tests.
Stereotypy and rigidity of behavior are considered core features of ASD (Peter,
Oliphant, & Fernandez, 2017; Zhao, Jiang, & Zhang, 2018). Moreover, the
involvement of the brain histaminergic neurotransmission in the pathophysiology of
Tourette syndrome, a condition commonly comorbid among ASD patients and
featured by stereotypies, has been proposed and has been associated with a premature
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termination codon (W317X) in the L-histidine decarboxylase (HDC) gene.
Consequently, such a premature termination of codon (W317X) impairs brain
histaminergic neurotransmission (Frick et al., 2016; Paschou et al., 2013; Rapanelli,
2017a; Rapanelli, Frick, Horn et al., 2016a; Rapanelli & Pittenger, 2016b). In the
current study, VPA-exposed mice subchronically pretreated with DL77 (10 or 15
mg/kg, i.p.) or with the reference drug DOZ (1 mg/kg, i.p.) displayed comparable
reductions in stereotyped repetitive behavior in MBT (Figure 13A). Moreover, the
DL77 (10 mg/kg)-provided effects in MBT were entirely abrogated when mice were
administered the CNS penetrant H3R agonist RAM, but not with the CNS-penetrant
H1R antagonist PYR or the H2R antagonists ZOL (Figure 13B). The mechanism by
which the repetitive behavior is improved is not clear, but it might be explained by the
capability of DL77, as a potent H3R antagonist, to mediate the release of different
neurotransmitters besides histamine, such as dopamine, serotonin and acetylcholine,
in several specific brain areas (Brioni et al., 2011; Sadek et al., 2016c; Sadek & Stark,
2016e; Witkin et al., 2004). Therefore, measuring the levels of different brain
neurotransmitters, including histamine, in various brain areas of the VPA-exposed
mice with ASD-like behaviors as well as when treated with DL77 would further help
us understand which neural circuits could be involved in this observed behavioral
improvement. Interestingly, the results observed for DL77 in MBT are in agreement
with a previous study in which acute systemic administration of the non-imidazole
H3R antagonist ST-1283 significantly decreased the number of buried marbles and
significantly shortened the digging duration in adult male C57BL/6 mice, without
altering locomotor activity tested in an open field (A. Bahi, J. S. Schwed, et al., 2014).
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Similarly, DL77 (10 or 15 mg/kg) attenuated the percentage of shredded nestlet
in VPA-exposed mice with ASD-like behaviors in NST, and this reducing effect of
DL77 on stereotyped repetitive behavior in NST was reversed with co-administration
of the H3R agonist RAM, but not the H1R antagonist PYR or the H2R antagonist ZOL
(Figure 14A and B). The results observed for DL77 in NST are consistent withthe
current observations in MBT because DL77 facilitates the release of numerous central
neurotransmitters besides histamine that are involved in repetitive as well as anxious
behaviors in different rodents (Brioni et al., 2011; Sadek et al., 2016c; Sadek & Stark,
2016e; Witkin et al., 2004).
Ligands modulating anxiety levels or locomotion may give rise to a falsepositive effect in these behavioral tests (A. Bahi, J. S. Schwed, et al., 2014; Borsini &
Meli, 1988). Therefore, the numbers of entries into the closed arms and into open arms
in the EPM test were used as indicators of locomotor activity and anxiety levels,
respectively. The results showed that DL77 at a dose of 5, 10 or 15 mg/kg did not alter
anxiety-like levels nor locomotor activity in VPA-exposed mice as measured by the
percentage of time spent or the number of entries into open arms and closed arms,
respectively (Figure 15A-C). Thus, the improvements in sociability, social novelty and
repetitive behaviors observed for DL77 in TCT, MBT and NST, respectively, appear
unlikely to be associated with a modulating effect on anxiety levels or an increase in
locomotor activity of the tested mice. In contrast, the reference drug DOZ (1 mg/kg,
i.p.) attenuated the percentage of time spent and the number of entries into open arms,
indicating its enhancing effects on cognitive functions of VPA-exposed mice to assess
risk and evaluate anxiety, as reflected in the decreased number of entries into open
arms following subchronic systemic pretreatment VPA-exposed mice with DOZ
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(Figure 15A-C). Moreover, the failure of DL77 at all doses to improve this abnormal
anxiety and hyperactivity seen in VPA-exposed mice may have been due to the
imbalance of several neurotransmitters that are reported to be dysregulated in ASD
patients, such as serotonin (Chugani, 2002; Mabunga, Gonzales, Kim et al., 2015),
glutamate and GABA (Casanova, Buxhoeveden, & Gomez, 2003; Mabunga et al.,
2015; Orekhova, Stroganova, Prokofyev et al., 2008; Rubenstein & Merzenich, 2003).
Several hypotheses have been proposed about the dual role of brain histamine
in neurological disorders, and evidence has shown its critical involvement in the
modulation of microglia-mediated neuroinflammation (Barata-Antunes, Cristovao,
Pires et al., 2017b). To determine a possible function of DL77 in tissue defense,
oxidative stress parameters, MDA and GSH were assessed in the cerebellum (Figure
16A and B). The existence of lipid peroxidation is considered a key pathogenic event
in brain tissues, resulting from an unbalanced ratio of radical oxygen species
generation and the capacity for endogenous cellular antioxidant defense (Javed,
Azimullah, Haque et al., 2016). The results showed that VPA-exposed mice with ASDlike behaviors had a significant increase in MDA, with a concomitant decline in GSH
in cerebellar tissue. GSH is considered to protect against lipid peroxidation, and it is
depleted in oxidative stress (Thomas, Maiorino, Ursini et al., 1990), as demonstrated
in the observed results (Figure 16A and B). The results of the current study are in
accordance with recent findings that histamine may provide protective effects under
an inflammatory context (Barata-Antunes et al., 2017b). Subchronic systemic
pretreatment with DL77 (10 or 15 mg/kg, i.p.) inhibited lipid peroxidation, as
evidenced by the reduced MDA followed by restoration of GSH (Figure 16A and B).
Interestingly, the imidazole-based H3R antagonists, namely, ciproxifan and
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clobenpropit, control the elevation of various oxidative stress markers, including MDA
and GSH, in amphetamine- or dizocilpine-augmented oxidative stress in an
experimental mice model of SCH, indicating that H3R antagonists possess antioxidant
activity, which might provide antioxidant actions and at the same time control the
symptomatic features of SCH (Mahmood, Khanam, Pillai et al., 2012a; Mahmood et
al., 2012b). These results in an SCH experimental model strongly support the current
observations regarding DL77 in VPA-exposed mice with ASD-like behaviors, since
SCH and ASD are often comorbid and share several symptomatic features (Mahmood
et al., 2012a; Sadek et al., 2016c).
The protective role of histamine has also been reported in neurological
conditions featured by microglia-induced neuroinflammation and, consequently, the
involvement of brain histamine in the pathophysiology of multiple sclerosis and other
neurological diseases of several animal models (Barata-Antunes et al., 2017b; JadidiNiaragh & Mirshafiey, 2010). The current study demonstrated a significant LPSinduced exacerbated rise in the expression of proinflammatory cytokines (IL-1β, IL-6,
and TNF-α) in VPA-exposed mice (Figure 17A-C). However, subchronic systemic
pretreatment with DL77 (5, 10, or 15 mg/kg, i.p.) significantly decreased the elevated
levels of these proinflammatory cytokines in VPA-exposed mice. Interestingly, the
CNS-penetrant H3R agonist, when co-administered with DL77, completely reversed
the protective effect of DL77 against the elevated markers of oxidative stress and
partially abrogated the DL77-provided protective effects on proinflammatory
cytokines (Figure 17A-C), indicating the involvement of central histaminergic
neurotransmission in mediating the anti-inflammatory action of DL77 in VPAexposed mice with ASD-like behaviors under inflammatory conditions.
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Taken together the promising results of DL77 in palliating sociability deficits
and stereotypies present in the VPA-exposed TO mice model of ASD-like behaviors,
as well as its modulation of neuroinflammation and oxidative stress levels under the
inflammatory context, encouraged us to expand these initial data. Accordingly, we
further carried preclinical experiments using other H3R ligands and on other rodent
species to understand the translational potential of H3R antagonists in the therapy of
ASD and the neural circuits involved.
Accumulated evidence suggests that a variety of brain neurotransmitters such
as ACh, 5-HT, DA, GABA, Glu, and HA are implicated in the onset and progression
of ASD, substantiating the significance of this research area in the study of ASD
etiology (Bacchelli et al., 2015; Chen et al., 2017; Ellenbroek et al., 2015; Hellings et
al., 2017; Hellmer et al., 2017; Naaijen et al., 2017; Nakai et al., 2017; Paval, 2017;
Paval et al., 2017; Shah et al., 2006; Wang et al., 2015). Alterations in histaminergic
as well as cholinergic neurotransmission are thought to play a crucial role in the
phenotypic outcomes of ASD-related behavioral features (Baronio et al., 2015; Karvat
et al., 2014; Wright et al., 2017). Previous reports suggested that an impaired
cholinergic system causes cognitive problems that may include social problems, which
were reversed by donepezil treatments (Karvat et al., 2014; Riedel, Kang, Choi et al.,
2009). Numerous lines of evidence from preclinical studies indicated notably that H3R
antagonists/inverse agonists have been found to exhibit cognition-enhancing
properties (Passani et al., 2011; Sadek et al., 2016c; Sadek & Stark, 2016e; Witkin et
al., 2004). In view of that both acetylcholine esterase (AChE) and H3Rs (auto- and
heteroreceptors) are suggested to be involved in the modulation of several central
neurotransmitters including ACh and HA that are cognition associated. Consistent
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with these reports, we assessed for the first time the pharmacological modulation of
H3R and AChE by investigating the effects of a novel dual-active AChEI and H3R
antagonist E100 on ASD-like behaviors in C57 VPA-exposed mice. Our major
findings showed that systemic administration of E100 significantly improved social
interaction deficits in VPA-exposed mice in TCT, and stereotypies in MBT and NST
paradigm (Figure 18 -21). Importantly, the sociability- and social novelty-enhancing
effect observed for E100 was dose-dependent, although E100 (5 mg/kg) significantly
increased the SI (Figure 18A), it failed to improve SNI (Figure 19A), while significant
enhancement in sociability as well as social novelty behaviors were achieved by a dose
of 10 mg/kg or 15 mg/kg. However, E100 (10 mg/kg) effects were similar to the
enhancing effects obtained for DOZ and were not significantly further enhanced with
the dose of 15 mg/kg E100, (Figure 18A and 19A). On the other hand, DL77 (5 mg/kg)
failed to improve both assessed social parameters, while DL77 (10 mg/kg or 15 mg/kg)
showed significant improvement dose-dependently, with optimum effect exhibited by
DL77 (15 mg/kg). Interestingly, the observations for the dose-dependent effects of
E100 and DL77 on social impairments in C57 VPA-exposed mice, are in line with our
initial observed results of DL77 on VPA-induced ASD in TO mice. However, the
difference in DL77 doses exerting optimum effects (DL77 10 mg/kg in TO mice and
DL77 15 mg/kg in C57 mice) on social deficits, may have been due to differences in
strains and genetic backgrounds. Notably the observation of sociability and social
enhancing-effect of E100 are unlike DL77 and other previous studies in which the
effects of H3R antagonists/inverse agonists target H3Rs without inhibitory affinity for
AChE (Brabant, Charlier, & Tirelli, 2013; De Almeida & Izquierdo, 1986). As
observed, similar enhancing effects were achieved with E100 (10 mg) and a higher
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dose of DL77 (15 mg), despite the tests being carried on the same mouse strain (C57),
under similar conditions and by the same experimenter. This might be explained by
the dual action of E100 with the capability of H3R antagonists to mediate the release
of different neurotransmitters other than histamine, such as DA, 5-HT and ACh in
specific brain regions (Brioni et al., 2011), together with its AChE inhibitory property
that results in modulation of abnormal cholinergic transmission. The latter explanation
highlights the significant role of both brain HA and ACh in improving social
deficiencies and that not only histaminergic but also cholinergic transmission
represents an essential neurophysiological component in cognitive functioning.
Interestingly, the results observed for E100 in sociability assessments are in agreement
with previous studies in which systemic administration of the dual-acting AChEI and
H3R antagonist, namely UW-MD-71, exhibited cognitive enhancing effects that were
similar to those obtained for the reference drug DOZ (AChEI) in that study (Sadek &
Stark, 2016e).
Furthermore, E100-provided enhancing effects on sociability and social
novelty were completely reversed when mice were co-administered the CNS-penetrant
H3R agonist RAM, the CNS-penetrant H2R antagonist ZOL, or with muscarinic
cholinergic antagonist SCO but not with the centrally acting H1R antagonist PYR
(Figures 18B and 19B). This indicated that brain histaminergic and cholinergic
neurotransmissions appear to be involved in mediating the capacity of the dual acting
E100 to facilitate the release of brain HA and to elevate the levels of ACh in specific
brain areas. The results further indicated that histaminergic and cholinergic pathways,
through activation of H2Rs and muscarinic ACh receptors, respectively, contribute to
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alteration of sociability and social novelty-related processes in VPA-exposed mice as
observed in TCT paradigm.
Stereotypy, repetitive behavior and restricted interests are considered core
features of ASD. Recently, tic disorder has been reported to be associated with
histamine dysregulation (Bloch, State, & Pittenger, 2011; M. Rapanelli & Pittenger,
2016b), disorder commonly comorbid with attention difficulties and ASD (Rapanelli,
Frick, Pogorelov et al., 2017b). Tics are repetitive and patterned motor actions that are
typically associated with preceding uncomfortable sensory experiences (Martino &
Hedderly, 2019). Moreover, as alteration in brain’s the histamine modulatory system
has been identified to be rare genetic cause of tic disorders; histidine decarboxylase
knockout (Hdc-KO) mouse was generated to represent a promising model of its
pathophysiology (Baldan et al., 2014; Ercan-Sencicek, Stillman, Ghosh et al., 2010),
implying that diminished histaminergic neurotransmission maybe related to the
exhibited repetitive and tic-like stereotypies (Baldan et al., 2014). In addition,
Rapanelli et al. have implicated H3R in repetitive behavior-related pathology
(Rapanelli et al., 2017b).
VPA-exposed mice subchronically pretreated with E100 (10 or 15 mg/kg, i.p.)
or with the reference drug DOZ (1 mg/kg, i.p.) showed comparable reduction in
stereotyped repetitive behavior in MBT (Figure 20A). Additionally, the E100 (10
mg/kg)-provided effects observed in MBT were nullified when mice were coadministered the CNS penetrant H3R agonist RAM, the CNS-penetrant H2R
antagonist ZOL, or with muscarinic cholinergic antagonist SCO, but not with the CNSpenetrant H1R antagonist PYR (Figure 20B). The mechanism by which the
repetitive/compulsive behavior is improved following systemic administration with
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E100 may involve its capability as a potent dual-active H3R antagonist and AChE
inhibitor, to modulate the release of different neurotransmitters besides HA and ACh,
such as DA and 5-HT, in several specific brain areas. Consequently, assessing the
levels of different brain neurotransmitters, including HA and ACh, in different brain
areas of the VPA-exposed mice with ASD-like behaviors, as well as after pretreatment with E100 would further help us to understand better which neurotransmitter
systems maybe involved in the observed behavioral improvement. However, the
results clearly demonstrated that the signaling of H2R and acetylcholine muscarinic
receptors postsynaptically are involved. The results observed for E100 in MBT are in
agreement with improvement exhibited by DL77, although DL77 (15 mg) showed the
optimal improvement comparable to the E100 (10 mg)-provided effect.
Similarly, E100 (5, 10 or 15 mg/kg) reduced the percentage of shredded
nestlets in VPA-exposed mice in the NST, and this effect of E100 on stereotyped
repetitive and compulsive-like behaviors was counteracted by co-administration of the
H3R agonist RAM, but not the H1R antagonist PYR or the H2R antagonist ZOL or
with muscarinic cholinergic antagonist SCO (Figure 21B). These results further
corroborate the current observations in MBT regarding the capability of E100 to
facilitate the release of several brain neurotransmitters, besides HA and ACh that have
crucial functions in repetitive/compulsive behaviors in different animal species.
Negation of the effect of DL77 (15 mg) on repetitive and compulsive-like behavior in
NST with co-administration of ZOL, strongly supports the implication of histamine
signaling mainly through H2R. The effects of E100 on locomotor activity as well as
anxiety levels were examined to simultaneously rule out possible intrinsic impairment
of spontaneous locomotor activity that might mask anxiety parameter. Consequently,
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EPM test was carried to study the effects of E100 on locomotor activity as well as
anxiety levels. The results showed that E100 at a dose of 10 or 15 mg/kg reduced
elevated anxiety levels in VPA-exposed mice, similar to DOZ (1 mg/kg), measured by
the percentage of time spent and number of open arms entries (Figure 22A and B).
However, systemic pretreatment of VPA-exposed mice with E100 at a dose of 5, 10
or 15 mg/kg or with DOZ (1 mg/kg) did not alter the locomotor activity as measured
by number of entries into closed arms (Figure 22C). Similar results were obtained in
OFT, confirming the ability of E100 to modulate anxiety-associated fear levels by
increasing time spent in the center of the arena, and its failure to reduce hyperactivity,
as no effect was exhibited (for all doses), on total distance travelled (Figure 23A-D).
Thus, the improvements in sociability, social novelty, and repetitive/compulsive
behaviors observed for E100 in TCT, MBT and NST, respectively, appear unlikely to
be associated with a modulating effect in locomotor activity of the tested mice. These
results are in accordance with previous results that revealed anxiolytic-like effects of
a non-imidazole-based H3R antagonist with no differences in spontaneous locomotor
activity (Amine Bahi, Johannes Stephan Schwed, Miriam Walter et al., 2014).
Moreover, the failure of E100 at all doses and DOZ to alleviate the hyperactivity
observed in VPA-exposed mice may have been due to the well-known existing
imbalance of excitatory (Glu) and inhibitory (GABA) neurotransmitters, as such
imbalance was observed in several clinical trials in patients with ASD (Casanova et
al., 2003; Mabunga et al., 2015; Orekhova et al., 2008; Rubenstein et al., 2003). With
regard to anxiety, comparing the results of E100 with DL77, it was observed that DL77
(15 mg) only modulated anxiety of VPA-exposed mice by increasing the percentage
of time spent in open arms and failed with all doses to increase number of open arm
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entries in EPM and time spent in the central arena in OFT. The latter results agreed
with our initial data, in which DL77 with all doses failed to restore anxiety levels in
VPA- exposed TO mice. These results highlight the role of AChE inhibitory effect of
E100 in anxiety modulation. Our findings agreed with previous studies supporting the
role of AChE on abnormal behaviors, in which transgenic mice overexpression of
synaptic human AChE (hAChE-S) show social recognition impairment, hyperactivity
in the novel open field and increased time in open arms of the EPM (Cohen, Erb,
Ginzberg et al., 2002; Erb, Troost, Kopf et al., 2001) .
Previous studies have found that several proinflammatory cytokines including
TNF-α, IL-1ß, IL-6, and TGF-ß are elevated in the autistic brain (Deckmann,
Schwingel, Fontes-Dutra et al., 2018; Depino, 2013; Goines & Ashwood, 2013;
Vargas et al., 2005). IL-1ß disruption was reported to have a variety of neurological
consequences relevant to ASD. It was also reported earlier that IL-6 overexpression in
the mice CNS show alterations in cognition and avoidance behaviors (Heyser,
Masliah, Samimi et al., 1997). Additionally, Vargas et al. found that TGF-β was one
of the most prevalent cytokines in brain tissues of individuals with ASD and is
involved in social behavior. The levels of TGF-β in serum are inversely related to those
in the brain of autistic individuals. Notably, increased TGF-β in CNS was reported
with activated microglia cells (Ashwood, Krakowiak, Hertz-Picciotto et al., 2011;
Ohja, Gozal, Fahnestock et al., 2018; Vargas et al., 2005). In addition, several studies
reported that cerebellum of autistic subjects exhibited consistent oxidative stress
(Nadeem, Ahmad, Al-Harbi et al., 2019). Consistent with these findings, the results
showed that the levels of TNF-α, IL-1ß, IL-6 and TGF-ß were significantly increased
in the cerebellum of VPA-exposed C57 mice as compared with age-matched control
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mice (Figure 24A, C, E and G). Systemic administration of E100 (10 mg/kg, i.p.)
significantly modulated the levels of the proinflammatory cytokines (Figure 24A, C,
E and G) and oxidative stress in VPA-exposed mice (Figure 25A, C, E and G). In
addition, when co-administered with E100, the CNS-penetrant H3R agonist partially
abrogated

E100-provided

protective

effects

against

increased

levels

of

proinflammatory cytokines (Figure 24B, D, F and H) and entirely nullified the E100provided effects on oxidative stress levels (Figure 25B, D, F and H).
Similar results were observed with DL77 (15 mg), indicating the involvement
of brain histamine in facilitating the neuroprotective action of E100 in VPA-exposed
mice with ASD-like features. Interestingly, the current observations are strongly
supported by a previous study that demonstrated that JNJ10181457, a histamine H3
receptor inverse agonist suppressed LPS-induced microglial IL-1ß, IL-6 and TNF-α
expression, indicating that JNJ inhibited the activation of microglia associated with
inflammation (Iida, Yoshikawa, Karpati et al., 2017). In accordance, another study
showed that ciproxifan (1 mg/kg, i.p.) reduced the level of pro-inflammatory cytokines
IL-1ß and IL-6 in transgenic mouse brain (Mani et al., 2017). These lines of evidence
demonstrate the strong impact of histaminergic neurotransmission in modulating
microglia-induced neuroinflammation and associated pro-inflammatory cytokine
expression. This may suggest that as cytokine imbalances could impact neural activity
and mediate behavioral aspects of ASD, H3R antagonists may serve as potential
therapeutics for this disorder. In support to our results a previous study provided
evidence that fifteen days treatment of ciproxifan prevented cognitive deficits,
improved cholinergic transmission, and attenuated neuroinflammation and oxidative
stress in APP transgenic mouse model (Mani et al., 2017). The neuroprotective effect
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of E100 were further supported by a study that showed the free radical scavenging
effect of DOZ associated with memory impairment in mice. The study reported that
DOZ (AChEI) may protect neurons against injury in AD through prevention of free
radical-mediated neuroinflammation. This suggests that the AChE inhibitory property
of E100 may be involved in oxidative stress modulation of VPA exposed mice
(Umukoro, Adewole, Eduviere et al., 2014).
The regulation of immune response is mediated by NF-κB via induction of the
expression of inflammatory cytokines and chemokines. Activation of NF-κB is
significantly increased with ASD (Nadeem, Ahmad, Bakheet et al., 2017; Naik,
Gangadharan, Abbagani et al., 2011). Young et. al, also, observed elevated levels of
NF-κB in blood and brain of patients with ASD (Young, Campbell, Lynch et al., 2011).
Moreover, neuroinflammation is characterized by reactivity of microglia and
astrocytes, activation of iNOS signaling and increased expression and release of
cytokines and chemokines (Monnet-Tschudi et al., 2011). Evidences indicates that
ASD subjects exhibit ongoing neuroinflammatory processes in various regions in the
brain involving microglial activation (Rodriguez & Kern, 2011; Vargas et al., 2005),
consequently aberrant expression of cytokines and their signaling intermediaries are
often observed. Furthermore, recent findings showed that disrupted COX-2 signaling
in mice might serve as a novel animal model to assess ASD (Wong, BestardLorigados, & Crawford, 2019). In the current study, the expression of NF-κB, iNOS,
and COX-2 were significantly higher in the cerebellum as well as hippocampus of
VPA-exposed mice compared with saline-exposed mice (Figure 26). However,
systemic administration with E100 (10 mg/kg, i.p.) significantly reduced the increased
levels of NF-κB, iNOS, and COX-2, and the CNS-penetrant H3R agonist, when co-
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administered with E100, reversed the E100-provided neuroprotection in both brain
regions (Figure 26). The latter observations further indicate that brain histamine is
strongly involved in facilitating the neuroprotective action of E100 in VPA-exposed
mice with ASD-like features. Recent study demonstrated that histamine induce
decrease in NF-κB, in inflammatory environment but not in the healthy microglia
(Apolloni, Fabbrizio, Amadio et al., 2017)
Microglia, a representative immune cell in the brain, plays an important role in
synaptic refinement (Kim, Cho, Shim et al., 2017; Koyama & Ikegaya, 2015), and are
also supposed to be associated with the pathogenesis of ASD (Kim et al., 2017;
Koyama et al., 2015). Moreover, previous reports have also shown changes in the
activation of microglia in patients with ASD (Morgan, Chana, Pardo et al., 2010;
Pardo, Vargas, & Zimmerman, 2005). In the current study, the observed results
showed that expression of iba-1 positive microglia was significantly increased in the
cerebellum of VPA-exposed mice compared to saline-exposed control mice (Figure
27) Microglia activation is also considered to be sign of ROS and inflammatory
activation. However, systemic pretreatment of VPA-exposed mice with E100 (10
mg/kg, i.p.) significantly decreased the number of activated microglia comparable to
the saline-exposed control mice, and the E100-provided effect on activated microglia
was entirely counteracted by co-administration of RAM (Figure 27). The latter results
signify the brain HA in facilitating the anti-inflammatory effects of E100 against
activated microglia of VPA-exposed mice. These findings agree with the previous
study in which the H3R inverse agonist JNJ10181457, exhibited an inhibitory role in
vivo on activated microglia and regulated LPS-induced upregulation of microglia proinflammatory cytokines in mouse brain (Iida et al., 2017). Therefore, targeting
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microglial activation by modulating microglial function and suppressing their
deleterious pro-inflammatory neurotoxicity maybe a valid therapeutic strategy for
promoting neuroprotection and managing ASD-like behaviors.
Taken together, the novel dual-active H3R antagonist and AChE inhibitor
E100 alleviates sociability as well as social novelty deficits and stereotypies (presented
as ASD-like behaviors) induced by prenatal exposure of C57 mice to VPA (Figure 34).
Moreover, E100 modulates the levels of central HA and ACh in an inflammatory
context, mitigating the increase in the levels of proinflammatory cytokines, oxidative
stress levels, and expression of NF-κB, iNOS, and COX-2 in the cerebellum as well
as the hippocampus (Figure 34). These results demonstrate the palliating effects of
E100 in a battery tests conducted in a mouse model of ASD.

Figure 34: Schematic illustration of possible mechanism of action of E100
Chemical structure of the dual-active hH3R antagonist and AChEI E100, it’s in vitro data with regard
to HRs, AChE (Ee: electric eel), and BChE (Eq: equine), and its putative mode of action by inhibition
of the metabolizing enzyme of ACh and blocking the hH3R acting as auto- and heteroreceptor.
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After many years of scientific efforts, the genetic cause of ASD for majority of
the cases remains elusive, therefore it was more powerful to include a well-validated
model of idiopathic autism in my study to further corroborate our results. This was to
authenticate our findings that histaminergic and cholinergic systems dysregulation are
implicated in ASD phenotypes and that H3R antagonists maybe a potential therapeutic
agent for ASD. BTBR mouse is one of these idiopathic models. The BTBR mouse
continues to attract researchers with its complex genetic, molecular and physiological
background, a complexity that supports the BTBR mouse as a model for the idiopathic
form of autism (Meyza & Blanchard, 2017). It that displays behaviors consistent with
the diagnostic categories for ASD, namely impairments in social interaction and
increased repetitive behaviors.
Our results determined that E100 significantly improved social deficits
exhibited by BTBR mice This was evident by significant enhancement in sociability
as well as social novelty behavior provided by dose of 5 mg/kg or 10 mg/kg.
Importantly, the sociability- and social novelty-enhancing effect observed for E100
was not dose-dependent, since E100 (15 mg/kg) failed to further improve sociability
or social novelty preference (Figure 28A and B). In fact, E100 (5 mg/kg, i.p) was
observed to show the optimum effect. The observed results regarding the doses are in
agreement with previous results of memory-enhancing effect observed for UW-MD72, the effect of lower dose (1.25 mg/kg) was significantly higher when compared to
the higher doses 2.5 and 5 mg/kg (Sadek, Khan, Darras et al., 2016a). In a further
experiment, the E100 (5 mg)-provided enhancing effects on sociability and social
novelty were completely reversed when mice were co-administering the CNSpenetrant H3R agonist RAM.
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The observed results support the effect of E100 to release several
neurotransmitters, such as histamine and acetylcholine, provided by the inhibition of
the H3R. These neurotransmitters areimplicated in the regulation of arousal and
cognitive processes in several previous studies. Earlier experimental study revealed
that antagonism of H3R attenuated impaired social behavior in rodents exposed to
phencyclidine (PCP), a finding in line with our result (Griebel et al., 2012). Notably,
the reference drug DOZ improved both social impairment parameters of BTBR mice
following subchronic systemic treatment (Figure 28A). Recent studies demonstrated
cholinergic deficit and low levels of ACh in BTBR mice (McTighe, Neal, Lin et al.,
2013). In addition to the well-established positive effect of AChEIs on cognition in a
wealth of studies, DOZ treatment was reported by Reidel et al. to relieve social
memory deficiency (Riedel et al., 2009). This evidence fits with our findings, as E100
has AChE inhibitory properties which may account for improvements in social deficits
observed in E100 (5 mg/kg, i.p.) pretreated BTBR mice. Moreover, the selective H3R
antagonist JNJ was reported in a previous study to normalize ACh neurotransmission
and positively impact cognition (Galici et al., 2009), supporting our results with E100.
These therapeutic effects of E100 may be explained by the modulation of
histaminergic and cholinergic systems, hence reduced cognitive rigidity, that
consequently increases social attention and elevates sociability levels.
The ability of E100 to enhance cholinergic activity in BTBR mice and exert its
potential effect on cognitive deficit associated with sociability impairments was
confirmed by measuring AChE activity in the cerebellum. The results revealed that the
activity of AChE in E100 (5 mg) -treated mice was significantly reduced compared to
BTBR mice and compared to DOZ treated BTBR mice (Figure 29). Considering the
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role of this enzyme which is responsible for degrading the ACh, it has been reported
in a previous study that AChE inhibition augmented acetylcholine in the synapse,
relieve cognitive rigidity and ameliorate social deficiency in BTBR mice (Karvat et
al., 2014).
Furthermore, E100 in BTBR mice also exhibited the same trend toward
improvement in repetitive and compulsive-like behaviors (Figure 30 A and B).
Analysis of MBT and NST results revealed that E100 (5 mg) exhibited the best
behavioral improvement that was significant from effects of E100 10 mg and 15 mg.
A previous study reported that acute administration of mAChR agonist oxotremorine
attenuated the elevated self-grooming and marble-burying behavior in BTBR mice.
These findings suggest that activation of mAChR can attenuate certain repetitive
behaviors (Amodeo, Yi, Sweeney et al., 2014). This evidence may explain the results
observed by E100 on repetitive behavior in MBT, because E100 tend to facilitate the
release of ACh through H3 heteroreceptor and increase the level of ACh in synapse by
exerting an inhibitory action on AChE. The increased level of ACh may exert mAChR
transduction showing the improvement in repetitive behavior observed. Additionally,
and as mentioned earlier, several previous studies including our findings reported the
positive effects of H3R antagonists on repetitive behaviors of VPA mouse model of
ASD in different mouse strains. These findings suggest that the pharmacological
manipulation of the histaminergic system by E100 due to its H3R antagonistic effect,
may positively impact the elevated repetitive and compulsive-like behaviors in BTBR.
On the other hand, BTBR mice have been reported to have elevated oxidative stress
with deficient enzymatic anti-oxidant response that is suggested to be associated with
the exaggerated repetitive behavior (Nadeem et al., 2019). Based on our finding of the
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capacity of E100 to modulate oxidative stress level in VPA exposed mice (Figure 25A,
C, E and G), the improvements observed in repetitive/compulsive behavior by E100
in BTBR is strongly supported.
BTBR mice display a variable profile of anxiety-like behaviors in comparison
to C57 and other inbred strains. In the current study BTBR mice spent less time and
had a reduced number of entries into open arms of the EPM, demonstrating high levels
of anxiety (Figure 31A and B). This observation was in agreement with previous
studies (Benno, Smirnova, Vera et al., 2009; Pobbe, Defensor, Pearson et al., 2011).
Conversely BTBR mice spent more time in the center of the arena of the open field, as
compared to C57 in OFT showing low levels of anxiety, reflecting impulsive behavior
(Figure 32A and B). This contradictory result is in consistent with several previous
studies (Chadman, 2011; Moy et al., 2007; Silverman, Yang, Turner et al., 2010; Yang,
Clarke, & Crawley, 2009) and may be explained due the to stress condition exhibited
by the EPM over OFT. In fact, previous studies suggested that BTBR mice displayed
high risk assessment behaviors (stretched postures and head-outs stretches), as
response to high level of stress, reflecting exaggerated responses to stressors which
might have influenced responses in EPM. Interestingly, E100 with all doses was able
to restore these abnormal levels of anxiety in both tests, hence, our findings suggest
interplay between histamine and ACh level dysregulation with abnormal levels of
anxiety and impulsive behavior observed in BTBR. This is supported by a recent
report, in which lower acetylcholine level in the prefrontal cortex region of BTBR
mice showed attention deficit and impulsive behavior (McTighe et al., 2013).
E100 at all doses and DOZ failed to restore the hyperactivity displayed by
BTBR mice in EPM (Figure 31C), conversely the hyperactivity was totally restored in
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OFT with E100 (5, 10 or 15 mg/kg, i.p.) or DOZ (Figure 32C). As mentioned earlier
both OFT and EPM tests are standard tools to analyze activity and profile anxiety in
rodents. Open field determines behavior based on combined exploration and aversion
against open and bright areas, whereas, in EPM the behavior of rodents is based on
openness combined with elevation predominantly related to anxiety (Schmitt &
Hiemke, 1998). This explains the sensitivity of each behavioral test in testing the effect
of compounds on anxiety and psychomotor activity using the same mouse strain.
Although E100 improved increased activity in BTBR mice, it failed to restore
hyperactivity in C57 VPA-exposed mice in OFT. This may be due to variability in
sensitivity of mouse strains to drugs. This finding agrees with a previous study in
which the antidepressant-like effect of fluoxetine was compared in seven inbred mouse
strains in the forced swimming test, the results revealed improvement in three strains
only (Lucki, Dalvi, & Mayorga, 2001). However, co-administration of the H3R agonist
RAM reversed the elevated locomotor activity improvement exhibited by E100 (5 mg)
in OFT (Figure 32C), that strongly correlate regulation of both histamine and
acetylcholine neurotransmitters with hyperactivity observed in BTBR mice.
Several studies now provide evidence for ongoing neuroinflammatory process
in various brain regions involving microglia activation, in individuals with ASD.
Microglial activation can then result in a loss of connections or underconnectivity due
to the sustained production of mediators longer than usual, contributing to the loss of
synaptic

connections

and

neuronal

cell

death.

Several

studies

reported

underconnectivity in ASD individuals (Rodriguez et al., 2011). Emerging evidence
implicates compromised inter-hemispherical connectivity in some cases of ASD,
where greater callosum reduction was proportional to severity of the disorder.
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Moreover, histological analysis showed that the corpus callosum was absent in BTBR
mouse brains. Nevertheless, important finding suggested that genes regulating corpus
callosum development specifically are not likely to be responsible for the social and
repetitive abnormalities in BTBR, evidenced by postnatal surgical disconnection of
the corpus callosal fiber tract in C57 mice that exhibited no social deficits or repetitive
self-grooming characteristic of BTBR mice (Yang et al., 2009).. Our promising results
strongly implicate the histaminergic and cholinergic system dysregulation in the ASD
phenotype.
As mentioned earlier, one way to control neuroinflammation is to reduce or
inhibit microglial activation. It is plausible that by reducing brain inflammation and
microglial activation, the neurodestructive effects of chronic inflammation could be
diminished and contribute to improved developmental outcomes. Consistent with
previous studies that reported microglia activation in BTBR brains (Heo, Zhang, Gao
et al., 2011; Zhang, Gao, Kluetzman et al., 2013) our results demonstrated remarkably
a higher expression of Iba-1-positive microglia in BTBR cerebellum compared to
C57, reflecting an increase in activated microglia. Subchronic systemic administration
of E100 (5 mg) significantly mitigated microglia activation in BTBR, evidenced by
attenuation of the expression of Iba-1 (Figure 33). However, co-administration of
RAM reversed the suppression exhibited by E100 (5 mg). The data clearly indicate
that E100 has the potential to inhibit microglial activation. The current findings
complement the earlier observation of E100 (10 mg) on activated microglia of VPAexposed C57 mice. Since microglia constitutively express all four histamine receptors
(H1R, H2R, H3R, and H4R) histamine has a well-established role as neuron-to-glia
alarm signal in the brain (Hu & Chen, 2017). It has been reported in a recent study that
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histamine counteracts proinflammatory microglia phenotype in the SOD1-G93A
mouse model of Amyotrophic Lateral Sclerosis. They demonstrated that histamine
exerts its beneficial action only in inflammatory SOD1-G93A microglia, and on the
other hand elicits a pro-inflammatory effect in nontransgenic cells (Apolloni et al.,
2017). These findings complement an earlier study that demonstrated a dual role for
histamine under physiological and inflammatory settings (Barata-Antunes et al.,
2017a). Additionally, HA deficiency in HDC knock out mice has been reported to
make microglial cells more vulnerable to an inflammatory challenge, which further
emphasizes the importance of HA in regulating microglial function (Frick et al., 2016).
These reports fit well with our findings that brain HA and Ach are involved in
providing an anti-inflammatory action provided by E100 through its action to facilitate
the release of brain HA and elevate the levels of ACh in synapse which may be be
consequently responsible for the improvement in ASD-like behavioral outcomes in
BTBR mice.
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Chapter 5: Conclusion
In conclusion, to our knowledge, this is the first study to reveal that DL77, a
non-imidazole H3R antagonist palliated core symptoms of ASD, represented as ASDlike behaviors induced by prenatal VPA exposure in two different mouse strains,
demonstrating the therapeutic potential of H3R antagonists in the treatment of ASD.
In addition, we provided evidences that modulation of central histaminergic
neurotransmission

by

DL77

under

an

inflammatory

context

attenuated

proinflammatory cytokine release and oxidative stress levels that are considered as
predictors of intensified symptoms of ASD.
The promising results of the target drug DL77 and the standard drug DOZ lead
to additional investigation into the potential applicability of dual-acting H3R
antagonists/AChEIs in the modulation of ASD-like behavior. The observed palliative
effects of E100 on behavioral deficits and the mitigating effects on the levels of
proinflammatory cytokines as well as oxidative stress provide evidence to suggest that
brain histaminergic and cholinergic neurotransmission are potential targets for ASD.
The current study is the first in vivo demonstration that a potent dual-acting H3R
antagonist and AChE inhibitor is effective in improving ASD-like features induced by
prenatal exposure to VPA and in the BTBR mouse model of ASD (environmental and
genetic models).
The latter result adds further support to the therapeutic potential of dual-acting
H3R antagonists and AChEI in the treatment of CNS disorders, especially those
characterized with chronic neuroinflammation such as ASD.
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DL77 and E100 showed similar results, with a higher dose of DL77 exhibiting
optimal effects, hence we propose histaminergic signalling as a novel mechanism for
understanding ASD, and the H3R antagonists as a potential target for therapy.
Future direction
Future studies are essential to investigate which signalling pathways and HRs
are involved in this histamine-provided neuroprotective role. Altogether our results
opened a novel therapeutic window for managing core symptoms of ASD. However,
the examination of neural circuits implicated with the histaminergic and cholinergic
neurotransmission systems is an important goal for future work to decipher the
pathophysiological mechanisms underlying the observed effects.
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